var title_f8_5_8272="Mammary duct fistula";
var content_f8_5_8272=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mammary duct fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 245px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD1AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDKb7gyM8ntVqEgoST1I/KqJcGFWJwQf6VZtpUwqA5zyABzXgnuXsbSusUe5vukdc56VzunlpppJyCDIS/5mp9VuyujSSOAjHAA3c4J4/Sq1hIEWNR249qU9dC4u2p0VsgVcjJYDqKvK+1QWI54xnisu1mB7c+1WxODtAxn+dStEPVs0YpQQMZx6e9T7/l4GCefzqhHIduccY6ZqaFtzYPTGelDsWkasbBI8A+2MVMoLKSc9apw4H3gcjkiratnnBH41OxJLGTwCAMdPepDxgAd+x6VCh5BIPHr2NScjJBxu6Ubh1HKSMjnOcYzUqEY2YxxjPWoUy6HBOSPvelWDjb37D60DQgcbyMYHf0qQKDjGcEVGxC7QBkmpMM2cMSTxnpTKGMSzZyMDpS7XOGX7w6k00LgE4O0HGcdKmAHGOpPYUFXsRAjzW3cH2705vMTa20ADnOetLNkqQQCexJ6VFI7kKrAqCMHjgUbBuSIWlPBHJ65zTiRkgkgDtRGhUfL0GBx3pXViwyBkgg/T3oAeGKwKQMsakB7dKZEUICo276dKmwo5JOT3pC2ETlQeSQce1IzHtz7CpNind1GOB9aaF2gjgfSgSIo3PmgEYHarSKpGNmMe/WozGvBJwfbmpd4jyMkihMJO+wigYyMjOfehF2qDnBY/pSAmQ4BbHTg0+M7s7sA9DTRJG5GFyu0A9ajwoxkcH9am2HzPmA29s80nAztwTnnPGPpTAgABYswwB6daVV+UgAcn8zUxVNmdu0nnFNT5HBYdehzTaHcTBDBSM+wpXU8Z4HrTgRljyMVF05IOT07mkIsBgQf7oPX1obJ6cKDkH1qENvdlUYH6VKz4UjjdjpQFrDh245xnFMYKrZI57GnRH5fmJ3EdaVwueg3Y4JpCsQKTuJGQe/oKkKHZjbk9RTwAVwwwemRS8A4BBX+tMH5FcqTk9MU0lRnaasuBgAjrxSMuPlHQUguVJAODgZB4zSlcjHGRxUjImAWyx7A009zjGOgoKBlGcdxTFPz5PPqKkXHJPJ96Y4HXGMelAmtQfAT9eR2oL5z0FRhgykHj8KegIUjGSe1VuGw4cZAwc+lIUwccgkClPA55z+dHIXIOcUITGMNuWJP19abj/8AXUhOcjB57UzBOcE49KpPoS0QFCJWIzkjH/1qR+FJPWpx1Y9h61WZtwHGKaJuQyHanGMtz9KgcjOemfap5WUxgjODxxVeRiNu7hRxz2ouNDHGeMEduPrUVz0UgZP1p8rkjnPT/P41XkPDZJA9KaEMnIaJQc4xyBWNe/6sjHGDWnuHklTwAeB7Vkai2Tz6UPYEY+mfudVfoPMXdRUEsypewsOSx2ntRThZXuROV9imrhHaIDhh3PQ1MzFUjJ692HOPwpJUJjVj16H3pVUKPldvLHXPNKxVyjql9G+ny25Qs5yFIGOR/Wq2lXpl2CNd23HU96uvu+yTRhfmVty8dQa520nFtqLRAjD5dfb2pSXUafQ7eCbaRt4LfpV2GQK53HJ6DntXPWty8rqsa5c98dK3LSLrlsnjk81i3Z2NIxvqait5jDBOO1adsnyjHPPr0qjaIN394H+70NaUQwOeCenHf0pJlsnT5V6kk55z1qwG4ByAfSq4LHHAH9KeD2AyfahE2uWQSR1wc9c1IM7QBzznrz/9aowBgADB9qlXsACAeKAJ4vlIJ69TSnlm4JkHcHPpTQwzhTk9TxTXDbWQA7mXhycECgaJJm24ZTnnBAqQA7cHHrkUxEPlqCpz6561IhKrgcEUx3JcbgMdPXNM3chug5zzzTCxzlTx3A609YcMCT0piFVhKMgYzjtUgX5x6Y+tNKgttTPJzQqeWSo5GaLjSAjCbuSF7DqTQuHbjIz2PWjc7TAEYUcg9M1ISolKZ54OD/OldFWFUEpjaB9DUyqCcHOPrSKVB55I5wBQWw3Ax/WgnViqpUk8DHryKOT1wcnr700kso6kj3qJy5YAAntnii40rkozyBkH602QZAJOKM9gc/SpNuRnOcHBxSHsRorcEMDzmrMZGPw5qLhWJDHk9+1P46KeMc8EU0RLUeG6DacUoGQeM4pBtUBV7HpTsHdyev6VZDIZE+YAjIxRIo4wOPT1qWTIwDjNV1dXYgBsA457UMpXAgrgk5IxxTypIz39utNZiCCD3xikRjgkcnFSw1HptYEqeWprjAxkMfX1pY2JXJHXjp0pxzheQCTRcNmIp5yC3PapCSQc8n1phGe31OaVwAPm+770AOUcEZOBSuP9ril3hV9B2p3ynvz2IpoVxinK8k596axIZguTj2p2cnp+dNxk/TtSYEb9CP4jzimsoBGT1OOvSp1weB09TSAgn6dD60WKuQldvUHJAPSgAEDv9adJznrnOOaQMepOM8YoE9iIxnnAPNRoxBwDnP8AOrEjevJz3qMgAcKQaq4vUXjPJx2pyqACSflI7VC4J2+3SlYsMAn6igSQ49B3yfWoymSoDY79cVIT6dB09aa5AHB+XrRsJkZHGMn0qo7Ackc9qsuQuM5x61DPxjgnJzVIRBOemc5H+FVZidwOAdvNPmYrJ17cCoGlBcKW47DH6VQkIX4OfTrVeZxgYIx7d6ldsA4HDZyRVS4YbMDoKEDK7PsJCnjsax9VlABO7oc4q5PLsznsePesDWbtSM8cjgVW5LdjIactqNsgzndmiqulsJb+SXOFRdoJPeimoJ6mblbQ2zlovlwec5/CmZ+ZmHPZgB3qYZ4ADE9M4ximTgqu7GVzj/GpNGyhfMIVdxuMaKQPXrXMajbCGOKaEZdZAXc/xE//AK66y6iM0JXoWHI61i3EL7hC65UMMZ70PTUatsbOjRlYenzHqfbuK6Wxh+7vByeRWXpUWFGQRx0rctzhcDoeOBXGtWdRfQoowmc9M1PHk45zVeNCSpAwp44q9Ch6L1681ZJMqZK5OOMZNS8qCW5PPSmx9cZJzz16VMi7gccY9fSggXIqSJOCfUcH2qMEsSFX8T61OE+RSAC2M9f6U0FrD4kCnIwCeD61NhdmVyAOcmoWG1ctjJ4p6DcQwGAOgxz7UWHruSAgt74704Zydq9u/ekRPm5xgevansRGMsBwOKFoIYVAHYHGc+lODhUxuViP4vWqwQnoT8wz1p8cDsSXAA6DFBrayHSXkUMqguu/pjOatI4J6jPaqEGnRx3CykAt2zz+VakcY5zgYqiW10E2jzBkAg88mkITfkjr3p7A7SAo2jkY703eCAxyRikND+CApyPfNOIXIwc8DrUY5B3HjNBPOCcgCkIQRndgHgntUpBGQCfypsOMfNjPWlZskgEgH370rg97DNw6d/enj72M444pi/e+ZSMU8DGeCeKNxsa/3vqOM0/cN3zDA/rTSAQcLz6Z6U0ggAHp1470ySdDgE4688+tWok3HhutU42ySAcAd+1XbZc5ZT0NXDciehBIAMjGQfequ3bhc9OtWbklSx49qgO/OVGMetEtxoHJAAJ/SkGW5B475PFKx+XMgyeg7U3cpDbPWpGSldp689uelR7TweNueKVPmJZs56D3pHDZwO3IxQMmYsB0FJvBH+FQpIPLJfHHalYKSAmADRcViTJXOemKTzRzx9D71GSQpDcj29KcoBXHU+9K47D88ds54pxG5Tzgjr7VEBz0xRIVywByRx1ouKxId2SOCuODSL8pIB4zmki3fKSRinHHzbsY9hTAa2G9QQe4oORwSD/s0jLhMZycd6XLcbdo/GgBuRu4FR9OCcAGkkBDDafxpjZD8tgGmOwrEg5zxmlbHU46ZHNIdpAz61G24ggjAHQHjii5A7fv3DGFpGztOR2xmlPCjnPYe1N74zxTuJkWThjg8jGQKh3ZXAOOKmkGQRkj6HrUDIATkZO3HHemg3KsyjcMghsc1TuAMjHJHqOtXHwxOOvrVSc5LAc49aLhsyAv8oP+RVSdgOMfSpHZk3YB4Hp0rPvZAMkfTirQupn6jJt34zjofeuP1u64Ur1zgVuardY3qemOvrXHO5nv/lwUQ556Zqo9yGaliojgWPnkZciiiCXeMKuAP1orZabGT8zoEYODtOTmkI3qc5B/u4qGOQr269R71PIMgSpj5uM9s1gaMpyrlht+4evqPSq7Rb54k+UgHc34VckBw2Pl5z9Kfp8QlmM5UjP3c9cVNWXLE0pK7NWxiPI6cflWvBGOxJHeq1shCkZx2rRtk2ovJ/GueKN2yeJdpByasRZVR1DUxBxwArEY4NWI1ZOH2n5en9aqxNx4G4dx35PGKlRfk3MCMevNMQMTzwBwOOvvUgbgcDPTAPWkIeQR93qvepVAKZB561Bu3H95u4/nU6xgNhRxnqvrT3HYazb+MZzwMnpVi3H7sANgDocUCBGAypP1p0ERTA/h7CmPRoWNS27zDuOf4e4oc4Ry5AUfmKlKFei8+3anKCFORk4wf60WFchCAgbTkgd+tSxDaOvBHPpSDAbBYZFPJyV69fyoG9R4XcwLYx6U7ap+UOM+tNQ8sS2VUcA05Nu0HA5NFxbASI/lODxjNMQMWbHC44FSuiYPoOg96ED8BcEHrS3C5WTdvIcHOfXirO0FtpwABSOnXk57k0oIVcty2KBt3G4DbjxikxgNkj1pVA6rz3PGM04ADkggdjSC5GHYKAOn6mnA8McjHrQ2CSRwevpTFPy7scetAhfunhhik5IAbGB3pQMYpPM25IAOaYXJIjn5W6Zzz3rSgysZ6c+9Z0YBYbSeavqCIS3p3zWkEZT1Kc7gMcdj0qDdkAZJXpSyuC5LHGaaOTjHA61Ld2WlZDmbcuCfwqNuOecZxikckOAVJHFCsxY4GM8e9SUSB+AuB17U5HPQ7j7A8VGcYA701DgYyKAtclOBkcY6AU7HQHBPt2qLJIPVe9OQnbh+SaXUYpBKjqQOc+lLGCVA9800YL4HXPHNSxLj5hwD2NMGxzEducUwDPbIPcClXBfgL+dLINp789hTI2AZUYA+maZj585IxwaXzCP9rPQ44+lJwecds0BqgZ/l9eabvI7+vWm4xx+P1odBjcQc0AAYlhu4BFI4IA6YJ5qJjsBAHPWlEoIHQYNA7EnygH0HrUTDH3fXnmlPOcjrUIJD8/dPQUDSJV5XhuexpCWJzg5pVAJ7DtmlIG7k5IpkvQrybgSc5wOKic5xnJA9KsdR3zjBz/KqxbB2kbSOtCYmU5eCSQMA+vWoGZc5fkZ+pq1L1JzyexqrMMAkjCnkHFO4WKF18jHDEDPesa+O0Enqf0rbbncGHzD0rIvlJU9cjtjvTvoFji9fmKBmz81YdhC5Q+YSGc7gM1seKLeRoyVByTjHtWfCjKPm6YFa07MynoWGZY2CxjLHjdRU8EYUhhkkHPtRWt2ZGlAcq4Q85yD07VNFLxg45ORjvVOFsfeLctg/lTrhW25HGPm3e1ZpGjLEw80pEOGblj/dFatlFl2yuAOnHNZ2nxNje+dzdfat62TYNuPauWT5mdEI8qsW4o/7vPFX4VG3r0596gt1IXcMDA4GKuQocAr8zE8+lOw2yVcc4+9mpI1DfIACfc00Yzg9SKsQqdnQ80Ei8kE8n+tPRAQNhHGBikT5y2COD0qyq4GBwf50h7DlA3EbeR/OpUXCEg4yeAO9JEpCruYZ/ix3qdB0OOOeOmKaAjSFsAMwYdeKlHGM56cCkLFQDzjvinLhmLAjGMAdKChgYg8n24P6VKyg425z37imyAHHOR+dSRFSCT9SaEJvQhK/OWbjPYUvzIeMkdeal2hgScnPGaXgrucY9OcUxNhHgHAPNOVBtwo4z65qJTt7j8KlbOcBfm9aQajih289qCNuOOMZFIuCSSSc9qlAIPDdu3NINiCTJx8vFIudoBb5RjOKmcfKcD6VEowO230I6UDuLzycAc9qRX469TzQTlcYxUZOx85AzwAaAQ5cAE44Paofm6Lyo4HtThlepG2jZluPwOeaEgvYVvm4Gcnnr+lRvuIPHc446U6SUZwBn60ZyQOelMRPCxDdPrVyQ4t++COBVGAglSetT3DAKADwRVx2M5bme7EuAvJHPPShWYd+p7Upwj5B5PNNb5sg84NRZmvMh0j5wTyewpUcEANjPSosHdtJHqPegECQjGR6UCtcsHawIbkdSDSDbj5MgdKFBVR09PpTS2DkDp3xSGhynIG7seTT15Bxj6moo2BXI607IBwACPTNK4x53AZA5z0qUOwwCDz14pgKgn2GM0u47iTyccUwHxjC5ypz6UjkDJ7fSkwNuS2e1CISnYUCt1EQjnGeeoNOk4wRyPb+VDowAJ/SlKsQAMA0AV2JDDAJHU5p27BAI5xUhTBAAIHvVa8hZ2R42KlefrQOybJCqnBI9setR+UQT6HpzUkQ3KBuzinyoBycg9ePSgT7FdScEHnjilCjg4OcVPs+UMB25qIoc/KOP6Uw0Im3BwvY9M0mGIKkHk5BJqR8AgYzSH6DigTIQxywIPtzUUh4PAJqZhjAPOT61BK+MHOSO1MW5XkG9cn8xVaTOD0z35/WreDsIPDdsiqkjZByBgdj3oBlO4XBPB21mXC7lNa1weBk/MR1NZlwCFIb+VUtUG5ymuW/yN3xWAzqgIOAT7V2F8gkVlbJz61xF4DDcPHtzg8ACtKUrOzMqkSyZRx2wKKoKJHzuO0eg60V0JmNjciLMqsMgZzU0jGRkhHCnLsfYVVjJIH1zz0NXNOAkneTGccLj0H/ANeuao7RN4q8jXtxhFGMk9CK2bQYBX0rOtkJYZIyRzWtbqAVCj5a54qxtcshPmAXnH8P86sEsBtx8g7D+dMjJBxwWPPWpF3E8bgPX1q7CZLCOoO4sO9XYkAB7sepqvAqg855OCatqSCMHBP6UCEKKoDFcH9aktgzBieuenpTlwXByOcgkc077uSO3QUWKT6FgfKASByOntTkbI5GTnp6VBljnYQMc5/wqYZwdmMg9T0oHYc24Dg80qIwy36U75WwBwT1NIHG7JPQUAKg3c9/WpYiCOOuO1JGc7uMqaQZXChepziglkqHghuD9etMAzwV4P5CnhQWbk5HQUp4fphPbpmixle7K6bVYjrg4zUpAUHJ+Y9s0eWokByMHqKV1IbPocc9qdi4u7GMC8R2sQWyAen41kaFpF5Z3dzLc3bSq3CqTkf/AK63o+F7A+tPznjjHTipa1NlVlGLitmNbIwFG4YOTUZDHIVcD61IxyoCnOOxoPA5OB15osZXIigTJ6DHOajeP5s8n3qQnIy2AcdKN3ydR+NA72IeAWQng/zphO1QMnJ60rswwCevpTXOWG3j6npTAjUAc+/OKcmD3+tNP3cZIyc896AWwFzx3FLYNywh43L/ACouJCyDcpz9aiQ7GX0/OqtzOC+BkA5FO9kPkuyXJwSOgoRcnc3TNRIcZGfwqwpwBkfhRcVrCEDrgA/SoyAz8Z45qYfNkYApFyox0IpD2DIwvPBGacQTgA4XpnvTcccnj0FSpwoIUZHrxSY1sRoNsmMD14p4Py4bJP0p4QHHQeoFNkJAwoHPHFAbjlY7Sy5OPUUkQYvkgBcd/WlRmz1PsKlQ5YkDP4cCgTdg8vOM8c/hSgAEDrilYHgfQninkd+nt60WFcUccHvSYHY/nSMCWHPU9PSlPI6cDgetMCNkLDjoenqKdt+XDYx1pzDgfrSJkZVhQgexA6BRx2qQsSvI59DQxYy449iPSnBARweadiWRPhV/zxUe4YPOM1YlVdoJHPvUDjj+HmgqOpCw3D5eneom3DIB96tMgUgnPTB4pjbdx6n60xX1IWHy89SKpTcOAQc5q83tggDtUUijqqj1pDSKrOeoPbv3qqoJzuHXnirZU5JA+U449KiYADk5/SmIz5Rtlyeg/lVG7wOCRk9/WtOVcMxwC3Y1RuI/mYnuAKa1C5iXMZYHPJI4HtXH63AFnL9j6V3NyuSwIwa5fxBEPLHB4GfpTi7SFPVWOdjO0Yj4yaKRV+YcnntRXT6GC0NNWBjJJ6ZOK09FT/Rw3Bb6fzrFc4gJ3Gug07iJUx0AzXLPoaxNa2yQMLgHj6VqQnDAjoOBzWXbMcsccYwOK1IztHy9KhGi2LYK/MT24zipskKgxz1qnBk8kZHSrKsSMLwM5+tUKSuWxIVAOSSf1qRWJUMvJJ/Sqy4JA6fWrFu27PTHqO9IEuxaQbgCvy1IFcPk5JOOpqNJABwRnGQKlTPPJwelO6BNoI/9a46HPFW1ATg9PUVCgAccDLd+5qdcsD69eabQ3LsOU555+uM8UrD51yDmnIORg4wc1Iy7OchiepptE3dxMBen3TwaiJZchTknIqRTuU8Ec4zmm/KH2jkjjB70LQFdk0SlQAMYHSkcNkEdBzgVKF4G3pSrgZJI655pC21IJUOzOOQefpUqsflIyf6VKEG4sBy3b1qIxnccEjB9OlVuib6jio79PSnLncQD7VG7bRknJ6U3eWLcc1NrF3HyHZ2yO4qISL0PI+lOf5+RgHGOaZIgPbB6fUUcouZCxkEnrye47UkpHzAKQPUd6ikYgY7juPSmyMQuVP15pB1EDAs3HAqF2HQflSlioZiM57gdqr8DI65HrTsC3JC4AAA6immbGADgnvUU8mB1wcZqqGLuS33R6VmaqKLyt/E2fzqtNKBIFAyKmyAi7up5GDwKo3L/AL8YGO34VTWhcS/Ew4yufbH6VZ3nOR+FZ6t8p5P51aRyy4ycr70jORYUh87c8dMGn7R68fnVYP8AONp56dP0qzuPToSKBg2FB6nt60E8ffAPY0knIxSRdGy2e1Npk3sTgEKOcsT+VKckYx3pD0GPriljyeD9c0rDvcdGnAzkZ59qVQAWx8uMZzTywA4Iz7UoQHOOM859aBPXcjSXLY6CpI2yvzHJFNAGTwQT3NIymPnJx+tNEvyJ8enbtQdpPI5qKJs9ycn61ITjI96drhcUAA8Go2yqsRjH86lGMc5yfWmnglscmlYdyuN5kIGcds+lOQkHg555p4UZznA6cVG2E6HJ9KB3HkkcEE56+lQycADHvUm7aPQUzjqD3oEiNm4OcgYxmogAwZSfpipJm544z3FRAgE4OO3rTAaMLnPfpTTgHDY5NK+c/MQOOKhlJIC5OKW49BkgABPRuvFVgQuDnr1HrU0jEscjkVFMMoQCeOoHpQBVu1V2AA5HI9vaqbjIA3AjHOB0q7LIFYDaQAPSqMgzkHjOeBxVIlszZsMT65x+Fc/rSZV8YAxXRyplSVzxWPqQ3LnkDbzTe9wexwVy4WQj3oqO+xHcyqB3znFFbpuxi9DQdsxnHTIzzXR2GRGAOBntXN3ACoTjjcMY+tbunyDaiE8Z7965pbmq2Z0FrwwP6VdV8gA/lWbBIN3cd8dqtxuOvGOfepLReidTuHGAuKnkfZGvzADOMms5pFWMID1pplLyHcSCOB6UnLoXGNzQjmI25ORnqO9WlmBUBSOayxlflOMgD6ZqYN/o4YFj9B0ouNJG8jAAMQOlX7dwwGQPpXPRyuVHmNw3AyOorVtJ1baQDkcH1rSLIlHqaORvJIxj2qRHDSeXtGRySD1FV4jvLEAhh69zU+EbJ/5aAce9XuQrEoJ+YDgDHSnbskAAnPPHaoDMMAHls4x2qZcZ3E8/WhKwSBN2SCcqOcYpQg83cM+2KbHuDEcZx1z1q1AoAyx5PJxRYlSsKv8AEz9B0pm0Nz1Gc/WpmAbjHv8AjRtG3AAH4cCk12BManG0E8CnNtByfl+vegHawG3r3NOHzjbxx6+tVEl6lcfM2c5APbtTthyWTINPAwSNpIx1oBOeBn8elGgmR/eDD7pHvTGC7jnk+wqV+5HXuKYygpgfjj0pajViuxwu4dKi6qWI5I9KfKwGQv3SKhZs8dD9aXL1KbIR87sCCOe5pkgx0G2pJCqN17ZNU7yfAGeKTZcSG5bD7WOfQ1Er7ep59qrXMp8wKuTmmmQhlQemT7Vmt7mnQ0C7OynPHYGqtxLvkB6H61GZ1XqScY4BqhdXGZfm4/GtNwRqCUgYJyK0I5cR/Kef51gwTBm6jbjoOa07ZwwG78/Ws9ga7msh4yAcfWpQSwIGR7iqYYbVAYgdAatRnoM4YdqZBNjPQHPtUYUo2e2amjOAMdutIcsACMEck+tNIlskjfcfnwKnQKOnUHpVQY9PY81YDKHwOc02Md0bJXHtUqYKjsaT73HSnqisOPzpJBcMY5P5YpGUnkY4HSnrgsRjJoIweKBXIIwcg9qd1J4AqXZwe3vURXB5yKryF5i9s9fpSc808nC9selIDxwAKHESdyNRlz1qN0wxYdPap8nsue+aa4+tKxSID90/WmlM4OeQeTUrLyAOKQhhkAjn3oY2yoyFiSePY/zpu0c4BB71YZQW54Hv3qIjnHfsKmw73KjsMDfwuePaos7nJBPTHpmrNwvG4EEqee5qs8YwSpOevSmFlYYeOOo96jfhgQOoqTqOT8wqGdgCCecHJ4/SqWpL0K83J5B5PeqR+XcCxwTxntV2ZS6FhnH06VSlGVJAHrjrQvIT1KkpyTjg/pWLqWQAOSPStiYrsPAwPU1j6i24gkDGKYbnn2rI325sZx6HkUVZ1ZR9qfGATxmitkZtIW5Y+Seeh59q2LBiYhkdORWPckG2cd8H+VXtLk/dISPvAY9qwktUaLY6q2YMRtXnvUyPgFQSD29qz7aTAIOOMHFOnuRC4JPFZsaL6PvIwe/HNTA8HGck8isuwkWSaQ7+UOFA6ketaAJVQ7nBGeCKhRNb9yxEWBX39+lXIwQhRmGeox0FZEl9FGwDMMg89SadDqSMhKncvTpV8o7t7HQKCFw+RgY4qe2fZKm7IA6VlQXpkAJGV6HnpVlbjMg/ug+lNaA03odDayEtg8de1XMhRnrzzWWk4Cxlc9OlWI7jJ+XB961uZpXRZkYlS5ACg/lU8chJOcEDtVVmPQcqaA5WM4bJBAz+tMbjdF7hnB5xjJHapYnUZ+Y57k1RgfcGBI4qwJVB4xkelBly2ZaSRYwC43U87S+7uTz2qgxkLZZfl6VbtcyJhsDjoeKFqXKKSuTqGI5GT70iMA/cHrUgbcuCeKGxwFGBjGaqxjcjIOSBwCeeaa5UfKeTj9KdISvbA7nNQMTvDdaTHuJ5ihSPfOTUTkkc9BxzSSFecE59KrvJngHLKfyoUdBN9glYs/I/WmM+zthSeKa7cAHn8eajnk2kYIOcmkxxRFJJndjgdqzbl8Lkg89BVqaRVB5xnrmsy5k25zzz0rOSNolYyh2Ln14NZt/qawuUXLykcBeafM01w4gt+pPzOO1dBonh6KFPMlUNIR1PWkvM0k0jnLOWc/OLaaRz3I4pl9c3MsZElpJnrXogswFxhdp9BVe80wNGcDGKamS5Hnmk34ecxuXWRDkBxgkV1NnJgYzu/GsnWNKdHMsSgSx8ggc+4qbT5i6RuvQ9R6H0pNDvdHTR8hcfhmrMJ3ODxsxWZBNvQBuM960InXJyPyHShEMuAhevfvT4/mO3A645qBMHvjNTKVAXHJ9DVpEeQ0oyHcOg6+9PRydvy/gKcfnTnGfp1oxsJx9RmhDZYiyylvwqcdRtyc1TjY4HIyT6VaXOBnqadiL2JQNvJxz3pdoPPNAUlRkfTHSpwuFwcE+9OwrkIUlSKaYzjIzkd6nGAc5pHBzjHFFgUmVpFOOM/SooxxjGcdDVsEL+FROBg4HehICL6/TimMwZsrjNPkU4yeABxTUHQY+b1x2pWKTEYMSefrTXUAjv2zUzdAeenpUbkDODz6YpWGnchlJXrUTDAyP1qVjlcNwfpmq7Nkn0xzUlbDHCsBg8noPSq7kc+uOM0s77QOeCeDVOeUl+OST60rCHK2FOex61XmbKnjPepoyWycdvzqOYcY7HuTVbIRXLHHy8KcdT3qpKCuT36irjhVIB6n0qjccyEnAx0HrTig6lC5ORjrznFYuoOSfTjjFa05Ck89BWLfMGibIzkVQpHGatze475opb6DzrwsCeBiitEiAuGBQrg4wafo05azXAJYHaV96Zcj1Az2FUdImMWoTW7nG8b1waiSurlo7a1fAVPujOAc4wadfZeLJzlcEmqlu4liBBAYHBzVt2woz1Aw35Vk0NMk01084FepGM+tP1W4dmWCNiAx+ZsZwvrWNG5tpwVz7Y/lVq8u8XcbFtyTR7SR65pJGn2rF+FUgjLgDAX5Wz1q3bRwzAsgDArkjuKzZy6CJwFkDIyFAMbfQ1LoheOd9/GQQCD1qnBG6uaFszJdSqB9049MitWJ8k7cbcViW83m3lxImSm7aK0o2EajHTqRUdRWN2Fj5K5xuOR9KswtkqB07ZrHt5cqM53DpVgys+DyNvFaIOSxtJLtAQ55FPLHcQRyRkYrIguSFGFLetXYJVlUHGGHGPeqRMlYuxljJxxnpkVbjwEJHQ9hj6VRLEqSOg7KetWIfM3jJGD1p7mLdzTgUE84yKnw23gDjpiqoYDnj60x7xC2ATj1FNaGdnJ6F7G07SeTyRSg4VqrW8pkJ5HBpzsxDenr3qlqRLRhJL8zBs7R+tV5JdysRn8KdIxIIDE+9UdzFmABP16UrC5hZX+YAZ56H0qPKo5B655prt84LDpUMpUsAxzxk9sUgtdkvmKVzj/wDVVe4dQvyknvnrUbuFGAQT646VVklG0ZIPeoZrFCzzKi5/pWJdTPPOsMAJkJ64+7T7q5eWQQwD94w6j+H3rd8P6YsSbnGWIzn19ajc1+HXqJoukCGBG79cnk/jXQRA7QMjjjNSxoMYGM1MI1GRkeuKh6sV+4xSABlgSKY5BwQMD6VKYwSCp5z09absGfm4PpQwVjG1CHflsryO9ce6fYtQdB/qpDlT23V6DcQKwAxXK61YmVSMEMMsrehqou6swWjuMgkOORgdPxrRjcPtLEgA/nXP6bcbjtkH7xeGB4rWt3GTyetCKejNuA7ugz6HPSrQUg8/yrPtGySGzkenAq+CHUFcfhWhlexYj6DOADUxA8sk8iqoHTfxn9amwBtzzx0oExsYyygDHOc1cj4boPcmq4GePTuKnRuMVdiHqy4gyAMjA6cdaV/mb2qKFhgZ6fWpVyB2waYthCCeBkcevQUjtkcY474pWZe+M1HyGJI4PNA0DsAhJ7dqidsDIGM9qklYkZxz16dKrkYPOcH9KLADYI55Apu7axJ5OMCm7wW4JHqKSVxtGeMdakLD92O+CeBxUTYJOOT37imy89B7imbs5wRx70rGkQkITqenORVW4kypUDBPtU1w6hMck9MVn3D/AMXQcnFTKyGlcgkfLD0HQVXkIwD1AomYncMDI5AqnKxCtzkdcE1mpl8pdEoznknHT0pryhuvAqikpQFuCO49KBMr+n4f/Xq4u5DjYnmYZyeM9Pas+6kJzg8HpUlw2QuMDnNVJGyCARn1q0Su5TuZF2gVhalIBE+PXANad7yp5+bvXO6pKMMB0HaqW5nJ6mZbDzLiVsZBOMmilsE/dsQW+Y9aKuNrDtYrXB3Y2nkHk1gagWtbiK6jJLxncf8ACugls183kkjvVa+04eUQcvxkGhBfU1tNug8aSRN8kgBGK1I33ptzgE561w3h298i4ksZm6HdGScfhXYWsu4na3pgispRs7FXsTPCJYcKf3ik59x2qjIQymGZSAvKn+6fWtBXyeV+YHr6j0qO4gWT5gDuA6Z4IqTS10RWV4yIySgu3HIHDVaMss42xgxoRhn9R7VmSpIOR09PQ0+N3HBPHPFK9ty05S0N+CaK3QJFxt79Sakt7svJyfwFc4Zivcn6nmtPToJ3tFmYxqpAKqW+ZqOW+psnGFuZnSQSsRwcHGfpVkSscMOR/nrWHpeoh22/xA7SvrWojlWIB2qTgAU3HlN076GjGzKMjp/OtS1lBJ6bsjBx0rLtjv4DEY7YrQLlRvVsmmtDCpvY01AdskcCp4xjAyWBrPguMjkDr0qYHbyOq1aOSSsaSsE2r69M1H5UQDSkHPpmqDSFQcEnnIJPNI9w8YU8FQw4HenYlNovJfJHKFAxk8Y71cefK5PAH61lJKGIZgo9PWnPI4AXdyT3NXFEVJXJprnBADYyfyFM8zBwzZ7YqrLIFO3q355pkkyjByMk1LZMY2LLynBJOPSqkjlhvzj2NV5rjLAk9DxVK4uSTsH0HtUt6GijcluLgbmxnPvWZPNJMxjhUtITg452+9PAluXKW45I5btj2roNF0hYl6ZOclqjc15lD1K2i6SygM+C5OSx7100MQQBVGfWpoIEjUBQMdqnCqT6j3FRLXYlS7kUWVQ4B9s9KVYwpbbuyamKj+EnFKVHTI/KpsHMQZZOD1/nQxyQ3PAPWnvgkdcetI3TPVTxQClqQyE4YbazL+MyAttKjrgjpWvwRxjB7VGZI5DIkbfOh+ZfSi1i76HAavbNby/aIycjG8YxkVNa3KyqrIw57Yrpr20SVSWXPauOvIJNMuCV/wCPdm7dEJrRrqJNPQ3bSXeQS2MVsQyfKAw56Vy8EzNzkD6VsQTt1Y/N0xTREro2wR8uTz79Kec5DDBxweapxS8HI46VNE+GyelOxNy0Sdvy8elOg6jLEt71WD7Twe+eakidedvLD3q0iGX3bOWHr+dSDcTk8emarIQQMH8M5qTeFIB64pjTJ1DYBJGT1psjqTtJyMdqa7jp3FMmcKB0yPTtQNagznoenTrUJfHBx17058kYx8pqvKcMTnIHGTQUkNZsn5eAT0NRs4PIb86jmA7n6gVSlc4GByRwM1DNFG5dmmG7bnB9cVDJMRnHPqKx573yBk89+KS31Bbk4bHzHnHSmh+za1NeS4HlcH5u+ewqjM+QxZj3pR1IyCD+NRSAHIcE5HX0rGWrEtCnKQTnnK8kZqpNMNhwcnvinyHywxY4PQ81l3d5EoO1wfcGosbXQpmxKyqc4waiiuWkkIU8k4J9apfaMk7Tyeh70223KcZ+bGeD0oXkTJmy8hJw3c96gnIIJ4ApplVY9zHOOlVp5QQccdq6Ec8paWKt7IFU4wQemf6VyGsT7UJJxuOBW7qM/wApIyAfX0rkryU3OpIi9E64q0tDNatGvZERwgAdBnIoqFWKjGOAAMk9vwopNGq0LZjyCSuA3B9qrycjBO45x0q4cnv0/Xiqrgq7b/uE5+lUjNq5x+uWjQzi5gJV1OQR1rd0TUlvIFkB2sOGX0p97CtxEUYDPQY/lXINJLpF+ZIuOcFfUU7cyt1HuektKdoIIz+VW4peORzjoea53Tr6O7tllgIZG6/7J9K04JTtJYnjvnpWPWzNIsvMFKjO3OORmomjRCNp49xShuMZyDzUiYIxkDFBtBIx76FmBCDJHOKWBYo7tLzz7rcMYgblF9ce1bLwKxy6/UilhskHA79CaSbSsaypxqblLTTL9o3j7pbOK6q0LEjIOPeqFtBtKEqAO2PWtK3RlYKQc9u1DfNobJqCNKA4A28Ec4q3G5bBCnLY5zVWJMqPl4HcGp45duVUc471aVjmlLm1ROsvlY6bh0Aq/FMGUYPUZwOtZZZGJJ+/6dKlhkjQrzkj1FO3YxeqNFyQcjof0pmzpliSOmahd8x5XOPQ1AzKrZLEMR0JpmWxaMmZdxOai3qh3sTzyFJ6Vn+fmUgHG4+vSnuQ4PmYxngChiWrLsj+YQynj0z1qrJceijGODnpVea7A/douAo55qoJZLqQx2iGRh1/ur9TUN9jXltuT3VwFLBmA9PrUun6fNfYLgxw+/U1d0/RliJmuGE0vXnoPwrftljKgquB1p8l9ZGbqdIDLDT0gwEjA7ZFa0caxkZAz34qKNyuBkcUSXCqSzdO+BmlJkotDnOcYHp+lIcD7hqq1zgcN6VXlvVUjHOfQ1LSGr3NEsC6nceOMetKX+brisk3QY8k59OlL9qznaDU6FWZpyEdePc0wsD16dKz/tWeGYdfWkM4A+U/hS9BpM0kdcjkZ9c0p28kAfN1qjHOGx1B96txHPH8zTsGwjRqRhR9Oayb+zSWJkKB1YYI61s45PT1ziq0oJJ4/MVcdCHqcFNFLps+ybJhb7jkdPYmtG2lzt7jrx3rfv7GK9gaOVRtI646VyU8c2lXHlz/AOpJAjl/xpuLWpcJqWj3OhjuMgoTg+1W7eRtuCTnpyKxIZgTkfXg1oQynAKAn8c0J3FKNjSVy0gDD8alQjcevFUkm3geo7+tTwuD90Y9STjNUiLlyOQBssPlzn6VYSUM3b6YrNlO4E5P+NENwUOHAHNUTbqjT8xTjPOTjj1p0khICjn9KotcAN65BwfSlEgYfe5pNFrUsZK8knFQPIec/l2pskp2kB/m6DPaq0kjDkKRx+uKGaRV9RXY7Dyo9/asy6mwDngjpz0qzM5K/dwxFY14XMYBIDjqM1D1N4K7MvUrpUlbfuO4ZPes7TNSLSmRFZYlwG56Gl1IP5pPJ3DBI649KzY3ihuJWUkCVgAmM7amUn0OmfuxstTvUlEiB0brzmpDIUiy4+bpgHrWLDc/KBndgd6la5JRlDLk9B/9ei1mcLRl+JbgqwUs6IxKnaawdRFukOYnIOOPc1taqFurV1IUnGfxrmWtG+9PJ8nZRRoabLQu6Ud0TEjH4ZNWAW5bhcnp0p0GyCwQKNhOck1A8qs4XeD7elRa7M2zR3DaAOc8AelU7mUKDyPfn9KGmwhA6gVlX0wUnOTnrW0UYSdzP1i8WNHZ2yBz17+lYGk7nLTSZ3MSeai1+6N1eLZxDCIQz/WtCyj8qP5RnAxmtHtYcVpdljPykncM8Zopu7nnoehoqNS72LrykJtbjFRu/ANQvIcEZxxjHY1H5hI2sxGOPTn3pq1iXuISdzEYPpWZrFitxEWUAsODWivK4z/Fxmo3dgMMfxxVInroc/oNrcWbS3BLBD8oXsfc109neg47g9QafBD8gXaTiop9OIIeA4buPWsJVHJ3ZqkloaaPgDax2Y4x1q1b3GVw2MEc+tc5DdvA3lyjaffgfhV9Jt6ll5z71V9Bq8dzeWTyyu44HsOKngkVixycKPzrGt7sgYPzKfxxVtJguGjIIPWmaKZuQEHaAM5OM5q5GcMvHB6HvXPQXgOMk/n0rQjuwSR+JosVztrQ2w7KMAlWODzU0crAn5SQfTpWOtxtHLcY5xUq3XGSF6ZyDmrRndmn9oO7AIOOpp4mjGRICGz0rL85Sp+bHbnvT/PVTk4JouS9TUE8YG35/p3qvPOuPlzj1BzWe9xnLEkD0zVCXU4S3lxAyyD+FBkA/Wp5kieQ1fMUkOAeT+VJPqDJmNMu2c7VG41mItxOc3DiKP8AuoeSPrWnaTWlnjYV3AdzzSd2CajtqyxaWFzctuuGMcRP3V6n610NqIrZFSJNgHSuek1yFcZZScdjmkGuRgAIshY9NqnPrSuo7CcZT+I61X+UguBnp71IJVVe/wCJ5rkk1K6nwIbGY88FuKsRLq8vCwxxqf7zHIqXURSpM6GS8AHyMfzqB9QyAoKkdKzE0rUHOZbiNc90Xp+dWYtBZ+XvJiMnhQABUOZfs11JGuWJba2MHt3qEzEff6gdN1Wk0C3VlLtM+MjLOealGh2I6wgkc5JzUOY1FIpLdZTKhj7Cl+0SZxjg8elW20WzGP3WD9cU06PbEHAIHsxpc5XKVFnLNgZyOuakMpJOHxn8aU6NtGIriRQDkZOQfzqtNYXsZIimjcgfxrj+VNSDkLq3W7O49OAa0ba7zjcwyO+a5S4N5F80ltn3jbP44qIaskTEOzRkdQ4xVJidNs7wTHeCTj05/pSvIG+nrXJ22r+ZjDg/rV2G9ByScnoRmtEzF02bXZjk+marX1rHdwlJkV1IIII7VXS6IAxjA9RxUqzZJLnPcY4zWkZGTicreWc2kyErultOue6/4irlleKVBVhg9CPWt5281CMZX0Peud1HSWjkaawOxurRE8N/hUuPWJoql1aZdW4y5BParsVwxbhjkDoa5e3vj5nlygpKvBQ9avwXXz4HGB+VCY5RZvtJiPBz1x7Uxc5OOBxz3qgJ+Ruxg+nepEnXoRx1zjFWiC87uFwvQ98dKmjkYxfNkj+dZyTjjaQR9al847ScDgVWhL0LpkUsvAAxnrQ4GwsrEe1Uzc8NuwPwzTknXPGD3JBqWWpXGysFBYMeT+dUJQmehPPWr7MhU4XOOKqS9CQvHX6UrPqaqoYl7HuJC8emOKxWsM3IZo+c8c10rwDaSSMHrg81RmjCg7RlhxUuNzoVaysiswKLwV9DVee5ZcZIz6g1LE7M5jdPl7Zqvd27EcYx2+lJrsYylqVnuT/Hk4/Ks95S824n5QwIFPnjfdxuOOtVZI3XC7T16/1pKJLmTz3JZ8SqD6c0tuyoNzYBPSq4VQ+epHc+vtTJpxyGPToP51cYGMp6WRNcT4QqCd3fPWuc13VBZQnHzSt/qx6VNrOqRWEDSzcufuL3Y/4VxcDzalqBmmyS3b0raMdLmaV2a2iWpYNK4BdiSSa6CONScE8DHANVrSNYUAzyB3qfcQSFGT04rNvqzbcHYbtvAPPAoqBnODkDP60VOw9xSwxk8+oFQGTc5PI7c09iQpJ7HOfrULDc2QOPWqihMldyRlfl7UtspknQE5xycVCScAHp0yTVrTirTuewAH4056RdiVuakcYB3DjPapGAXnj0GKWIA5I5OOcdqk8vc+BgDuawUSmVZraOZNsicnvxmsybSpYTvtJSPRX6Gt7aN27HA/KldQMHJ59u1OyC7WxzP2q4tmxd27cHG6Op4NWthkl3Rh/eWtUxbskn8O9Q/YUc4ZEJx6ZxTuy79yNNQt2Yn7Sg/HrUseoxDO6ePAHXNIukQnOYU9cgVPDotruAaFCfTFUpN6hdIQanHDndOhXOfvdaeuu2kYz9ozkdgTmrKaPABnyI1H06VYt9KXdkRR/UJQHOigmvo5Agt7idgP4VwKDf6vPn7PZxxISQDIcn8q6G3sdpA2r0q2tsSRgA+o/pS5Rc9tkceun6pcuGvbndjsvAFaNpp0w2jzGVemE4rpkt1LZxz1HHFXbWzyuQAR9MZqrWJcmzn7fSQ4VXaZx33Ma07TRLc8+SpI7kVvx2gLbsnFaUFp8oKj8ql2BNmLBokWMCNfyrRt9KRRjaMdwBWukIjUYP4VNHGCOAB6dhWTLT7spwWojGAvTjp2qdYh0Xg1Z2kEZBPGc05FBGcH3pcoKRAIVxye30p6xABQOvapVTpz0HcU8jbGAQMnj60cg+Yr+Xk5HBz60rKQMdqmQ/mO2OTTmIG1sde1Kw7kCJ83zD86RoRjpjPFPXIHJAP8hTg4KhTyRSsNsrtCBwOB3qNrfII7VdDALgjPbrUe4K554o5UCkyp9jjPJXt61UutNt5A29FYZAwwya1+D94enOKa4U/dIx3zS5UUpM5O58NWrqxRXRh3TiqMuj39sM291kdQJFzmu32g9CD6d6YYNw+br6daFdDcr7nBtc6jaczWxYL/HG2evtT4dfiBCuWjPcMDXXXNnuPzKPbvWZd6RFL83loT6VcZMh8vUqQatFIvySbvQ5zViK8V3OWyCehPasu58P2ysSqmNs/wAJxz68VSawuoTut7lyo6hhn9a0UiHGLNvUrG2vgQy7WX7rg4asK5iurCTbKpnhHSReq/Uf1o+231rxcQ7h/ejP9KcmtW7/ACynYx7P2qtGSoyjtqiS1vhIoZXDDgVa+0gkkc5rMuYba43SwHypf7yHg/Wqcl1dWX+vj82H/npGM8e4p3aBWZ0Uc4Uoc4P0qUXRPKsMH9PrXPW+pQz58uRSe+eCKsJc4XJYD9apNMTizfFxn5W6H2p8ZWIk7uOtYiXi5HT8TTmvSejD3p2uTaxtfaAAw6DmoppA6kdB71nLckZwOSMZoa4GRuJ4/GmkCdi25G0ZOT/eqtIy8AMR61Xa5BDDIPr6ZqB5ufu575PSjqNvuLLgMCOg6ioJ2z8oHyjrk9f8aiuLng5bA71Ue7GM5Ix15oepLkPkOHxkEnrWdcP1Jwc9s8Cie8AB8tuvP0rJvb5UTdI4AxTsSWJJAvTkHpWXqN+sIIX5pQOFFVTd3F4+y0Bx3Y96emm+QQ8h3vnNS3fRFcttZHFTvc6jfM0zM7k/lXR6bY+TGpIGcc1ZNjEt2ZlUBWPP1qfcqsMjHr7VUp8wJWF3NuHy8YyTmnIRuUZ4wR1xTdw356DGM05WCjBOeePcVD1LQyQ4IJ4P6fSiop2xjB568UUWHdonmBwu7p2wahwACcAn0p+7IAzznjNMdzuHTpjg9KF2Ja0EdlA6AHpgU6wbbcSIe6g4qJiGGAvvVfz/ACNQiZiMONvscU5RvGxPU6mByRgnr71dPGcHPH1rJtpgTkHrWkkgJz1rBbFMkH39uOR1pCuRk55HU96IsHLHscZ9am24BTjrxTAhaPlQQOfXvVpI9oGBye4/SnpGhUZVTg9fSp1GGGCO1DAbDBllyMCpVgUNjbjnrirFuNxH171KoDNwc5PT0ppCEWAKvHpxxViKLaudp5/Slj3NnB5xVmBCQeTzirVgaGxx5OAvTvUwQbQq/N3PHNSqpKMMckgADvU8cal13jGPzobBIZbwqG54IH1q/aJIt40bwD7Pt3LJuySfTFSxQquCo/MVcgiAGG4HoRxUXbKVkPXZnIC8Gp0B3d/oKhdcHAK/NnocU+NtnVuOuD2pMViYKVJ6nn8qkGVwcEZpiyAjPy9aeSCOPyFIocHY4xnFKTjAA68GhWXaSMZ96cmDyV5oBApx3I7EUv3S20596AuTx0/On7RnJOSeKNyrohJJOWPOOM96coGA3OB29DSEDoR365oAx64PFJoLgwGCD1ApxHbdyTgg0MeoOB+PWkbgnuOoxUg2R46e9R+aDKQMnHXipM556HuaQjHHPsTSKEEme/4Gl6k9j6UgQAHOaci4xtA2ntmnYd7Ap2g4H60KxA52gk8VIyAn5Rk+tBUDkn8PWpsLmIpDk46Z6VAYywyGPp6VdKA9x9Owpjpg5JxzyKdhJmXNakndjcelZ9zAwBAAbHrwa6IgNyc9PzqOWBTuJXpVK4NnJyR5HzrnjgmqFxZQyq3mICe4IFdZLakSfKpJx1qm9rjg4/EfyrRa7kt2OLn0dAv7stH/ALpIxVJ7S7h/1Nwwx1DjdXay2gHXgHsapXFmpPO3jofWqSFz9ziLq3mcHfBG7Duh2mqrXF1a8oZGGcbXAP612ktpkKozk8dKqT2KMNoGR69KOUHI5ePxFHG2LqN4znrtJBq1Fr9m5HlXUWfQtirdzpkbAEqCD26ZFZN34ctZwS0ERbHXA6U1dE80WbKakrrgOrA9wwOKGvsnAbIrkZvDEXWJpYyOco5qnNod0gIjv7gDHTNUD5Tt3v1PLcY/rVWTU0CHkDsCTiuIOk3+WDahNjpzSf8ACPPMczXcz+xNNJEux013rEKgmWeNc8dc1mXHiC3XhS0rDgbaitvDdqOXy5Hqa2bLS7e3PyQqGxngAmhvsK8V5mEtzqmoMVt4fJT1NXbLw6S/mXkxlcdRXQIgGAMY6gHtVjaC3GNuf0pNX3JdR7LQpJbLGmyFFUDrgf5zVa5jBQqMDgj61pSgpkL0HYVnucgg/MevPSmtCDJmjITpxjoB0NUXwHzke2a0bo4DtgLgdjVTgqNo79RSRqmQZ27s/LnFDt0wePp0NLtA659s801sAHBAPtQabEEjFUIzj+lFQTMckD68HFFUkQ2aBJcHnHNM3cMcc4/pRRUIqWhGfuZPJrP1hc2hfOGT5hRRWsTORf0W+kntoXYAMy5610VvLk4AwAoPJoornmrN2LRZilIHGcHkjPFWo3w3Izjjr7ZooqU7g9EXUBGCWz+FTKMFfzoopoC5brn0ANSov71jnt2oooBFu15fPqMH35q+iArjp1PFFFX0LLEaBuDxx1FWo0AKk85yee1FFQxFmD5gAPlGKs8lcE5xRRSEIhGd4GMcYqQDDZye1FFD2GT42nIyMgcCnNhc+vXNFFIYoBLEZwPYVJEegPO44oopiJMDJX8R7UsYxHng89CKKKTARgNuTzyRTC/GOfzoopsqIdcHvRjg9KKKSExrgLvGO9CHgjtRRUoroSFBtz6Y4oX5VzgH+dFFUhDiTtLZ74puenqRRRQ1oA0HJHGDTyMKSOvWiipQ2MxznuabncQD0Y9O1FFAMjkXI44qCRBkk8kd6KKcSWUpoxvY+nGO1VZ4QWOCRmiitIiZRliG7gnjpVWRR8+ee/PvRRVxJZnzqoJwO4FRPbj5gDgDpgdKKKollGZAr/LxVZ4l3Hk55OfwoopdCblZ7dMtn19KjeBCh9jjiiijoJO5JHCquy9cZGe9P4bjGAOKKKFuDH7doGeSOMmpMHJOcYOKKKET1IXOdx9KzJ3w3AwPSiiqWwGTfk7No7tUQjG8jnrRRSNYjDjAb371Wdshj05A496KKSNXsRLHvvIkzgsw59OcUUUVLbuZM//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A mammary duct fistula is a communication between a subareolar duct and the skin, usually in the periareolar area. This patient has bilateral fistulae.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_5_8272=[""].join("\n");
var outline_f8_5_8272=null;
var title_f8_5_8273="Dorsal displaced fx";
var content_f8_5_8273=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Dorsally displaced complete distal radius and ulnar fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dorsal bayonet or \"dinner fork\" deformity.",
"    <br>",
"     (A) Typical distal metaphyseal fracture with dorsal bayonet showing a dorsal angulation of the distal forearm.",
"     <br>",
"      (B) Usually the periosteum is intact on the dorsal side and disrupted on the volar side.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"      </div>",
"      <div class=\"contractual\">",
"       <br/>",
"       <a href=\"file://www.lww.com\">",
"        file://www.lww.com",
"       </a>",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_5_8273=[""].join("\n");
var outline_f8_5_8273=null;
var title_f8_5_8274="Juvenile xanthogranuloma periocular";
var content_f8_5_8274=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile xanthogranuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple periocular lesions in a young child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_5_8274=[""].join("\n");
var outline_f8_5_8274=null;
var title_f8_5_8275="LUL atelectasis Lateral";
var content_f8_5_8275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left upper lobe atelectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral view of left upper lobe atelectasis. The left hemithorax is occupied mostly by the hyperexpanded left lower lobe. The major fissure is markedly displaced anteriorly and delineates the collapsed left upper lobe, which is pancaked ventrally (white arrows). Anterior to the collapsed left upper lobe, the hyperexpanded anterior segment of the right upper lobe is accounting for the retrosternal lucency (black arrow) and for the clear outline of the ascending aorta.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal lateral chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 368px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFwAPwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5l0fTf7RkdPOEW3HJHHOff2rXPhRQRnUoMYzkLn+tVfC/3rj/AID/AFrpAzHgIAfZeaAMS48KrCVA1GKXcuf3aZ2+x561e8N+BxrWvafpg1BojdzCIOLfcRkdhuGfzFaYScKB5DDcMgmI8j1HHSui+G0bN8QfDiPuQm+TtgjigDpV/ZfuWhLf8JJJvy3y/wBnDnAOOfO74H51zXxI+BUvgrw/BqcmvfajJOIWhNl5RXOcHPmHPSvsC18P2qzyXBaeSSVgzbn4yPQdhXn37SluX+HcshH+ruoW+nOP60AfG3/COf8AT1/5D/8Ar0v/AAjf/T1/5D/+vXRAU4CgDnR4Zz/y9/8AkP8A+vVi18IGeVU+27c9/K/+yreReeK2dDtjLeRcfKGBPvQBd8KfAOfXxkeIFt1OME2ZbI/77FdpH+yVOwBPjGIKe400n/2rXtPgWwMMFuyIFBUV6OowoHpQB8pn9keXjHjNOvOdMPT/AL+02b9kicL+58ZRu2ej6aVGP+/pr6vooA+S0/ZKvT9/xdbDntYsf/Z6av7JWob23eLLUL2IsmJP4b6+tqKAPkd/2S9TBOzxVZEds2jD/wBmqEfsm61nnxNp2P8Arg/+NfX1FAHyB/wybre0/wDFTabuyMDyHximn9k7X+3iPSz9YpK+waKAPjtv2T/EXO3xFpJ9MpIP6Uz/AIZQ8TZ/5D+jY+kv/wATX2PRQB8cH9lDxP8A9B/Rvyl/+Jpjfso+KsfLruiE+5lH/slfZVFAHxn/AMMpeLf+g3oX/fU3/wARTX/ZT8XKpK6zoTH0DyjP/jlfZ1FAHxLL+y941jxi70lx3ImYAfmBWTqH7PXi+xyZX09lH8SXCnP65r7wPIrmPEdmGR/l4NAHwLqPw/1LTnZbt0Ur124b+tZT+Hihw1xz/uf/AF6+kviLo+0u4XHrXi2pweXIeMUAcbfaR9ltnm87dtxxsx3x61lV1et/8gyb/gP/AKEK5SgDo/BiyvdTC2UtL8pUDr3rqI/tZJmXOehdsdQRxz6EiuS8Lkg3JH+z/WugErA5AXP0oA24rfVpDAFXmY4jBCgnp+nTr/jW34Ajmh+I/hxbz/WC+izyDwQcdK437RJgg7cHr8tS2N9c2V1FcWknkzwuJI5EGCrDoRQB+gFmF8oZNed/tCWwl+FuslfmMYjk/KRa+bB8SvGmAP8AhJb/AB7FR/SquqeN/FGrWM1lqWu31zaSjEkMjjawznBwPWgDnwKeopFFSxrk0ASQJuau9+H+lNealEVQsqnJGM1yOnWzTTJGgyzHAr6C+HWhizsosjDHk+9AHqHhSy8q1jZ+SowB6V0VU9Ji8q0UYxnmrlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVS1WISW5Jq7TZV3RsPagDxnxxp4e3k+XPFfOvie0MNw4xgZ719XeLbbejxx/eJ6+lfOfjrTXhvZN4yR1NAHk2uDGmTj/d/9CFcpXYeJE2WNwP8Ad/8AQhXH0Abvhn/l5/4D/Wt4Vg+GP+Xn/gP9a3hQA4U9aYKeKAHinLSCnrQA9RVmBc1CgyRW/wCHdLfULpFCkoD+dAHXfDrQDczx3MqZXPyjFfRXhnTgixkrwK47wRoi2dvGGX5utep6XB5cQYjHGKALwGAAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5jXbTMQx1xnPqa8K+Jlgqq8pzz6dzivojWrZJICwyD7GvIPHuniS3djlmXOCe1AHyz4xiKafMSMHIz/30K4SvTviDB5el3XGMMv/AKEK8xoA3fDHW5/4D/Wt4Vg+GOtz/wAB/rW8KAHinCmCpBQA9akSohU0YyQKALljA00qooPJr3T4deG1tYI5Zk/eEdPSvO/AekefeRM655yP8a+gNBtNiRgdhQB0mi2gTbhc4rqlGAB6VnaRCFi3Y7cVpUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQ3ab7dh7V5t4vtfMt5RjqK9OYZUj1FcT4khBWTjkjHSgD5G+K9v5Ol3vGOV4/4GK8br33442vk6RenHGUI/77FeBUAbvhj/l5/wCA/wBa3hWD4Y63P/Af61vCgBwp4pgp4oAeK1dHtTPOuRxms6BPMcAdK7zwfpZmmTC8fSgD0T4f6UEjWUr9K9b0W2yQMcd65bw5aLDAiKBgDANd3o6rHtd+F7D1oA3YU2RKvoKfTIpBIMin0AFFMklSP77BfrVWS+Xa/l84GaALjMFGWOBUf2iLONw+tc7d6pI2QvIzVRLxmVsHvjOaAOwV1f7rA06uYsL0hgHZsE10D3C+SXU/nQBI5YghePc1V+1Ipwzsw9uKr3d5sjcjqTgHtWPJdOp5xyf4uKAOot50nQsnbgipa5TSL9Vu9qksATiurByAaACiiigAooooAKKKKACiiigArlvESff+ldTXP+Ik4Y4HNAHzF+0Hb7fC93IB3Qf+RFr5or6p/aIjx4Hv2/2ov/Ri18rUAbvhj/l5/wCA/wBa3hWD4Y/5ef8AgP8AWt4UAOFSICTgVGKt2sZZgO9AGlo1m00yKoySa9q8G6WlvAnyDceSa4/wPpCuquVy5PpzivXNJtVhiU4AHpQBt2CCNVHTjJIrWjvVXGenQCudlnaOMAk5PJ9vSqd7rUOn2cl1cuDGg4A6sfQUAdjNrfkLl3WNfrVJvFBlJETlsfxE8V4tqHiqfUrsvM+F3ZWNei/41qaRqZMgTIyevP8AWgD1SPVTM292z9TVr7YSj7Tztz71wkF+ryBBICw5wDmtOG8eQFQQoxxmgC7PqOwbS3zH37VFDqC/vME5HFYF/wDMP3bh2ByR/hS2czB8YCkJyaAOssromVSPmB5+ldK85a1jJYfMOAO1cHp8hEgw5yBzmuwgGbGPfnI9+goAfd3A8sEDODkD0rnL+6wA25gM9c960b2YbdvAc8dK4vXbomf5nK9guOAPXFAG1omrJb3qkyfMDx3r0Cy1TzFzJhs5KlTnK+p4GD1456dTXiUUoWRSqcyEDcTg8dcDtXo/haUyIg2EnoBzxnpQB3lFAGABRQAUUUUAFFFFABRRRQAVla+m6AN04rVqhrGDbEH8KAPmz9opf+KB1L/ei/8ARq18m19b/tHLjwDqn1i/9GpXyRQBu+GP+Xn/AID/AFreFYPhj/l5/wCA/wBa3hQBJGMmt3QbQ3F3GnqayLePJHFd74G08yXquRwikmgDvvDNktpAjDjjpXTx3rKuWjIUVz1rIAuDn5eASePpTPEetW2labIZHUSbdoA55PagC1rvim1sYpJp5wozj1LH0FeY+IPFlxrEgCgpCp+UHqfc1zOp6jLqF200rE5PAPaoo26UAbENw7OCWx24rptGZmVW3lgDwCa463kJYenoK6bSpNluSo3EnH0oA77TZCs0T468fL610ccnlMJDjk8DtiuS8OXKy7YiQNvPJrVXUWYsh2k9gf5igCLULhjPIseeDnbS2U6s+ZpSzcZUdao6nNNJMu4HaVwcHHSr2n24yZGAMZ6470AdNYTbgDEn8OORk/XFdhpYaaM+cSRwc1x2jDy5gTnceMdSa9A0aNJXVTkcZwB1oAzry0G4gAbs/pXIavpbuDKwUZPAPUivRpYHlecuRGM9AM8Vny28DjOwu2eMjtQB5vZ6RcTyhpE2jO4MT0HSu/0OIWsSrESWkI57/Sny6c05yV8sMOgGM+1XdFAhnWL5SQ2SxGfwFAHSoMIoJJwO9LRUMtwkTbTkt6CgCaimRyhzgdeuPSn0AFFFFABRRRQAVm60cQ9ccVpVkeICFiB70AfPv7SHPw91Jh/eiB/7+pXyJX1x+0S+fh3qo/2oT/5FSvkegDd8M/8ALz/wH+tdDEuTXPeGOtz/AMB/rXV2cW5lAoA0dIs2mlUAda9h8I6aLPTZJCuCwC9PzrkvBukmR4zsJzx0r1c2gtrBIcDC4zQBzszrA0sznKQrkD37V494p1h9S1CTa5MKHC+/qa9C+JF/9h0ryUI8yU5PsO1eQM2SaAJFb61KhOec1WBqePDY5xQBftCd3HFdFaROYkcOAfTNYlhGnmKrSBV7mul00IjbQN4bv6CgDq/DiMYySgVl6MD1+tbUFoSzcINpyprF0W5gjlaGUNkjGOgFbSOE27HO7OPm7igCxNZmeJBvYbCenOT9av29pHHbxISwUcnJ6mots4s4pFGTIxI56dqmjwB5crruA6daAN/SI4xJHL8oAG3p1rsNEk86+dgHwOOOmK46xliito9oyVPNdh4akZkaRtqIfWgDYltgwb5toxyoqtHDGjsxHy+nvV65ISF2ZtoxzXP3upwxriNuT7UASXswQMNwA6DHT8fWqGm3LrcBsq4X5sdqoyT+YSTIzqewHT2q7oSB5JGKdSFXJ60AdhG26NW9QDWfcAtcPh+T0ArS6dKqmErISijcf4j1NADrZCijzMBvQd/rVioVIc8sCV5OO9SjnryKAFooooAKKKKACsTxETsx2xW3WD4iPyHrjvQB88/tDt/xQGpj1aLj/tqlfJ9fVP7QzZ8D6iP9qL/0alfK1AHQeExukuB/u/1r0Tw3Y/aLqMFTiuB8ER+bdzqB1C/1r3HwXpZ8xHYAAcUAeg+D9MS3tlmKgAD5f8au6jepI/lQkELwT61W1K7+zWMcMRC/L27iuL13X00zTrhwwMxXCexPegDhviRqX2zXpUV9yxHAxXIdTTriZppnkcksxySajz7UASj61KhqBcmrEa9KALlvJjGOtatlcyKRtJBHfPSsqAAH0q/BnkDPHPSgDrdKvFuCqXLsknRXX+tdSYncJnlcbs9if8a4fS4pJXyiZ459q7bQLlhJFbz5ZOBzzQBtaJdPeQsjhnEWQpYcCqDzyWtyGuGxNtxtA7Z65ruLK2traA7EHz8n61k+J9BN2sE8TMrY2kqvH40AN0m+EaPJcHbGBkc5JrdtPEoMkMKKcN90D19a8t1W9exsRbiN0PmBeeprc+Ga3dzrTT3W7YqMy56Z9qAPTm1d5BMZ5ZFVlwoY8is5X82TLPkL/CorEmnZzMXkOGlPIPOPTNWoJ9iBU4Y9+pNAGzE+3JVQpJ79BXTeHQpCZRS+Cxb+VclbBp8YBJJ+ldloYSKN2LHjCAUAbOfTmqTSwoSJCGfuBzikuLrCOq4yB27VixzgEksScH6/SgDY+1oXWNGwPRRxVuKZGwoYE/rXMyT+WTj7xHJHNW9NlLtwCAOrHtQB0NFRLLHuI3jPuakVg33SD9DQAtFFFABXP+JDjP8Au10Fcz4jkzu+lAHzp+0I+fBl+v8AtR/+jFr5cr6X/aCn3eF71PVkP/kRa+aKAO5+EtsbvX5IgM5TOB7Zr6V0rTvstguB854zXg/7OdsLrxtMh7WztX1KmngrEuMAn/8AXQBwvjK4Nkd38KKBjFeLeJr+W6uirt1+cge/b8q9f+JqZzkgB5MHH90cn+VeF3cvnXMkn95iR9KAIc0DmkNKKAJoxzzVy32gjcMn1zVNMj61YiySBQBpxyR4xwD3OKu28m1QwxjsRzWbDExIDZPsK27SERDcyjd0wKALFnqDxkrk5bjntW/o1/KtzGTbvNJ0AIwAc1TsEspQvmKY3zkNjiul0WHbPgpu5ypAzn3BoA9D0m7muJoWnRVDgcdePwrtp9L82yV4Dnb81cFpMqzLCIidwGCcdK9EtLjyNLkV2DyBSRgdOKAPOfEVh5uoKPskagDhgucn6nvV610d9Nsrq+U7JXj8tULYwP6U7U9XeP0O3uRkg1BDr6T6dJDIvmyIykO56AnjigDk4Bc8LtY5diX7HJ/zxW/YSwpGC5LSDjAHFY2uxsZhJ5jADqo/pU+mogwrN8pPTPX8aAOqsZ3aQFQAo/SustJ0t7NQD8x+YknpmuHspHMiwICqA8nuRXSJ83BbPHNAFySd5QxAJLEComjEMSqGLXJ7DoP/AK9Txu62/wAvlqOmT940yGWUMpVI8k8twaAI4YPmVpWyf7uf5mtW2YtgImFB69h+FVnS5ZCcxovqxHP4VYtJbhDth8s54LMaALssBK7m+Qdy1T2UaD5owfcnqf8AAVBNbzOVZpQ5A5zwBVy1j2JyQzHqcYoAmooooARjhSQCfYVx3iOXashOe+K7FhlSPauE8XIYkkPJUUAfNnx3mDaFdL3yn/oa189V7h8aJzLp14CejKMf8DFeH0Ae1/sow+f8QbxcZH2CQn9K+tp7Mw2rOVIIHGPevlP9j2HzfifcEswCWErEAZ3dBg/nn8K+yNbQLaqnPrQB8/8AxaQ2+kzzlcbUKgn1bA/lmvAG619CfHkpF4aUA/NJcKPwAr57agBKB1pKcgyaAJolz1OK0baKMFSzD8aoxgDFWoW6EdaAN+OKKGFG3/fHYUqzJx8x4PTFZkW/HGfxqwImbALbc9KANAXSNlWyCDwT1Ndv4X1H9z5aIzqvrgZzXnscQX73UdMmut8MyyGVUizggfd4z9aAPXPD22RFBxGWwcDrmuyfCwYHDdG+mK5vQITLJDJLtAAA2iumupI+Aq4YdRQB5rrkuPPjHL5zj1rn7HUoljuQ7qCCpAPcA/8A16i8aarc2OtXWz5Y2+VcgEVgaHCL+5diSdyncff2oA6bWtUZhuiXG1ck54/CnaRdzXEBaJAT6HgfQVpX3h9HgBB/gXAJ9qzdIW5hZUihICdSBwT3+tAHU6M0r5eR4w+8owU52EdVPvXRQTbVKxvww2k96xdOhuJSGVWwR3HStYlbVBuGWz0K0AaMZCwbSykZydx6Uxrpg4MYOM/eFVDMjxM75znHA600XMShWOVA7GgC1NM4+8ct1PNPs7rZIcuSfSsk3LNJtQMamt1TeDLuJ9AePxoA6yO8MuMH5c9a3LYgxjbn6kYzXFrckKu04QHtxiozqc6S4WRgOwBzQB3tFUtJuZLm1V5R82ME+tXaAE3DJHQj1rh/E7hklQ46EV1GpziGQAE7iufw6VwHiO7x5uT2NAHzF8Yn3WN1nrlf/QxXjFeu/FWTzNPuj1GV/wDQxXkVAHvf7GzpF8StRd8YXTZD/wCPpX1druoh4kP3cgmvkT9k0kfEG/wQB/Z0mc+mR/8AWr6B8f6o1hp8zKQPLjwPdj2/WgDyb486yt3eafZROGVFaVvqTgV5Ma2vF1011rMhdtxjREz+HP6msSgAp6UgFTRjkYFAEkQq9AoHXH86ggjz2P4Vpwwu2CsZNACxbuBg/lVrZuyxbHPJNSQQMRlsRjtitFdL2ASO+9T3HAoAq28Hn3UUIDMHOAwHT8K7rSLrStJuVijbexHUJuJPcVysu8p5dviMkj5QME++etXdOPmXKRMCZnIDOo+YD0zQB674e1DyYGk+7zxnqvt9a3orxJ4iWZUHdmNee38kelQQsGL8YCLx/kVy2t+ObkFra0VYIR97uTQBu/Ee2R5N6keWh3M56fQe9cfoWoG3uvN2DDN5YUHgA/561H/bAutMS3upHMckm8MTnYOeTVrT7eIFFj25PALdfqRQB31rrxnlACR+WBgkn0rT0nWbVS/mfeXjbt6DNebxWE00rqH3PGenI4Pep7aWKBRGqvJcg4G1s7/QECgD1b+2kjJ8v5lI4wOn1oULcXClrglTyfYV5f8A2+8RaHcwlBwwJ6H0rb8O63It1i4yIXUbj3FAHpXn6fIPKjuEDqMKvIqFbZJQR5sIHpu5xVNbqweNXsoIpUbncQCT680w6nCP+XaH8uaALwsYo+VliUd/nyTUXmWqOqm4DZ67VqlLqFqww9tEyn+6SDUYntGcAQFUPXY/86AN1ZrYxHy5A2O2DTrKKOSVSw+QHmq1sbbydiQoAee+TV21lTgEBV9KAOw05VFuNmcZ7VaYhRk8CqOmOs0HyvkdMY6VODuRo5WHpkHmgDn/ABFdFn+XoF4x9a818XXZWKQjPQ84ruvEKPDOdzZU9GrgfFNl9rs2YOY36Z7GgD52+JbhtNuAPVc/99CvKq9R+JEbxWV2kow6soP/AH0K8uoA92/ZBQP8Q9TyCQNMkP0+Za9c+MGfsGyM4kkcj04ryv8AYzj8z4jarxkjS5Mf99oP617J8R7LzruFXAKiUD9aAPmbWONTuh6SFfy4qnireqEPqF2y9DM5H5mq6rk0AKozVu1iLngcVHCmT0rVt0LYA4FAFi1t1/iYL9K1ra3Z8IEZgOgqTSNMa5ZDsAT+8ea7rTbGKyVdsXmS44O3/OKAObsdDkIaS4+RE52gVt6fYrPMgucR2eRvB9Pata7USN5k6rGPuhFOAKhisWuHLTfu7cNnHdv8KAGx6fpsMzPDGTGx2r5rcH3H0qxYwadpDq5VGbGOuBVe6cLMEt1VkHqOQPasu9Bih82U53A7eM5P0oAzvFeuT3E0yrhUGeccAe3rXCzzSPuwMMR+dbOsvJMAW3Fm5Pt6CscrzgDk8UAO0cl5WiPJbuea6nQEc3sMb53Ff5HFUvAeli61Xc7KvltwGPB9q6fUrK307VbgXD7REvyon3m7n6dqANPT72OCCZj80gBXIH6Vxkk11BfSXUcwjkYnkDge1b+nS2oMeybKDDMvXGetUNaSG5u2+zkEbscY5+vpQAWdwiZJj3vnJdjlsnr2qzLqKsQS7rjhi3NYkbvFGFQLlT+BP1pqLdXUmYA7nrtXtQB3Oh6p+6TYzqgZlyV5roYbpZUAl3CQEHeD1HpiuS0uyura3jR4iT1KY5/Gtmzs5pX3urIgGQep/CgDQju03fJ8/POetK0zQOZJX2RZGG7t+FVZVh06EyyFo1HIc9TXGaxrzSykRSfKOiv/ADxQB3N34kKbVg2qp65OScVB/wAJ3FaP+8lHuAM15ld6pK1v/pE21i3BXvWA1w89yqpIDlucigD6p8KeKluAskUkcqlckAc12Rv4p4pZk2/IuGGe9fPPwttLsyrKznZhkB6g4r06wkkt4XgG4L/ESeSe5oA09b1KBrHfIOVODiuV1kxnTvMTkMSQD6VNq8gS1CsS5Ljk4xXPa3fAaTtznGcZ9aAPEfjHte0kkAGWC5x7OK8br1b4nT+dpkvOcY/9DFeU0AfQH7Fxx8StUPppb5/7+R17L8Qr5YdUUFsBXLDPrivEv2PphB4/1h+Af7KkwT670rufiNqaTa7w5LqH3e3ynigDxOc5kY9cnOaIkyacwDPxzU0CZI4oAs2cO48jA7+1dZo2lB3XIIXuzDiqOi2HmL5kmAiHkGu90iBplRQpCjGAF4/+vQBNp8O5kSFf3fc45Jrp7C3bICqDjpxVrSNHVFC4wTyxxyK3RFHb/u4VAboT15oAwXsFjCtcKplHIUrnbms29t2mfIICg9OtdTLDub5iW/xqE28afM475xjNAHKxWpgHmyphclUHXJrldcLSTF3znP3fT0rudSBI3MNijIXJ6Z9K4zV9iD5cnnlsUAcVqLMszjcS5JBA5xVBFZmA6D+X41pXpHmsy7m71TDR2+8OMkj1oA674eQKk4YLuJJYn27VL4tH2nWLqWDdufALdhx3/QVm+Fbn9zceReRQbU3NvbGQBwBUWl6ppN9PO2u3kkEO04MYJy3pQBzcNy9neDY3GcZX3robGUXk+xZURxjO4/Kf8awr2MFTPCwktCxw69vr6VFYyncQjhj0BPFAHQawjxSPOGTBYLxwB7j2qx4fe/uLyP7LcRpIvzLuO3Hv7ms+5iBsCpkViuDk8YNZEWoT28iSW8gV1PylT0oA92tLqZFH2srLIBy23BJ78dKq3mrRQmRowue5AB/rXnMfiu+dcSziNguCAODWNfaxO28RTEBuSq8UAdfr2vzvv2Xak54V4Rx9Oa4bUdVvpJiSyH3ESgVmXV5PMcyEk+tV0RywJJUHvQBeme6ugN4Qntgc/lWroWjO1wrT5Azkr0NZ1pOtuTlsHpuxWnYassM6hVdycDrtoA9p029isNOtpbeILHFhDg9O1dPazpqcP2iEgSFcMCMc1xngHVLXVLOaxuURJgMjLDLD+ddfoMUMdy8cU6vjgp34oAxNbd1IiP8ArBn5TXD61dsNPYNw2SOlemeKLSKaBJxhnj43eorgPEdmlzphIwJQThv8aAPDvHUm7Trgd/l/9CFec16D42RksLpXGGBUH/voV59QB6/+zTcvaeKtZkj4b+y5R091P8wK2tSea4vWJBZsMSOp6GsH9m10XxdqSynCvp8i/qD/AErvfEHk2wkMPQgrkDB/GgDzGKPOexrd0Ww+0SYYcDnJqDTrJ3ddoG4ngHmu90fTCqrHgFuC5HbNAFjw/pSyOqhOmOvOK9C0TS1i/eSc/j0qno9qsESjaQM4y3GRXSWS4PI+X0oAsKwHyqCD3x3qbyep/WiMYZmCjA6elS5AJA6dyelAELRjlzyOhI6VQvHwR90KO3qatSyZJAOe2ayL6bAIJxjk5HegDI1B8PvfoD37VxHiCb7ymTcB02j+VdD4hvtiP5bEHr06e1ed6jM9xIwVuB1NAGfd3bbztyQP0rGup2YEnByevpVqchXYE8+npWZM5kBIHI9KAG+Y2Dk9qieQ4ApG+VTk1FnNAGvp11JBCyo2Y2+8p6GpFvjFJzEmAcjaOKyYpMDFSOwwdp60AddPqFlLZh2hZSR2PeuZvSPNIhJ2tyMUWk7lDETwfWnwxrMWQna3ZiOCfSgCMy7WHUDGOOaa8hY/Ln6+lXIbEk/vm2oO4Oc1JJAkQxHICvoRzQBTj8sA79zNTJXOSBwPQdKfMqqxy469MdKrO69m596AEeUgdc0gu2XGOcVHJyB0H0pkCF5VXuTigDvfCV8EkhuVkMToRk46DPP4Yr1LwzeltXudQRDEpQoUz94f3q8m8HWYWdUuF6OU2kdCRwT+NdB4fu57bWLpWBBBIce+aAPStU19VsXEqArkAY69awdSkjfRvPh+67ce1Y2rPJJsjiyd7ZIHatG7j+yaCkDk5Hz8+pFAHivxMUfY5XAA3Af+hCvL69P+JEgbT5VBzgj/ANCFeYUAesfs5xmTxffAHBFm5H6V6ZrOkuHvrpudsbKi9iTwDXmv7NzFfGV6Vxn7G/Jr3LWY8WgdThp2BIHUgZ/rigDhPDejl7rc44QHHfmu+0mxWLG0KCeS1R6LZiCNYwmWbJYnsewrWhwTgdF646UAXbYDzFzjaK1IpFUbQOh9KxoG/eA571chmySAOR096ANXzAByeetVri7VVxnr6VRnuCpEeQWPLe1UZ7lljbJOSeM0AWri7YnHQDmue1O+bdsQnBOCas3MoUBNxEn3m/wrImHmydGBJwB3NAGJfq7na4bnJ9zXM6sVTKR8OBzn+prt7uLyIpCmFJ6sx+6PavNtfkAmKq2R1JoAyp84PBz6niqOdp5JxnkCpp5NyhQxIFUZGOetABO+5iB07VCDig9aSgBwPPFShuM5qEe9PX36UATKxG0ir1kqeYXaQocZwRxVJMqPapLZxu2v36UAbFzIiAMiqox19azp7ssNrFcfSo5pGaLaWJxVJiaAJJH3E5NRkAnk03PvSj3oAfsBGF61csY9soJ654PpVeJ9oqzbSyGQBPvfnQB1Gow3dnNHKqOUnCujg8E/413nhqwj1mGW4Zds0m3ef7retZXhA/2job2+oywNsb9yGIB9x7CvRfBUNt9ilEEIhYHDRj2/mKAMOPSzZ3JWXGcY3nuPas/xk/lW+2MfKB0r0HUIEn8v5Rw3OPpXnfjpWh3knEZzgmgDw3xy26xnP+7/AOhCvPa7/wAZnOnXP1X/ANCFcBQB7B+zLF5vjPURgHFhJyT0r3vUXjgmijbgRr8gA6ep/OvBv2Y22eMNTY8AWD84zjkV65qWrwRXk7E+YxOcAdPagDdhlwuVwsYG4n/E1A15Em4qdzMetcnNqc158rfIp5CKf510OjaRd3irKylU7ORyfoKANG1umcg9FUZJ6VaW6JX93n1Jq3H4enchd5A7gjrSS6BfxAiJRKnfbxQBmNO2OQcHpTRKQckDf05qydGvyWM0UkQ7Z9KX7FsjC4KgHuOTQBnNbl3Ds3TrznFQ3dxHApEK9/vNVvUZ4rdCCRj0PrXI6pq8WyVSA5xtDDgD6CgDP13U1O7O5iDxzxiuA1OUPMxJyK1dUuvMkPJ2+lc7OxdyTQBBK2eBUBFTsM1GRQBGRmm4qTFJigBoFSCmjrR34oAkjPUHFRliG9qPWkGCec0ASbyRzTG5pVIzRwDkUANAzTqUlSMgUmV+lAAxx0p9rKVlUnoD1qNxkDFXNNtPtEjJkA9snrQB2lpGTY8DZGCHZh9DXo3w5vlOmSOpcbSUBbrXnPh3dMBbSsQjwsjZHAI5Fd5oYFpo52fJjt+FAHZQXyyypC5+di2CO/Fch43xPZXER+8vzL+FWrC6MupxBj9yMkHHQn/9VVvGhKs3B5Gc/hQB8++MD/xLLjP+z/6EK4Ku88ZYFldAf3h/6EK4OgD1L4BTNBressis7NYMgC+5FevaF4T1TVZy4gkVXPLMuBj29a4z9jmxjvvH+rRzIrIunM2CM/xqP619nWtjBbD92gz60AeaeF/hutqBNeKJJuo39B9BXb23h6KL7xXAGMAVu0UAUI9LgTkgk1OlpCuMIOKsUUARmCM9UB+vNZup6XZzod1tESeN2MYrWqOZGdcLgH1NAHl/iDwLp9yjFJZ7d25+Rsj8jXmPiL4fatErGyuIblM8Lgq9fRk2kvIxJmXnuVzVSbw2snWc5+lAHxtqml3tm7rcwOhU8k1iOpya+vPEXw1tdXhPnl2fB2lSBivGdW+FF5bXUiQ3AdAeCV60AeSMtMZa9CuvhxqsQyNh+orDvfCOp2w+aLJ9BQByxWm7avXFpNAxEsbKQcVWK0AQ4ppFTFaYRQAwiheDnFOIpMUALkd6Q4x0oNFADcetAAzzig5FGRQBJ8uBgVc00N9pjEeMkiqIORxVm1kdXUoBkHgYoA73ybrRb9XjJaOQblx3z1zXX6fcGXTPOKMGY/MMdOO1cr9qW706yku1Aba20hun19K7/wAP2yyaPAdi+XKCcDv7UAVNHHm3+4cr3qr40nG1+eQK3LHThYO6ocjdnnt7fSuN8Z3H+s/LmgDxzxiQ1hcH1I/9CFcHXc+LD/xLpwP9n/0IVw1AH0T+xN/yULXP+wWf/RsdfZdfGn7E3/JQdc/7BZ/9Gx19l0AFFFFABRRRQAUUUUAFFFFABVO606C4bcygN64q5RQBzeoeH43X92M568VxOveHflciMlunHFetVma5ZG6tSI1BbPPqRQB8weItDJmdY1DOD9c1h3PhJ5IY3SByzDJwuBXv03hh/tm/ys4OenSrY0JSuGjG76UAfLl54Sv41LQxmTHJUdcetYE9rJCxWVGVvRhzX2Fb+FlMpfy+OnSub8TfD+yvkk8y3G49GXgg0AfLLJzTce1eneJPhlqNirzWaNcQDnH8Y/xrhbrS7m3JV4JFI6gqQRQBlYpMEGpXUqcMCKYaAGk00innFIQMcGgBucdKmtpwjjK7h6E1WbIpUH50Ab0l3IYY1C/KrdvQ17t8OJ0uvCVqHVkeMnbnuDXiGhWRvIDxnH617Z4YQWfhy3QjazjJ4oA27pAtzICPlx19OK8k8dOY5pEz34r1GO8W4+092TANeWeP2V7kOOjDHHtQB5R4mOdNn+q/+hCuKrs/Eh/4lk//AAH/ANCFcZQB9D/sUHHxD1nnrph/9GpX2bXxh+xWcfEXVh66c3/oxK+z6ACiiigAooooAKKKKACiiigAooooAKKKKAGmNSeVFN8mP+4KkooAAAOgFV5rSOUHIFWKKAMefR0bnaD7Vyvibwlb3yMZYVLY4IGK9CprorjDAEUAfJ3jjwUbS5ZjCwVjhXAyD/hXneo6JJbk459q+3NW0GC9iZSisD1DCvFviD4KksozNBEXgB5xyV+vtQB85yRMjYYEGmbRiup1nSWRyQhArnLiBomII49aAKrDBqSFCT70uMmpoEO4ccHigDqvBVyiTNBIcbvu8dPWvV5ryOCzhWMqVVQOteJ6JlLnGMnOMV3uo3LLAI93zAYOO3agDovD12JTdsGyH9a4LxhJvDf7JrqPDRAt53X+AE4z7HH864jxVcfM6gn5j1oA4DxGf+JZP9R/6EK46uw8Q/8AILm/4D/6EK4+gD6C/YuIHxI1IHqdPbH/AH2tfaVfFn7F5x8SdR99Pb/0Na+06ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqt/Zx3URV1ByMHI61aooA8S8dfDyMu1zp0YU8/uj0/CvG/EHhp4xtZQrDOQxxj619k3VskyEFQc15d8RPCUWoWj+WoWRclWAzQB8n3FuYJdhIPoQetbfhO3EmqwpKm5M5IPSodfsp7e7lhmi8t0PpS+HrnbMqucMDgZoA2F09I9cIgK+WWJ+X+E55FaV0MsVH3Qc/jWtpGlsbW9u9oLL90459T+lVILZnlVACSx4+lAGjpcZh0SeTG0yNgfhXm/iSQNcED1Jr1fU41ttLEfZQa8f1583TYoA5jxB/yC5vw/8AQhXIV1uvn/iWTf8AAf8A0IVyVAHvn7GrY+Jt0PWycfqK+2K+I/2Om2/Ey6bOALKQmvtmORXGVNAD6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsXWYBJkEcd62qrXse9OlAHi3jfwTb6qrsiBJv4XHrXhLaJcWutSWrxYlGflPrX1/c24+bIFeaeJPCsb+IrTVFGDEfmAHUe9AFWwsRa+H44pwPMMRZ/xGBWTbWAjKzMBwMCt/WryGaRbaJiGk/u84UdKrlVNt5Yxx0oA5bxdceVY7R6eteP6o5aUknk16R41uc7o+1eY37ZagDD13/kGTf8B/8AQhXJ11euf8gyf/gP/oQrlKAPcv2RW2/Ei6P/AE4y/wAq+yrWcqcEjBr8+fhN47Pw+8Svqw0/+0A0LwmHzvK+8CM52t6+lexr+1MVAA8H4x6an/8AaaAPrFJ8dTkVIs6k4zXycP2q27+D8/8AcT/+00v/AA1Y3/Qnf+VT/wC00AfWYlU59hmn18lx/tXFGLf8Idk/9hT/AO01YH7W7Ac+C8/9xX/7TQB9WUV8q/8ADXP/AFJP/lV/+00g/a3wMDwSAPbVf/tNAH1XRXyr/wANc/8AUk/+Vb/7TSH9rg/9CV/5Vf8A7TQB9V0V8qj9rg9/BX/lV/8AtNH/AA1z/wBST/5Vv/tNAH1VRXyr/wANc/8AUk/+Vb/7TR/w1z/1JP8A5Vv/ALTQB9VUV8q/8Nc/9ST/AOVb/wC00f8ADXP/AFJP/lW/+00AfVVFfKv/AA1z/wBST/5Vv/tNH/DXP/Uk/wDlW/8AtNAH1VRXyr/w1z/1JP8A5Vv/ALTR/wANc/8AUk/+Vb/7TQB9VUV8q/8ADXP/AFJP/lW/+00f8Nc/9ST/AOVb/wC00AfVVRzHjFfLP/DXP/Uk/wDlW/8AtNRyfta78/8AFF4/7iv/ANpoA+lp13HNczrsJVXwM9uleEN+1bnp4Nx/3FP/ALTVK7/ae+0dfCGB/wBhP/7VQB280EkN/KZc7t3Gew7VbB2Ws0zn5VBxXjmofHlbty3/AAjOzPUfb8/+06r3vxy+0Wf2dPD3ljuftuf/AGnQBp+KLnc7ljnPNcNdPukNVNR8efbGJ/s4pn/pvn/2Wsd/EW45+y/+RP8A61AFvW/+QZP/AMB/9CFcpWrfav8AarZ4fI27sc7898+lZVAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_5_8275=[""].join("\n");
var outline_f8_5_8275=null;
var title_f8_5_8276="Technique end to side grafting";
var content_f8_5_8276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Technique of end-to-side anastomosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 434px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stitches 1 to 6 are placed in the left internal mammary artery (LIMA) while elevated off the coronary artery (CA) (A). After stitch 6, the suture line is tightened (B) and the remaining sutures are placed (C,D).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_5_8276=[""].join("\n");
var outline_f8_5_8276=null;
var title_f8_5_8277="Isoniazid: Patient drug information";
var content_f8_5_8277=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Isoniazid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     see \"Isoniazid: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/24/38278?source=see_link\">",
"     see \"Isoniazid: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Isotamine&reg;;",
"     </li>",
"     <li>",
"      PMS-Isoniazid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700702",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause hepatitis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat TB (tuberculosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702330",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to isoniazid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703781",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703756",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had liver problems while taking isoniazid in the past.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696832",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 1 hour of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694864",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow a diet plan. Some foods and drinks taken with this drug may cause very risky effects such as sudden high blood pressure. To avoid these problems, get a list of foods to avoid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694534",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid eating foods like aged cheeses and meats, soy sauce, soy beans, Miso soup, Italian green beans (fava beans), snowpea or broad bean pods, sauerkraut, kimchee, yeast extracts (Marmite), red or white wine, and beer including alcohol-free beer. Very bad side effects may happen. Ask your doctor for a list of foods to avoid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695129",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is stopped, follow diet for at least 2 more weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10774 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-218.189.88.190-EF2F3CD7BB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_5_8277=[""].join("\n");
var outline_f8_5_8277=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184784\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027631\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027633\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027632\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027637\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027638\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027640\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027635\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027636\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027641\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027642\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=related_link\">",
"      Isoniazid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/24/38278?source=related_link\">",
"      Isoniazid: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_5_8278="Loratadine: Pediatric drug information";
var content_f8_5_8278=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Loratadine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"    see \"Loratadine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/7/34932?source=see_link\">",
"    see \"Loratadine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alavert&reg; Allergy 24 Hour [OTC];",
"     </li>",
"     <li>",
"      Alavert&reg; Children's Allergy [OTC];",
"     </li>",
"     <li>",
"      Claritin&reg; 24 Hour Allergy [OTC];",
"     </li>",
"     <li>",
"      Claritin&reg; Children's Allergy [OTC];",
"     </li>",
"     <li>",
"      Claritin&reg; Liqui-Gels&reg; 24 Hour Allergy [OTC];",
"     </li>",
"     <li>",
"      Claritin&reg; RediTabs&reg; 24 Hour Allergy [OTC];",
"     </li>",
"     <li>",
"      Loradamed [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F190024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Loratadine&reg;;",
"     </li>",
"     <li>",
"      Claritin&reg;;",
"     </li>",
"     <li>",
"      Claritin&reg; Kids",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"      see \"Loratadine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-5 years: 5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;6 years and Adults: 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal (GFR &lt;30 mL/minute) or hepatic impairment:",
"     </b>",
"     Administer dosage every other day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid gel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin&reg; Liqui-Gels&reg; 24 Hour Allergy: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 5 mg/5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: 5 mg/5 mL (120 mL, 240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin&reg; Children's Allergy: 5 mg/5 mL (60 mL) [dye free, ethanol free; contains propylene glycol, sodium benzoate; fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin&reg; Children's Allergy: 5 mg/5 mL (60 mL, 120 mL) [dye free, ethanol free, sugar free; contains propylene glycol, sodium 6 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alavert&reg; Allergy 24 Hour: 10 mg [dye free, gluten free, sucrose free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin&reg; 24 Hour Allergy: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loradamed: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin&reg; Children's Allergy: 5 mg [contains phenylalanine 1.4 mg/tablet; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alavert&reg; Allergy 24 Hour: 10 mg [dye free, gluten free, sucrose free; contains phenylalanine 8.4 mg/tablet; Citrus Burst&trade; flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alavert&reg; Allergy 24 Hour: 10 mg [dye free, gluten free, sucrose free; contains phenylalanine 8.4 mg/tablet; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alavert&reg; Children's Allergy: 10 mg [dye free, gluten free, sucrose free; contains phenylalanine 8.4 mg/tablet; Citrus Burst&trade; flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alavert&reg; Children's Allergy: 10 mg [dye free, gluten free, sucrose free; contains phenylalanine 8.4 mg/tablet; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin&reg; RediTabs&reg; 24 Hour Allergy: 10 mg [mint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F189988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes capsule, chewable tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer without regard to meals; place Claritin&reg; RediTab&reg; (rapidly disintegrating tablet) on the tongue; tablet disintegration occurs rapidly; may administer with or without water",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of nasal and non-nasal symptoms of allergic rhinitis; treatment of chronic idiopathic urticaria",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6699703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Claritin&reg; may be confused with clarithromycin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Claritin&reg; (loratadine) may be confused with Claritin&trade; Eye (ketotifen)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lorcaserin hydrochloride may be confused with lorcaserin hydrochloride",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - varies based on comorbidity; Strength of recommendation - varies based on comorbidity)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F190073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, malaise, nervousness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, stomatitis, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hyperkinesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: dysphonia, epistaxis, pharyngitis, upper respiratory infection, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal hepatic function, agitation, alopecia, altered lacrimation, altered micturition, altered salivation, altered taste, amnesia, anaphylaxis, angioneurotic edema, anorexia, arthralgia, back pain, blepharospasm, blurred vision, breast enlargement, breast pain, bronchospasm, chest pain, confusion, depression, dizziness, dysmenorrhea, dyspnea, erythema multiforme, hemoptysis, hepatic necrosis, hepatitis, hypotension, impaired concentration, impotence, insomnia, irritability, jaundice, menorrhagia, migraine, nausea, palpitation, paresthesia, paroniria, peripheral edema, photosensitivity, pruritus, purpura, rigors, seizure, supraventricular tachyarrhythmia, syncope, tachycardia, tremor, urinary discoloration, urticaria, thrombocytopenia, vaginitis, vertigo, vomiting, weight gain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to loratadine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use cautiously in patients who are also taking ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, or other drugs which may impair loratadine's hepatic metabolism; although increased plasma levels of loratadine have been observed, no adverse effects with concomitant administration have been reported including QT interval prolongation which has occurred when similar antihistamines, terfenadine and astemizole, were combined with these agents; while less sedating than other antihistamines, loratadine may cause drowsiness and impair ability to perform hazardous activities requiring mental alertness. Use cautiously in breast-feeding women as breast milk levels of loratadine are equivalent to serum levels. Some tablets contain phenylalanine which must be avoided (or used with caution) in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and adjust dosage in patients with severe liver impairment or renal impairment; Claritin&reg; syrup contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites; avoid use in neonates",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F190063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C8 (weak), CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F189997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May increase the serum concentration of Loratadine. Management: Due to reported QT interval prolongation and Torsades de Pointes with this combination, consider an alternative to loratadine when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1059892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration with food increases loratadine's bioavailability by 40%",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12881433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal use of loratadine has not been associated with an increased risk of major malformations. The use of antihistamines for the treatment of rhinitis during pregnancy is generally considered to be safe at recommended doses. Although safety data is limited, loratadine may be the preferred second generation antihistamine for the treatment of rhinitis or urticaria during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Improvement in signs and symptoms of allergic rhinitis or chronic idiopathic urticaria",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1059884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic serum levels (not used clinically): Loratadine: 2.5-100 ng/mL; active metabolite: 0.5-100 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-acting tricyclic antihistamine with selective peripheral histamine H",
"     <sub>",
"      1",
"     </sub>",
"     receptor antagonistic properties",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1059888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &gt;24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid; food increases total bioavailability (AUC) by 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Binds preferentially to peripheral nervous system H",
"     <sub>",
"      1",
"     </sub>",
"     receptors; no appreciable entry into CNS; loratadine and metabolite pass easily into breast milk and achieve concentrations equivalent to plasma levels; breast milk to plasma ratio: 1.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 97% (loratadine), 73% to 77% (metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive first-pass metabolism by cytochrome P450 system to an active metabolite (descarboethoxyloratadine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 8.4 hours (loratadine), 28 hours (metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 80% eliminated via urine &amp; feces as metabolic products",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/7/34932?source=see_link\">",
"      see \"Loratadine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drink plenty of water; may cause dry mouth; may color urine; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; notify physician if fainting episode occurs; avoid alcohol. May rarely cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid direct exposure to sunlight",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lin CC, Radwanski E, Affrime M, et al, &ldquo;Pharmacokinetics of Loratadine in Pediatric Subjects,&rdquo;",
"      <i>",
"       Am J Therapeut",
"      </i>",
"      , 1995, 2:504-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/5/8278/abstract-text/11850699 /pubmed\" id=\"11850699 \" target=\"_blank\">",
"        11850699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Luck JC and Evrard HM, &ldquo;Atrial Fibrillation Associated With Loratadine Use,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1995, 95(2):282.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lutsky BN, Klose P, Melon J, et al, &ldquo;A Comparative Study of the Efficacy and Safety of Loratadine Syrup and Terfenadine Suspension in the Treatment of 3 to 6 Year Old Children With Seasonal Allergic Rhinitis,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 1993, 15(5):855-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/5/8278/abstract-text/8269452/pubmed\" id=\"8269452\" target=\"_blank\">",
"        8269452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salmun LM, Herron JM, Banfield C, et al, &ldquo;The Pharmacokinetics, Electrocardiographic Effects, and Tolerability of Loratadine Syrup in Children Aged 2 to 5 Years,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2000, 22(5):613-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/5/8278/abstract-text/10868558 /pubmed\" id=\"10868558 \" target=\"_blank\">",
"        10868558",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12563 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-24A2ECD58B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_5_8278=[""].join("\n");
var outline_f8_5_8278=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190023\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190024\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059881\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059874\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190002\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189988\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059886\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059885\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6699703\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190073\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059890\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059873\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059872\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190063\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189997\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059892\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12881433\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059880\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059884\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059871\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059888\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059889\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059879\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12563\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12563|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=related_link\">",
"      Loratadine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/7/34932?source=related_link\">",
"      Loratadine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_5_8279="Irritable bowel syndrome in patients with inflammatory bowel disease";
var content_f8_5_8279=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Irritable bowel syndrome in patients with inflammatory bowel disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/5/8279/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/5/8279/contributors\">",
"     Richard P MacDermott, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/5/8279/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/5/8279/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/5/8279/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/5/8279/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/5/8279/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7353724\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A challenge in the care of patients with chronic inflammatory bowel disease (IBD) is differentiating gastrointestinal (GI) tract symptoms due to irritable bowel syndrome (IBS) from those due to residual inflammation from IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. IBS symptoms are more prevalent in patients with chronic IBD compared to control groups; 39 percent versus 8 percent in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/6\">",
"     6",
"    </a>",
"    ]. Coexistent IBS in the IBD patient can lead to significant impairment in quality of life, anxiety, and depression, as well as unhealthy coping strategies and increased use of health care resources [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. Furthermore, it can also lead to the increased use of IBD medications, with their potential side effects. Therefore, it is important to be able to recognize IBS in patients with IBD and also to use treatment approaches that are both practical and effective.",
"   </p>",
"   <p>",
"    This topic reviews the approach to recognizing symptoms of IBS in patients with IBD as well as their diagnosis and management. The clinical symptoms, diagnosis, and management of IBS in general are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=see_link\">",
"     \"Clinical manifestations and diagnosis of irritable bowel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=see_link\">",
"     \"Treatment of irritable bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6829220\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) can overlap. However, there are some clinical characteristics that can help differentiate between them:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal pain is increased in patients who have both IBS and IBD because the perception of pain can be increased due to hypersensitivity to painful stimuli. Abdominal pain due to IBS is often cramping, diffuse, and relieved by a bowel movement, while abdominal pain due to IBD is often constant, in a specific location, and not relieved by a bowel movement.",
"     </li>",
"     <li>",
"      Watery diarrhea is common in both IBS and active Crohn's disease. However, bloody diarrhea is consistent with active ulcerative colitis, and does not occur in IBS.",
"     </li>",
"     <li>",
"      Excess gas, bloating, heartburn, and dyspeptic symptoms are more likely to be due to IBS, rather than IBD.",
"     </li>",
"     <li>",
"      Nausea, vomiting, fever, and chills are more likely to be associated with IBD, rather than IBS.",
"     </li>",
"     <li>",
"      Weight loss is common in active IBD, but is uncommon in IBS. Nevertheless, patients with severe IBS can lose weight due to fear of eating.",
"     </li>",
"     <li>",
"      Constipation may occur in active left-sided ulcerative colitis or in IBS; these may be difficult to distinguish.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6829227\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnoses other than irritable bowel syndrome (IBS) should be considered when patients with inflammatory bowel disease (IBD) present with an exacerbation of their symptoms.",
"   </p>",
"   <p>",
"    The differential diagnoses of diarrhea in patients with IBD include infections such as",
"    <em>",
"     Clostridium difficile",
"    </em>",
"    (",
"    <em>",
"     C. difficile",
"    </em>",
"    ) or cytomegalovirus (CMV). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13722?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent hosts\", section on 'Gastrointestinal manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diarrhea in patients with IBD may also be due to coexistent diseases such as gluten sensitive enteropathy or bile acid malabsorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with Crohn's disease, small bowel bacterial overgrowth (SBO) may be a cause for diarrhea, especially in the presence of strictures, fistulae, or a blind loop. Studies have also demonstrated impaired propulsive function",
"    <sup>",
"    </sup>",
"    in inactive Crohn's disease that may result in stasis and SBO [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11990?source=see_link\">",
"     \"Clinical manifestations and diagnosis of small intestinal bacterial overgrowth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pancreatic insufficiency should also be considered when patients with IBD without significant ileal resection appear to be in remission, and have features of steatorrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30935?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Involvement of the rectum and perianal structures with fistulae in IBD may lead to pelvic floor dysfunction (PFD) in patients with IBD. This may cause urgency and overflow diarrhea, abdominal or pelvic pain, and bloating [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with IBD and severe abdominal pain, obstruction, abscesses, and fistulae should be considered.",
"   </p>",
"   <p>",
"    In postsurgical patients with an ileal pouch-anal anastomosis (IPAA), it is important to consider a diagnosis of irritable pouch syndrome (IPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32759?source=see_link&amp;anchor=H1121783413#H1121783413\">",
"     \"Pouchitis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6829234\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with inflammatory bowel disease (IBD), the presence of diarrhea, urgency, and pain in the absence of significant inflammation may result from specific diseases as discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/17\">",
"     17",
"    </a>",
"    ]. The first step in the evaluation of symptomatic patients with IBD is to exclude an infection with cytomegalovirus (CMV) or",
"    <em>",
"     C. difficile",
"    </em>",
"    , and to confirm that the inflammatory process is sufficiently controlled and unlikely to be the cause of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6829241\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cell count, hematocrit, and platelet count [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/18\">",
"     18",
"    </a>",
"    ] are more consistent with irritable bowel syndrome (IBS) rather than active IBD. In contrast, significantly abnormal blood work results are not consistent with IBS, but rather more likely to be associated with active IBD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6829248\">",
"    <span class=\"h2\">",
"     Stool studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stool evaluation for",
"    <em>",
"     C. difficile",
"    </em>",
"    toxin and CMV culture, in addition to routine stool cultures, microscopy for ova and parasites, and stool Giardia antigen, are important to exclude a concurrent infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link&amp;anchor=H15443551#H15443551\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\", section on 'Laboratory diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated levels of fecal calprotectin and fecal lactoferrin have been demonstrated to be very helpful in discriminating IBD from IBS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Studies have reported a sensitivity and specificity of calprotectin ranging from 64 to 100 and 80 percent, respectively. The sensitivity and specificity of fecal lactoferrin is 80 and 78 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6829255\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopy allows for an assessment of the extent and activity of both colitis and terminal ileitis.",
"   </p>",
"   <p>",
"    Biopsies can also be obtained to rule out infection with CMV. CMV gastrointestinal disease is characterized histologically by mucosal inflammation, tissue necrosis, and vascular endothelial involvement. Characteristically, cytomegalic cells (large cells containing eosinophilic intranuclear and frequently basophilic intracytoplasmic inclusions) are present in mucosal biopsies stained with hematoxylin and eosin (",
"    <a class=\"graphic graphic_picture graphicRef52984 \" href=\"UTD.htm?33/6/33893\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6829262\">",
"    <span class=\"h2\">",
"     Radiologic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a colonoscopy has excluded active colitis or terminal ileitis, approaches to image the small bowel include small bowel follow through (SBFT), capsule endoscopy, abdominal computed tomography (CT) scan, CT enterography, and magnetic resonance (MR) enterography. These tests are considered when there is residual concern for active inflammation (because of serum or stool studies or suggestive clinical features) and a normal colonoscopy.",
"   </p>",
"   <p>",
"    MR and CT enterography have high sensitivities for detecting active small bowel inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/21\">",
"     21",
"    </a>",
"    ]. MR enterography has the advantage of avoiding radiation exposure and better characterization of stenotic lesions. CT enterography has the advantage of better temporal resolution, mesenteric imaging, and shorter length of examination [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6829269\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6829276\">",
"    <span class=\"h2\">",
"     Dietary modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory bowel disease (IBD) patients have a chronically inflamed gastrointestinal tract, which leads to increased visceral hyper-responsiveness and hypersensitivity to foods and beverages, which can worsen gastrointestinal (GI) symptoms due to irritable bowel syndrome (IBS) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. Because many of the GI symptoms in patients with IBS in IBD are induced by multiple food and beverage intolerances, dietary modification is our first step in the management of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/27-35\">",
"     27-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A careful dietary history may reveal patterns of symptoms related to specific foods. It is important to note that the effects of many foods and beverages can be amount-dependent, delayed, additive, and cumulative [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/27-35\">",
"     27-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6829283\">",
"    <span class=\"h3\">",
"     Exclusion of foods associated with diarrhea, bloating, and cramping",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many foods and beverages that frequently cause diarrhea, abdominal cramping, gas, and bloating (",
"    <a class=\"graphic graphic_table graphicRef73175 \" href=\"UTD.htm?16/29/16860\">",
"     table 1",
"    </a>",
"    ). Milk products frequently cause diarrhea and abdominal cramping even in the absence of lactose deficiency. This is because milk contains many other substances in addition to lactose, including fats, proteins, sugars, and immunoglobulins, which may stimulate the GI tract. While skim milk and lactose free products will help some patients tolerate milk, for many patients, switching to soy",
"    <span class=\"nowrap\">",
"     milk/products",
"    </span>",
"    or rice",
"    <span class=\"nowrap\">",
"     milk/products",
"    </span>",
"    provides much more relief. These patients should avoid all forms of dairy and foods that contain milk products [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/27-35\">",
"     27-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A diet low in fermentable oligo-, di-, and monosaccharides and polyols (FODMAP) may help IBS symptoms (but not constipation) in the setting of inflammatory bowel disease, with a 50 percent rate of improvement in uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of irritable bowel syndrome\", section on 'Carbohydrate malabsorption'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For each type of food that causes symptoms, appropriate substitutes and alternatives are available (",
"    <a class=\"graphic graphic_table graphicRef82005 \" href=\"UTD.htm?0/33/540\">",
"     table 2",
"    </a>",
"    ). The foods and beverages that cause symptoms differ between patients and thus the approach must be individualized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6829290\">",
"    <span class=\"h3\">",
"     Food allergies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of food allergy in IBS is unclear. While it is possible that food allergy has a role in the development of symptoms, there are no reliable means to identify such individuals. Testing for serum immunoglobulins directed at specific dietary antigens (and elimination of responsible foods) has been proposed. However, the relationship between results of testing and improvement of symptoms requires validation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/37\">",
"     37",
"    </a>",
"    ]. Other methods used in evaluating food allergies (eg, skin prick testing, RAST testing, and atopy patch testing) have not been well studied in IBS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6829297\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic medications for diarrhea, cramping, and constipation should be initiated if symptoms persist after the patient has learned to avoid the foods and beverages to which they are intolerant.",
"   </p>",
"   <p>",
"    The addition of symptomatic medications for IBS can add to the complexity of the patient's medical regimen and may lead to decreased compliance.",
"   </p>",
"   <p>",
"    New medications should be started at low doses in order to achieve gradual changes in symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6829304\">",
"    <span class=\"h3\">",
"     Diarrhea",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For outpatients with chronic IBD and IBS who have severe diarrhea, antidiarrheal medications such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"       loperamide",
"      </a>",
"      can be helpful (titrating the dose and using it regularly to prevent diarrhea). As an alternative or add-on therapy, a low-dose tricyclic antidepressant at bedtime (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"       desipramine",
"      </a>",
"      ) can be very helpful. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=see_link&amp;anchor=H16#H16\">",
"       \"Treatment of irritable bowel syndrome\", section on 'Antidiarrheal agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who have had a cholecystectomy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      extensive resection(s) of the terminal ileum may have bile salt-induced diarrhea and may benefit from empiric therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"       cholestyramine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/26/12710?source=see_link\">",
"       colestipol",
"      </a>",
"      as a bile salt binding agent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8279/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6829311\">",
"    <span class=\"h3\">",
"     Abdominal pain and cramping",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For outpatients with chronic IBD and IBS who have increased severe cramping, the use of antispasmodic medications such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/6/27749?source=see_link\">",
"       dicyclomine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/9/29846?source=see_link\">",
"       hyoscyamine",
"      </a>",
"      , and others are also often useful. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=see_link&amp;anchor=H14#H14\">",
"       \"Treatment of irritable bowel syndrome\", section on 'Antispasmodic agents'",
"      </a>",
"      .) An alternative is a low-dose tricyclic antidepressant, or a selective serotonin reuptake inhibitor (SSRI).",
"     </li>",
"     <li>",
"      Narcotics should be avoided in patients with IBD. Chronic use of narcotics can conceal complications of IBD such as a perforation or abscess formation, and has been found to be associated with toxic megacolon, increased rate of infections, and increased mortality. Patients who chronically use large amounts of narcotics can also develop narcotic bowel syndrome, which can mimic small bowel obstruction.",
"      <br/>",
"      <br/>",
"      Patients with both IBS and IBD can often become narcotic dependent. A history of illicit drug use, alcohol abuse, stress, anxiety, depression, physical abuse, mental abuse,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sexual abuse is common in IBD patients with narcotic dependence. Therefore, the ideal approach is to work with a specialist in pain management in an attempt to avoid narcotic medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6829318\">",
"    <span class=\"h3\">",
"     Constipation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For outpatients with chronic IBD and IBS, who have severe constipation, fiber (starting at a low dose, titrating up slowly, and preferably with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8614?source=see_link\">",
"       psyllium",
"      </a>",
"      containing fiber supplement)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/19/23860?source=see_link\">",
"       polyethylene glycol 3350",
"      </a>",
"      can be helpful. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=see_link\">",
"       \"Treatment of irritable bowel syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6829325\">",
"    <span class=\"h3\">",
"     Psychiatric symptoms",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For",
"      <span class=\"nowrap\">",
"       stress/anxiety/depressive",
"      </span>",
"      symptoms, appropriate use of antidepressants and anxiolytics can also be helpful, although gastrointestinal side effects due to the antidepressants are very common, particularly in patients with both IBS and IBD. Lower doses of these agents may be better tolerated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=see_link&amp;anchor=H12#H12\">",
"       \"Treatment of irritable bowel syndrome\", section on 'Psychosocial therapies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Additional approaches include cognitive therapy, biofeedback, and stress relaxation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=see_link\">",
"       \"Treatment of irritable bowel syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1121782493\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Irritable bowel syndrome (IBS) symptoms occur with increased frequency and severity in patients with chronic inflammatory bowel (IBD). The clinical manifestations of IBS and IBD overlap, with some distinguishing clinical characteristics. (See",
"      <a class=\"local\" href=\"#H6829220\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first steps in the evaluation of symptomatic patients with IBD is to exclude an infection with cytomegalovirus (CMV) or",
"      <em>",
"       Clostridium difficile",
"      </em>",
"      (",
"      <em>",
"       C. difficile",
"      </em>",
"      ) and to confirm that the inflammatory process is sufficiently controlled and unlikely to be the cause of symptoms.",
"      <br/>",
"      <br/>",
"      Laboratory testing (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and complete blood count), stool studies (stool cultures including CMV,",
"      <em>",
"       C. difficile",
"      </em>",
"      toxin assay, stool evaluation for ova and parasites, Giardia antigen, fecal calprotectin), and endoscopy are usually needed to determine if the patient's symptoms are due to residual inflammation or enteral infection. (See",
"      <a class=\"local\" href=\"#H6829234\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In symptomatic patients with IBD in remission in whom a concurrent infection has been excluded it is important to consider other etiologies including celiac disease, bile acid malabsorption, bacterial overgrowth, chronic pancreatitis, and pelvic floor dysfunction. (See",
"      <a class=\"local\" href=\"#H6829227\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A large percentage of these patients have IBS that can be managed symptomatically.",
"      <br/>",
"      <br/>",
"      We suggest dietary modification as the first step in treating IBD patients with IBS (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This involves identifying, avoiding, and substituting the foods and beverages that induce IBS symptoms (",
"      <a class=\"graphic graphic_table graphicRef73175 \" href=\"UTD.htm?16/29/16860\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef82005 \" href=\"UTD.htm?0/33/540\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6829276\">",
"       'Dietary modification'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Symptomatic medications for diarrhea, cramping, and constipation should be initiated if symptoms persist after the patient has learned to avoid the foods and beverages to which they are intolerant. (See",
"      <a class=\"local\" href=\"#H6829297\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/1\">",
"      Bayless TM, Harris ML. Inflammatory bowel disease and irritable bowel syndrome. Med Clin North Am 1990; 74:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/2\">",
"      Annese V, Bassotti G, Napolitano G, et al. Gastrointestinal motility disorders in patients with inactive Crohn's disease. Scand J Gastroenterol 1997; 32:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/3\">",
"      Pezzone MA, Wald A. Functional bowel disorders in inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/4\">",
"      Ginsburg PM, Bayless TM. Managing Functional Disturbances in Patients with Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2005; 8:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/5\">",
"      Isgar B, Harman M, Kaye MD, Whorwell PJ. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983; 24:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/6\">",
"      Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2012; 107:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/7\">",
"      Simr&eacute;n M, Axelsson J, Gillberg R, et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002; 97:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/8\">",
"      Minderhoud IM, Oldenburg B, Wismeijer JA, et al. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci 2004; 49:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/9\">",
"      Farrokhyar F, Marshall JK, Easterbrook B, Irvine EJ. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis 2006; 12:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/10\">",
"      Jones MP, Wessinger S, Crowell MD. Coping strategies and interpersonal support in patients with irritable bowel syndrome and inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/11\">",
"      Barratt SM, Leeds JS, Robinson K, et al. Reflux and irritable bowel syndrome are negative predictors of quality of life in coeliac disease and inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011; 23:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/12\">",
"      Crowell MD, Lacy BE, Schettler VA, et al. Subtypes of anal incontinence associated with bowel dysfunction: clinical, physiologic, and psychosocial characterization. Dis Colon Rectum 2004; 47:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/13\">",
"      Shen B, Achkar JP, Lashner BA, et al. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol 2002; 97:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/14\">",
"      Schmidt C, H&auml;user W, Giese T, Stallmach A. Irritable pouch syndrome is associated with depressiveness and can be differentiated from pouchitis by quantification of mucosal levels of proinflammatory gene transcripts. Inflamm Bowel Dis 2007; 13:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/15\">",
"      Shen B, Liu W, Remzi FH, et al. Enterochromaffin cell hyperplasia in irritable pouch syndrome. Am J Gastroenterol 2008; 103:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/16\">",
"      Shen B, Sanmiguel C, Bennett AE, et al. Irritable pouch syndrome is characterized by visceral hypersensitivity. Inflamm Bowel Dis 2011; 17:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/17\">",
"      Camilleri M. Managing symptoms of irritable bowel syndrome in patients with inflammatory bowel disease. Gut 2011; 60:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/18\">",
"      Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/19\">",
"      Otten CM, Kok L, Witteman BJ, et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med 2008; 46:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/20\">",
"      Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Intern Med 1993; 119:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/21\">",
"      Siddiki HA, Fidler JL, Fletcher JG, et al. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol 2009; 193:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/22\">",
"      Fletcher JG, Huprich J, Loftus EV Jr, et al. Computerized tomography enterography and its role in small-bowel imaging. Clin Gastroenterol Hepatol 2008; 6:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/23\">",
"      Collins SM, Piche T, Rampal P. The putative role of inflammation in the irritable bowel syndrome. Gut 2001; 49:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/24\">",
"      Bradesi S, McRoberts JA, Anton PA, Mayer EA. Inflammatory bowel disease and irritable bowel syndrome: separate or unified? Curr Opin Gastroenterol 2003; 19:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/25\">",
"      Quigley EM. Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases? Chin J Dig Dis 2005; 6:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/26\">",
"      Grover M, Herfarth H, Drossman DA. The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. Clin Gastroenterol Hepatol 2009; 7:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/27\">",
"      Nanda R, James R, Smith H, et al. Food intolerance and the irritable bowel syndrome. Gut 1989; 30:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/28\">",
"      Friedman G. Diet and the irritable bowel syndrome. Gastroenterol Clin North Am 1991; 20:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/29\">",
"      Gertner D, Powell-Tuck J. Irritable bowel syndrome and food intolerance. Practitioner 1994; 238:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/30\">",
"      Simr&eacute;n M, M&aring;nsson A, Langkilde AM, et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 2001; 63:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/31\">",
"      Burden S. Dietary treatment of irritable bowel syndrome: current evidence and guidelines for future practice. J Hum Nutr Diet 2001; 14:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/32\">",
"      Floch MH, Narayan R. Diet in the irritable bowel syndrome. J Clin Gastroenterol 2002; 35:S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/33\">",
"      Dapoigny M, Stockbr&uuml;gger RW, Azpiroz F, et al. Role of alimentation in irritable bowel syndrome. Digestion 2003; 67:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/34\">",
"      Lea R, Whorwell PJ. The role of food intolerance in irritable bowel syndrome. Gastroenterol Clin North Am 2005; 34:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/35\">",
"      MacDermott RP. Treatment of irritable bowel syndrome in outpatients with inflammatory bowel disease using a food and beverage intolerance, food and beverage avoidance diet. Inflamm Bowel Dis 2007; 13:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/36\">",
"      Gearry RB, Irving PM, Barrett JS, et al. Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study. J Crohns Colitis 2009; 3:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/37\">",
"      Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004; 53:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8279/abstract/38\">",
"      Hofmann AF, Poley JR. Cholestyramine treatment of diarrhea associated with ileal resection. N Engl J Med 1969; 281:397.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15930 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.123.134.1-8BED796ECD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_5_8279=[""].join("\n");
var outline_f8_5_8279=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1121782493\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7353724\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6829220\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6829227\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6829234\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6829241\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6829248\">",
"      Stool studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6829255\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6829262\">",
"      Radiologic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6829269\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6829276\">",
"      Dietary modification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6829283\">",
"      - Exclusion of foods associated with diarrhea, bloating, and cramping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6829290\">",
"      - Food allergies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6829297\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6829304\">",
"      - Diarrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6829311\">",
"      - Abdominal pain and cramping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6829318\">",
"      - Constipation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6829325\">",
"      - Psychiatric symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1121782493\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/15930\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/15930|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/6/33893\" title=\"picture 1\">",
"      CMV esophagitis Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/15930|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/29/16860\" title=\"table 1\">",
"      Food intolerances IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/33/540\" title=\"table 2\">",
"      Foods better tolerated",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30935?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=related_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11990?source=related_link\">",
"      Clinical manifestations and diagnosis of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13722?source=related_link\">",
"      Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32759?source=related_link\">",
"      Pouchitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=related_link\">",
"      Treatment of irritable bowel syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_5_8280="Gell Coombs IVa-d";
var content_f8_5_8280=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F75626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F75626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 628px\">",
"   <div class=\"ttl\">",
"    T cell mediated hypersensitivity reactions (Gell and Coombs types IVa-d)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 608px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Celik, G, Pichler, WJ, Adkinson, NF Jr. Drug Allergy. In: Middleton's Allergy Principles &amp; Practice, 7th ed, Adkinson, NF, et al (Ed), Mosby Elsevier, Philadelphia 2009. p. 1205-1226. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_5_8280=[""].join("\n");
var outline_f8_5_8280=null;
var title_f8_5_8281="External cephalic version";
var content_f8_5_8281=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   External cephalic version",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/5/8281/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/5/8281/contributors\">",
"     G Justus Hofmeyr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/5/8281/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/5/8281/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/5/8281/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/5/8281/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/5/8281/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;External cephalic version (ECV) refers to a procedure in which the fetus is rotated from the breech to the cephalic presentation by manipulation through the mother's abdomen (",
"    <a class=\"graphic graphic_figure graphicRef63535 \" href=\"UTD.htm?20/38/21092\">",
"     figure 1",
"    </a>",
"    ). ECV is typically performed in nonlaboring women at or near term to improve their chances of having a vaginal cephalic birth.",
"   </p>",
"   <p>",
"    Several national organizations recommend ECV. For example, the Royal College of Obstetricians and Gynaecologists (RCOG) states that a skilled service for ECV should be available and offered to women with breech presentation at term [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/1\">",
"     1",
"    </a>",
"    ]. Likewise, the American College of Obstetricians and Gynecologists (ACOG) states that all women near term with breech presentation should be offered an attempt at version [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/2\">",
"     2",
"    </a>",
"    ]. ECV is also recommended by clinical guidelines of the Royal Dutch Organization for Midwives (KNOV) and the Dutch Society for Obstetrics and Gynaecology (NVOG).",
"   </p>",
"   <p>",
"    This topic will discuss the procedure for ECV. The causes, diagnosis, management, and outcome of breech presentation are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13448?source=see_link\">",
"     \"Overview of breech presentation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of ECV is based on its ability to increase the proportion of fetuses in cephalic presentation at the onset of labor and decrease the frequency of cesarean delivery. The effectiveness of ECV was illustrated by a systematic review of seven randomized trials of ECV at term [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/3\">",
"     3",
"    </a>",
"    ]. Compared with women with breech fetuses who had no attempt at ECV, women who attempted ECV had a significant reduction in both noncephalic births (relative risk [RR] 0.46, 95% confidence interval [CI] 0.31-0.66) and cesarean delivery (RR 0.63, 95% CI 0.44-0.90) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/3\">",
"     3",
"    </a>",
"    ]. Although ECV decreased the frequency of cesarean delivery compared with no ECV, studies have shown that the cesarean delivery rate after successful ECV remains higher than in the general obstetrical population:",
"   </p>",
"   <p>",
"    A meta-analysis reported that women with successful ECV had a cesarean delivery rate of 28 percent, which was significantly higher than the 13 percent in women with cephalic-presenting fetuses and no ECV [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/4\">",
"     4",
"    </a>",
"    ]. The excess risk of cesarean delivery was due to both dystocia and nonreassuring fetal heart rate patterns. Subsequent studies have confirmed these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no clear explanation for the increased frequency of dystocia after successful ECV. One theory is that factors common to both breech presentation and successful ECV, such as an unengaged presenting part or small maternal pelvis, are also risk factors for dystocia. Parity also plays a role in risk of dystocia. Multiparous women are more likely than nulliparas to give birth vaginally after successful ECV [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FACTORS ASSOCIATED WITH REDUCED SUCCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors thought to impede spontaneous version are also those that make ECV less likely to succeed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nulliparity [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/9-15\">",
"       9-15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anterior placenta [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/10,13,14,16\">",
"       10,13,14,16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lateral or cornual placenta [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Decreased amniotic fluid volume [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/14,16,18,19\">",
"       14,16,18,19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Low birthweight [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Descent of the breech into the pelvis [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/15,18,20\">",
"       15,18,20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Maternal obesity [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/14,15,18\">",
"       14,15,18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Posteriorly located fetal spine [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/18,21\">",
"       18,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Firm maternal abdominal muscles [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Frank breech presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/14,21\">",
"       14,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Ruptured membranes",
"     </li>",
"     <li>",
"      Tense uterus [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fetal head not palpable [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, rotation of fetuses in oblique or transverse lie is easier than for those in breech presentation since only small degrees of rotation are needed and these lies are inherently unstable, but there is a tendency for the nonlongitudinal lie to recur. For this reason, after successful ECV of a nonlongitudinal lie, some clinicians perform amniotomy to stabilize the lie, and then induce labor, which has been called a 'stabilizing induction.' In meta-analysis, additional predictors of success were posterior placental location (OR 1.9, 95% CI 1.5-2.4), complete breech position (OR 2.3, 95% CI 1.9-2.8) and an amniotic fluid index &gt; 10 (OR 1.8, 95% CI 1.5-2.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Black race appears to increase the chance of successful ECV [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. One possible explanation for this finding is that in blacks there is a tendency for the presenting part to remain high until the onset of labor, and descent of the presenting part into the pelvis makes ECV more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective study, neither ultrasound-estimated fetal weight, nor birthweight when birth occurred within a week of the procedure, was found to be associated with ECV success rate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of studies of ECV performed after 36 weeks (84 studies and 12,955 women) concluded that serious adverse maternal and fetal outcomes after ECV were infrequent (",
"    <a class=\"graphic graphic_table graphicRef64649 \" href=\"UTD.htm?21/9/21659\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pooled complication rate was 6.1 percent (95% CI 4.7-7.8) and included stillbirth, abruption, emergency cesarean delivery, cord prolapse, transient abnormal fetal heart rate changes, vaginal bleeding, rupture of membranes, and fetomaternal transfusion.",
"     </li>",
"     <li>",
"      Serious complications (stillbirth [12 cases], abruption [11 cases]) occurred in 23 cases: pooled risk 0.24 percent (95% CI 0.17-0.34).",
"     </li>",
"     <li>",
"      The pooled risk of fetal death was 0.19 percent (95% CI 0.12-0.27). Only 2 of the 12 deaths were attributed to the procedure; the remainder were unrelated or unexplained. The procedure-related risk of fetal death was about 1 per 5000 attempts at ECV.",
"     </li>",
"     <li>",
"      The pooled risk of abruption was 0.18 percent (95% CI 0.12-0.26) or 1 in 1200 ECVs.",
"     </li>",
"     <li>",
"      Emergency cesarean delivery was performed in 49 cases: pooled risk 0.35 percent (95% CI 0.26-0.47) or 1 in 286 ECVs.",
"     </li>",
"     <li>",
"      There was no definite correlation between the risk of complications and whether or not the ECV was successful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There were several limitations to this analysis. As an example, there were significant differences among studies in design, patient populations, ECV techniques, and",
"    <span class=\"nowrap\">",
"     ascertainment/definition",
"    </span>",
"    of outcomes. Since many studies did not determine relevant outcomes among women with breech presentation who did not have an ECV, a reliable comparison of the risk of ECV versus expectant management could not be performed. In addition, there was no assessment of maternal satisfaction, including degree of discomfort and, possibly, negative psychological effects in the event of failure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. However, the results were comparable to those in the largest single study, a series of 805 consecutive version attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials have been too small to determine whether the overall risk of perinatal mortality is significantly increased or decreased after ECV compared with other approaches. In a systematic review of these trials, perinatal death occurred in 1 of 524 babies in the attempted ECV group and 4 of 529 babies in the group of breeches that did not undergo ECV (RR perinatal death 0.34, 95% CI 0.05-2.12) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In conclusion, the small risk of the procedure-related complications must be weighed against the risk associated with persistent breech presentation, including cord prolapse, probable cesarean delivery, and complications of breech birth (whether vaginal or cesarean). Cesarean delivery is associated with well-described maternal risks, but also risks to the baby, such as transient tachypnea of the newborn and trauma during delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/32\">",
"     32",
"    </a>",
"    ]. Even with scheduled cesarean delivery, complications may result from precipitate labor, leading to vaginal breech birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21449?source=see_link\">",
"     \"Cesarean delivery: Postoperative issues\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ALTERNATIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of alternatives to ECV. These include expectant management, postural maneuvers to facilitate spontaneous version, moxibustion and acupuncture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Expectant management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options include expectant management and cesarean delivery (scheduled or unscheduled) of a persistently breech fetus or expectant management and trial of labor of a persistently breech fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13448?source=see_link\">",
"     \"Overview of breech presentation\"",
"    </a>",
"    .) In one study, the rate of spontaneous cephalic version following a failed ECV attempt was 6.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/14\">",
"     14",
"    </a>",
"    ]. For this reason, a case can be made for delaying cesarean delivery until late pregnancy or early labor. Risks associated with delaying cesarean delivery include complications of persistent breech presentation, such as cord prolapse or precipitate labor. There are insufficient data to weigh these potential benefits and risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Postural maneuvers to facilitate spontaneous version",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no high quality evidence that maternal postural changes facilitate spontaneous version, but data are limited. A systematic review including six randomized and quasi-randomized trials involving a total of 417 women found that, compared with no intervention, maternal postural management had no significant effect on the rate of noncephalic births, either for the subgroup in which no ECV was attempted or for the group overall (RR 0.98, 95% CI 0.84-1.15) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/33\">",
"     33",
"    </a>",
"    ]. Postural management included techniques such as pelvic elevation using a knee-chest position with or without a full bladder [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/34,35\">",
"     34,35",
"    </a>",
"    ] and a supine head-down position with the pelvis supported by a wedge-shaped cushion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Moxibustion and acupuncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moxibustion refers to a type of Chinese medicine in which an herb is burnt close to the skin of the acupuncture point Bladder 67 (BL67) (Chinese name Zhiyin), located at the tip of the fifth toe. It has been proposed as a means of correcting breech presentation and has been used alone and with acupuncture. The procedure is performed for 20 to 60 minutes, once or twice per day, from twice per week to daily for one to two weeks.",
"   </p>",
"   <p>",
"    A systematic review including eight randomized and quasi-randomized trials (n = 1346 subjects) compared moxibustion alone or with other maneuvers versus observation alone and versus other maneuvers in women with a singleton breech fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/37\">",
"     37",
"    </a>",
"    ]. Moxibustion did not result in a statistically significant reduction in noncephalic presentation at birth compared with no treatment (RR 0.90, 95% CI 0.67-1.19). However, when combined with acupuncture or postural techniques, there was a reduction in noncephalic presentation at birth and cesarean delivery. There were no serious adverse events, although some women complained of pain, nausea, or an unpleasant odor. Given the significant heterogeneity among the trials, we feel there are insufficient data to recommend for or against use of moxibustion for version of the nonvertex fetus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COST-EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECV has been reported to be cost-effective in studies from the United States and United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/2\">",
"     2",
"    </a>",
"    ]. In one such study, ECV was cost-effective when compared to a scheduled cesarean delivery for breech presentation when the probability of successful ECV was greater than 32 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, ECV is offered to women with a noncephalic fetal lie to improve their chances of having a vaginal cephalic birth.",
"   </p>",
"   <p>",
"    There is no general consensus about contraindications to ECV and no strong evidence on which to base recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/39\">",
"     39",
"    </a>",
"    ]. Based primarily on expert opinion, ECV is contraindicated in the following settings, which are associated with a low likelihood of successful version or increased risk of fetal harm from the procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indications for cesarean delivery irrespective of fetal presentation (eg, placenta previa)",
"     </li>",
"     <li>",
"      Oligohydramnios or ruptured membranes",
"     </li>",
"     <li>",
"      Nonreassuring fetal monitoring test results",
"     </li>",
"     <li>",
"      Hyperextended fetal head",
"     </li>",
"     <li>",
"      Significant fetal or uterine anomaly",
"     </li>",
"     <li>",
"      Abruptio placentae",
"     </li>",
"     <li>",
"      Multiple gestation is a contraindication to antepartum ECV, but may be considered for the second twin after delivery of the first twin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/11/5306?source=see_link&amp;anchor=H15#H15\">",
"       \"Twin pregnancy: Labor and delivery\", section on 'Vertex-nonvertex twins'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relative contraindications include previous cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/2,40-44\">",
"     2,40-44",
"    </a>",
"    ], maternal hypertension, maternal obesity, impaired fetal growth (estimated fetal weight less than 10th percentile), and decreased amniotic fluid volume.",
"   </p>",
"   <p>",
"    The risk of uterine rupture in patients with previous cesarean delivery has not been determined [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/2\">",
"     2",
"    </a>",
"    ]. A series including 42 women and another 124 women from published reports gave an overall success rate of 75.5 percent, with favorable maternal and fetal outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/42\">",
"     42",
"    </a>",
"    ]. Larger trials are needed to establish the safety of ECV following cesarean delivery.",
"   </p>",
"   <p>",
"    Although there is a theoretical risk of maternal to fetal HIV transmission in HIV-infected women who undergo ECV, the risk is likely to be very small and compare favorably against the risk of vaginal breech delivery (if cesarean delivery is unavailable) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREPROCEDURE REQUISITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to performing ECV, an ultrasound examination should be performed to confirm fetal and placental position (placenta previa is a contraindication to vaginal delivery) and to exclude oligohydramnios and fetal or uterine anomalies (which can reduce the likelihood of success).",
"   </p>",
"   <p>",
"    There should also be documentation of fetal well-being (eg, reactive fetal heart rate pattern or satisfactory biophysical profile score) before exposing the fetus to a potentially stressful procedure.",
"   </p>",
"   <p>",
"    In addition to a description of the procedure, some of the elements of informed consent include a discussion of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Why the procedure is being performed",
"     </li>",
"     <li>",
"      Procedure related discomfort",
"     </li>",
"     <li>",
"      Risks of any medications that may be administered (tocolytics, anti-D immune globulin)",
"     </li>",
"     <li>",
"      Success (failure) rates (eg, pooled success rate from a systematic review: 58 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/27\">",
"       27",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      The small risk the fetus will spontaneously revert to breech",
"     </li>",
"     <li>",
"      Management plans if the procedure is successful or unsuccessful (eg, amniotomy and induction, scheduled cesarean delivery, second attempt at ECV)",
"     </li>",
"     <li>",
"      Risks (eg, abruption, vaginal bleeding, fetomaternal hemorrhage, umbilical cord",
"      <span class=\"nowrap\">",
"       entanglement/compression,",
"      </span>",
"      rupture of fetal membranes, onset of labor, nonreassuring fetal status necessitating urgent cesarean delivery)",
"     </li>",
"     <li>",
"      Benefits (if ECV is successful, the patient is likely to avoid cesarean delivery performed because of breech presentation)",
"     </li>",
"     <li>",
"      Alternatives to ECV (eg, expectant management, scheduled cesarean delivery, vaginal breech birth)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Counseling is more effective and patient satisfaction is higher if a structured decision aid for women with breech presentation is used [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TIMING AND OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACOG recommends offering ECV to women with breech fetuses who have completed 36 weeks of gestation and have no contraindications to the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/2\">",
"     2",
"    </a>",
"    ]. The advantages of ECV at or near term are: (1) it is often successful, (2) the fetus is likely to remain cephalic after successful ECV (ie, the procedure is effective), (3) the fetus is mature or nearly mature in the event of complications necessitating urgent cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. There are no specific contraindications to attempting ECV after the estimated date of delivery, although data are sparse.",
"   </p>",
"   <p>",
"    With the established effectiveness of ECV at term, an important remaining question is whether attempting ECV before term (and repeating the procedure until delivery, if necessary) has any benefit over ECV at term. The largest trial to address this issue was the Early External Cephalic Version 2 Trial, a multicenter trial that randomly assigned 1543 women with a singleton breech fetus to ECV at 34 to 36 weeks of gestation or at &ge;37 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/50\">",
"     50",
"    </a>",
"    ]. Repeated ECV attempts were permitted, as was use of tocolytics and regional analgesia. Ninety-eight percent of the procedures were performed by experienced practitioners. The major findings from this trial were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early ECV resulted in significantly fewer fetuses in noncephalic presentation at delivery than late ECV (41.1 versus 49.1 percent; RR 0.84, 95% CI 0.75-0.94)",
"     </li>",
"     <li>",
"      The rate of cesarean delivery was lower with early ECV, but the reduction did not reach statistical significance (52 versus 56 percent; RR 0.93, 95% CI 0.85-1.02). Meta-analysis of data from the current and a previous similar trial from the same group [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/51\">",
"       51",
"      </a>",
"      ] produces a result with borderline significance (two trials, 1765 women: RR 0.93; 95% CI 0.85 to 1.00).",
"     </li>",
"     <li>",
"      Complications during the procedure occurred in 3 to 4 percent of patients in each group. The most common complication was a nonreassuring fetal heart rate tracing.",
"     </li>",
"     <li>",
"      Early ECV did not significantly increase the risk of preterm birth before 37 weeks (6.5 versus 4.4 percent in patients who underwent late ECV; RR 1.48, 95% CI 0.97-2.26), although a slight increase cannot be definitely excluded. The median gestational age at delivery for both groups was 39.1 weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, early ECV was slightly less painful than late ECV, but the difference was probably not clinically significant.",
"   </p>",
"   <p>",
"    Based on the above data, as well as smaller trials [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/51-53\">",
"     51-53",
"    </a>",
"    ], it appears that ECV at 34 to 35 weeks is more likely than ECV at &gt;37 weeks to decrease the rate of noncephalic presentation at the time of delivery. However, the decrease in noncephalic presentation may not be accompanied by an equivalent reduction in the cesarean delivery rate. Reasons include the possibility that fetuses in noncephalic presentation in the third trimester have characteristics that place them at higher risk of having",
"    <span class=\"nowrap\">",
"     antepartum/intrapartum",
"    </span>",
"    complications necessitating cesarean delivery even if they turn or are turned to cephalic presentation, a willingness among European hospitals to deliver the term but not the preterm breech fetus vaginally, and the trend to a higher rate of preterm delivery among early ECV pregnancies.",
"   </p>",
"   <p>",
"    The greater success rate and probable reduction in cesarean delivery rate achieved when ECV attempts are initiated at 34 to 36 weeks of gestation need to be weighed against the possibility of rare complications necessitating delivery of a preterm baby. Women should be informed of the relative advantages and disadvantages of early initiation of ECV attempts in order to make an informed choice. This choice is likely to be influenced by the value the woman places on a vaginal birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Version during labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECV appears to be a safe option for women who present in labor with breech presentation, intact membranes, and no contraindications. Two small series that included women in labor reported successful ECV using tocolysis as long as the fetal membranes were intact [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/18,40\">",
"     18,40",
"    </a>",
"    ]. Theoretical advantages of delaying ECV until labor begins are that the maximum time for spontaneous version has been provided, the fetal condition can be monitored continuously from beginning of ECV to delivery, cesarean delivery can be performed expeditiously since the patient is already on the labor unit, and administration of anti-D immunoglobulin can be delayed until the neonate's blood type is known (and thus avoided if the neonate is Rh(D)-negative).",
"   </p>",
"   <p>",
"    The disadvantages of intrapartum ECV are that the opportunity to perform ECV may be lost due to ruptured membranes or rapid labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure should be performed by an experienced operator in a facility with ready access to emergency cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/2\">",
"     2",
"    </a>",
"    ]. Given the low complication rate, intravenous access and avoidance of oral intake before the procedure are unnecessary [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A videorecorded teaching program on ECV technique is included in the World Health Organization (WHO) Reproductive Health Library",
"    <span class=\"nowrap\">",
"     (file://apps.who.int/rhl/videos/en/index.html;",
"    </span>",
"    CD available from RHL@who.int) and a model abdomen for training has been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/55\">",
"     55",
"    </a>",
"    ]. Modifications of this technique have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that ECV be performed according to a protocol. In one study, implementation of a standardized protocol for ECV was associated with a significant increase in the success rate, which increased from 47 percent",
"    <span class=\"nowrap\">",
"     (110/236",
"    </span>",
"    pregnant women) to 61 percent",
"    <span class=\"nowrap\">",
"     (85/139",
"    </span>",
"    pregnant women) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ancillary measures to enhance success",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several ancillary measures have been evaluated to look for ways to improve the success rate of ECV. Tocolysis appears to be effective and is the best studied intervention. There is insufficient evidence to recommend for or against other interventions (vibroacoustic fetal stimulation, regional anesthesia, amnioinfusion, maternal hydration).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Tocolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of eight randomized trials of ECV with versus without tocolysis concluded tocolysis was associated with an increased prevalence of cephalic presentation in labor (RR 1.38, 95% CI 1.03-1.85) and a reduction in cesarean delivery rates (RR 0.82, 95% CI 0.71-0.94) in both nulliparous and multiparous women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/58\">",
"     58",
"    </a>",
"    ]. No drug or regimen was clearly superior to another.",
"   </p>",
"   <p>",
"    Use of tocolysis also increases the success of repeat ECV in women who have undergone a previous unsuccessful attempt at ECV [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beta-adrenergic agonists are generally preferred for facilitation of ECV; one simple regimen is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    0.25 mg subcutaneously 15 to 30 minutes prior to the procedure. There are limited data regarding other tocolytics, and no evidence that any of these drugs are more effective than beta-adrenergic agonists:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Atosiban",
"      </strong>",
"      &mdash; In a small retrospective study, the rates of successful ECV with atosiban and ritodrine were 28 and 41 percent, respectively. The number of events was too small for meaningful comparison [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Glyceryl trinitrate",
"      </strong>",
"      &mdash; Intravenous nitroglycerine [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/61,62\">",
"       61,62",
"      </a>",
"      ], or sublingual glyceryl trinitrate spray [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/63-65\">",
"       63-65",
"      </a>",
"      ], have been suggested as alternative uterine relaxants that might have fewer side effects than the beta-adrenergic agonists. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=see_link&amp;anchor=H7#H7\">",
"       \"Inhibition of acute preterm labor\", section on 'Beta-adrenergic receptor agonists'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A systematic review of randomized trials evaluating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      for uterine relaxation found it was not more effective than placebo for relaxing the uterus for ECV [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/66\">",
"       66",
"      </a>",
"      ]. In addition, a randomized trial of sublingual nitroglycerin (0.8 mg) versus intravenous ritodrine (111",
"      <span class=\"nowrap\">",
"       mcg/min)",
"      </span>",
"      prior to ECV found that nitroglycerin was associated with more side effects (headache, fall in blood pressure) than the beta-adrenergic agonist, as well as fewer successful versions, 9 of 36 patients receiving nitroglycerin versus 17 of 38 patients receiving ritodrine [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/64\">",
"       64",
"      </a>",
"      ]. However, another group suggested that parity should be taken into account; in their placebo controlled trial, use of intravenous nitroglycerin appeared to increase ECV success in nulliparous, but not multiparous, women [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       Nifedipine",
"      </a>",
"      &mdash; A systematic review including two trials comparing nifedipine to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      before ECV and one trial comparing nifedipine to placebo before ECV concluded that use of nifedipine did not increase the rate of successful version or lower the rate of cesarean delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34864055\">",
"    <span class=\"h4\">",
"     Tocolysis and regional anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of randomized trials found that regional analgesia plus a tocolytic was more effective than a tocolytic alone in achieving a successful version, but this did not result in a proven increase in cephalic presentations in labor (RR 1.63, 95% CI 0.75-3.53) nor a proven reduction in cesarean delivery (RR 0.74, 95% CI 0.40-1.37) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/58\">",
"     58",
"    </a>",
"    ]. Additional trials are needed to clarify this issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Epidural or spinal analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of six randomized trials including 508 attempted ECVs found that use of epidural or spinal analgesia significantly increased the success rate of ECV compared with intravenous or no analgesia (59.7 versus 37.6 percent; RR 1.58; 95% CI 1.29- 1.93 ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/69\">",
"     69",
"    </a>",
"    ]. For every five ECVs attempted under regional anesthesia, one additional ECV would be successful. Use of regional anesthesia was also associated with an 11 percent reduction in cesarean delivery (from 59.3 percent to 48.4 percent), which was not statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34863512\">",
"    <span class=\"h3\">",
"     Vibroacoustic stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal vibroacoustic stimulation has been used to stimulate the fetus in midline spine position to shift to a spine lateral position, which facilitates manipulating the fetus into a forward or backward roll. One small crossover trial reported successful version occurred in 19 of 22 patients exposed to vibroacoustic stimulation versus 1 of 12 unexposed patients; the rate of failed ECV was significantly reduced (RR 0.17, 95% CI 0.05-0.60) with this intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/70\">",
"     70",
"    </a>",
"    ]. More data are needed to prove the efficacy of this approach, but a trial of vibroacoustic stimulation is reasonable since it is inexpensive, well-tolerated, and harmless.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Amnioinfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;To our knowledge, no randomized trials have been performed to determine the effectiveness of amnioinfusion for enhancing ECV success. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43203?source=see_link\">",
"     \"Amnioinfusion: Technique\"",
"    </a>",
"    .) Two small uncontrolled studies reported discordant results. In one, six women with failed ECV had a successful repeat attempt following transabdominal amnioinfusion with 700 to 900 mL warmed saline [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/71\">",
"     71",
"    </a>",
"    ]. In the other, however, none of seven cases was successful [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Maternal hydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drinking water during the few hours prior to the procedure may increase amniotic fluid volume [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/73\">",
"     73",
"    </a>",
"    ]; however, the impact of this strategy on ECV success has not been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various techniques have been reported, but have not been compared in randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/74\">",
"     74",
"    </a>",
"    ]. Our technique is described in the following paragraphs (",
"    <a class=\"graphic graphic_figure graphicRef63535 \" href=\"UTD.htm?20/38/21092\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We explain each step of the procedure to the patient as we perform the ECV. She is asked to keep her abdominal muscles relaxed and inform the operator if she feels any discomfort. Good rapport with the patient is essential to help her relax and keep her from tensing her muscles, which makes it harder to manipulate the fetus.",
"   </p>",
"   <p>",
"    The patient is positioned on a narrow, firm examination couch with the fetal back towards the operator. For the fetus in the left sacrolateral position with planned backward somersault, the operator stands on the woman's left side. A wedge or cushion can be used to tilt the uterus towards the operator and minimize aortocaval compression.",
"   </p>",
"   <p>",
"    We administer a beta-adrenergic receptor agonist (eg, salbutamol or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    ) to relax the uterus; however, if clinical assessment suggests that ECV is likely to be achieved easily, an attempt without tocolysis may be made. We apply powder (eg, cornstarch) over the patient's abdomen to help the operator's hands slide over the skin while manipulating the fetus. Alternatively, ultrasound coupling gel is used if the procedure is to be monitored by ultrasound.",
"   </p>",
"   <p>",
"    The breech is disengaged from the pelvis by slowly inserting the fingertips of both hands deeply behind the symphysis pubis to scoop the breech from the pelvis to a position above the sacral promontory. If the woman is steeply tilted on her side against a wall, the operator may sit and steady his or her left elbow on the examination couch during the rest of the procedure.",
"   </p>",
"   <p>",
"    The breech is held with the edge of the left palm, and pushed towards the woman's right flank and upwards. If version is not completed by this maneuver, the head is gently manipulated towards the woman's left flank and downward with the edge of the right hand, taking care to apply most pressure to the breech so that a flexed posture is maintained. Slight back-and-forth movement between the two hands may help promote fetal movement, but generally, pressure on the fetus should be slow and steady, rather than repeated pushing.",
"   </p>",
"   <p>",
"    For a forward somersault, the operator is positioned on the side of the woman opposite to the fetal back. The procedure is similar to that described above, except that once the breech has been disengaged from the pelvis, more pressure is applied to the head than the breech, to maintain flexion of the baby.",
"   </p>",
"   <p>",
"    The fetal heart rate is auscultated every two minutes, with interruption of the procedure if bradycardia occurs. In one large series, a nonreassuring fetal heart rate leading to discontinuation of the ECV occurred in about 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If ECV is unsuccessful after five minutes of attempts, we stop and let the woman rest on her side for two minutes before making another attempt, if the woman agrees to it. We avoid making more than four attempts at one sitting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Postprocedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the ECV, fetal well-being is evaluated by cardiotocography. The fetal heart rate should be monitored until it is stable and reassuring. It is common for fetal heart rate tracings to be nonreactive for 20 to 40 minutes after ECV. These changes probably reflect the fetal response to a transient period of stress caused by decreased uteroplacental blood flow during the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetomaternal hemorrhage is almost always less than 30 mL. This was best illustrated by a prospective observational study that performed Kleihauer-Betke tests before and after external cephalic version in over 1000 women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/76\">",
"     76",
"    </a>",
"    ]. Both tests were negative in 1214 women; 30 women (2.4 percent) converted from negative to positive: 20 of these women had only rare fetal erythrocytes on the Kleihauer-Betke smear, 10 had an estimated bleed greater than 1 mL, and 1 had an estimated bleed of 80 mL. Risk factors for fetomaternal bleeding could not be identified. Others have also reported rare cases of massive fetomaternal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most experts recommend administering anti-D immune globulin to Rh(D)-negative women who undergo ECV; given the extremely low risk of a large fetomaternal bleed, performing Kleihauer-Betke or similar tests to quantitate fetomaternal bleeding appears to be unnecessary before administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link&amp;anchor=H8#H8\">",
"     \"Prevention of Rh(D) alloimmunization\", section on 'Additional indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ACOG does not recommend immediate induction (ie, stabilizing induction) to minimize the chance of reversion to breech [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/2\">",
"     2",
"    </a>",
"    ]. The rate of reversion is small, while elective induction can increase the risk of cesarean delivery and iatrogenic prematurity, and can be costly.",
"   </p>",
"   <p>",
"    If the procedure is unsuccessful or the fetus reverts to breech, a retrial of version may be attempted [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/2\">",
"     2",
"    </a>",
"    ]. One study noted that, after unsuccessful ECV, multiparous women were more likely than nulliparas to have spontaneous version to cephalic presentation (12.5 versus 2.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8281/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with breech presentation, we recommend external cephalic version (ECV) rather than expectant management or other interventions (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). ECV increases the proportion of fetuses in cephalic presentation at the onset of labor and decreases the frequency of cesarean delivery. However, these women have an increased frequency of dystocia in labor compared with the general obstetrical population. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest avoiding ECV in settings associated with a low likelihood of successful version or increased risk of fetal harm from the procedure (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest performing ECV at 36 or more weeks of gestation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). ECV has been proven to have a high degree of safety and success at this gestational age. ECV attempts can be initiated earlier (34 to 35 weeks) to improve the success rate and this will probably reduce the cesarean delivery rate, but the safety of ECV performed before 36 weeks is less well-established. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Timing and outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ECV can be performed in early labor if membranes are intact and there are no contraindications. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Timing and outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To enhance success rates, we recommend administering a tocolytic prior to the procedure (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest using a beta-adrenergic agonist (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). One option is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      0.25 mg subcutaneously 15 to 30 minutes prior to the procedure. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Tocolysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     RCOG Green Top Guidelines: The Management of Breech Presentation. Guideline No 20. 1999. London, RCOG.",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. External cephalic version. ACOG practice bulletin Number 13, February 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/3\">",
"      Hofmeyr GJ, Kulier R. External cephalic version for breech presentation at term. Cochrane Database Syst Rev 2012; 10:CD000083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/4\">",
"      Chan LY, Tang JL, Tsoi KF, et al. Intrapartum cesarean delivery after successful external cephalic version: a meta-analysis. Obstet Gynecol 2004; 104:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/5\">",
"      V&eacute;zina Y, Bujold E, Varin J, et al. Cesarean delivery after successful external cephalic version of breech presentation at term: a comparative study. Am J Obstet Gynecol 2004; 190:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/6\">",
"      Jain S, Mulligama C, Tagwira V, et al. Labour outcome of women with successful external cephalic version: a prospective study. J Obstet Gynaecol 2010; 30:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/7\">",
"      El-Toukhy T, Ramadan G, Maidman D, et al. Impact of parity on obstetric and neonatal outcome of external cephalic version. J Obstet Gynaecol 2007; 27:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/8\">",
"      Lau TK, Lo KW, Wan D, Rogers MS. Predictors of successful external cephalic version at term: a prospective study. Br J Obstet Gynaecol 1997; 104:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/9\">",
"      Pluta, M, Schmidt, S, Giffei, JM, Saling, E. Die Ausere wendung de Feten aus beckenendlage Schadellage in Terminnale unter Tokolyse. Z Geburtshilfe Perinatale 1981; 1985:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/10\">",
"      Brocks V, Philipsen T, Secher NJ. A randomized trial of external cephalic version with tocolysis in late pregnancy. Br J Obstet Gynaecol 1984; 91:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/11\">",
"      Tan GW, Jen SW, Tan SL, Salmon YM. A prospective randomised controlled trial of external cephalic version comparing two methods of uterine tocolysis with a non-tocolysis group. Singapore Med J 1989; 30:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/12\">",
"      Dyson DC, Ferguson JE 2nd, Hensleigh P. Antepartum external cephalic version under tocolysis. Obstet Gynecol 1986; 67:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/13\">",
"      Rabinovici J, Barkai G, Shalev J, et al. Impact of a protocol for external cephalic version under tocolysis at term. Isr J Med Sci 1986; 22:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/14\">",
"      Ben-Meir A, Erez Y, Sela HY, et al. Prognostic parameters for successful external cephalic version. J Matern Fetal Neonatal Med 2008; 21:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/15\">",
"      Kok M, Cnossen J, Gravendeel L, et al. Clinical factors to predict the outcome of external cephalic version: a metaanalysis. Am J Obstet Gynecol 2008; 199:630.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/16\">",
"      Kirkinen P, Yl&ouml;stalo P. Ultrasonic examination before external version of breech presentation. Gynecol Obstet Invest 1982; 13:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/17\">",
"      Hofmeyr GJ, Sadan O, Myer IG, et al. External cephalic version and spontaneous version rates: ethnic and other determinants. Br J Obstet Gynaecol 1986; 93:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/18\">",
"      Fortunato SJ, Mercer LJ, Guzick DS. External cephalic version with tocolysis: factors associated with success. Obstet Gynecol 1988; 72:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/19\">",
"      Boucher M, Bujold E, Marquette GP, Vezina Y. The relationship between amniotic fluid index and successful external cephalic version: a 14-year experience. Am J Obstet Gynecol 2003; 189:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/20\">",
"      Wise MR, Sadler L, Ansell D. Successful but limited use of external cephalic version in Auckland. Aust N Z J Obstet Gynaecol 2008; 48:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/21\">",
"      Donald WL, Barton JJ. Ultrasonography and external cephalic version at term. Am J Obstet Gynecol 1990; 162:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/22\">",
"      Westgren M, Edvall H, Nordstr&ouml;m L, et al. Spontaneous cephalic version of breech presentation in the last trimester. Br J Obstet Gynaecol 1985; 92:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/23\">",
"      Kok M, Cnossen J, Gravendeel L, et al. Ultrasound factors to predict the outcome of external cephalic version: a meta-analysis. Ultrasound Obstet Gynecol 2009; 33:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/24\">",
"      Hofmeyr GJ. Effect of external cephalic version in late pregnancy on breech presentation and caesarean section rate: a controlled trial. Br J Obstet Gynaecol 1983; 90:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/25\">",
"      Mahomed K, Seeras R, Coulson R. External cephalic version at term. A randomized controlled trial using tocolysis. Br J Obstet Gynaecol 1991; 98:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/26\">",
"      Burgos J, Melchor JC, Cobos P, et al. Does fetal weight estimated by ultrasound really affect the success rate of external cephalic version? Acta Obstet Gynecol Scand 2009; 88:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/27\">",
"      Grootscholten K, Kok M, Oei SG, et al. External cephalic version-related risks: a meta-analysis. Obstet Gynecol 2008; 112:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/28\">",
"      Nassar N, Roberts CL, Barratt A, et al. Systematic review of adverse outcomes of external cephalic version and persisting breech presentation at term. Paediatr Perinat Epidemiol 2006; 20:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/29\">",
"      Collaris RJ, Oei SG. External cephalic version: a safe procedure? A systematic review of version-related risks. Acta Obstet Gynecol Scand 2004; 83:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/30\">",
"      Rijnders M, Herschderfer K, Prins M, et al. A retrospective study of the success, safety and effectiveness of external cephalic version without tocolysis in a specialised midwifery centre in the Netherlands. Midwifery 2008; 24:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/31\">",
"      Collins S, Ellaway P, Harrington D, et al. The complications of external cephalic version: results from 805 consecutive attempts. BJOG 2007; 114:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/32\">",
"      Tatum RK, Orr JW, Soong S, Huddleston JF. Vaginal breech delivery of selected infants weighing more than 2000 grams. A retrospective analysis of seven years' experience. Am J Obstet Gynecol 1985; 152:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/33\">",
"      Hofmeyr GJ, Kulier R. Cephalic version by postural management for breech presentation. Cochrane Database Syst Rev 2012; 10:CD000051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/34\">",
"      Chenia F, Crowther CA. Does advice to assume the knee-chest position reduce the incidence of breech presentation at delivery? A randomized clinical trial. Birth 1987; 14:75.",
"     </a>",
"    </li>",
"    <li>",
"     Elkins, VH. Procedure for turning breech. In: Enkin, M, Chalmers, I (eds) Effectiveness and satisfaction in antenatal care. Spastic International Medical Publishers, London 1982, p. 216.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/36\">",
"      Bung P, Huch R, Huch A. [Is Indian version a successful method for decreasing the incidence of breech presentation?]. Geburtshilfe Frauenheilkd 1987; 47:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/37\">",
"      Coyle ME, Smith CA, Peat B. Cephalic version by moxibustion for breech presentation. Cochrane Database Syst Rev 2012; 5:CD003928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/38\">",
"      Tan JM, Macario A, Carvalho B, et al. Cost-effectiveness of external cephalic version for term breech presentation. BMC Pregnancy Childbirth 2010; 10:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/39\">",
"      Rosman AN, Guijt A, Vlemmix F, et al. Contraindications for external cephalic version in breech position at term: a systematic review. Acta Obstet Gynecol Scand 2013; 92:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/40\">",
"      Flamm BL, Fried MW, Lonky NM, Giles WS. External cephalic version after previous cesarean section. Am J Obstet Gynecol 1991; 165:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/41\">",
"      de Meeus JB, Ellia F, Magnin G. External cephalic version after previous cesarean section: a series of 38 cases. Eur J Obstet Gynecol Reprod Biol 1998; 81:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/42\">",
"      Sela HY, Fiegenberg T, Ben-Meir A, et al. Safety and efficacy of external cephalic version for women with a previous cesarean delivery. Eur J Obstet Gynecol Reprod Biol 2009; 142:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/43\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice bulletin no. 115: Vaginal birth after previous cesarean delivery. Obstet Gynecol 2010; 116:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/44\">",
"      Clock C, Kurtzman J, White J, Chung JH. Cesarean risk after successful external cephalic version: a matched, retrospective analysis. J Perinatol 2009; 29:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/45\">",
"      Holmes WR, Hofmeyr GJ. Management of breech presentation in areas with high prevalence of HIV infection. Int J Gynaecol Obstet 2004; 87:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/46\">",
"      Nassar N, Roberts CL, Raynes-Greenow CH, et al. Evaluation of a decision aid for women with breech presentation at term: a randomised controlled trial [ISRCTN14570598]. BJOG 2007; 114:325.",
"     </a>",
"    </li>",
"    <li>",
"     www.biomedcentral.com/1471-2393/4/26 (accessed October 29, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/48\">",
"      Saling E, M&uuml;ller-Holve W. External cephalic version under tocolysis. J Perinat Med 1975; 3:115.",
"     </a>",
"    </li>",
"    <li>",
"     Ben-Meir, A, Elram, T, Tsafrir, A, et al. The incidence of spontaneous version after failed external version. Am J Obstet Gynecol 2007; 196;157.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/50\">",
"      Hutton EK, Hannah ME, Ross SJ, et al. The Early External Cephalic Version (ECV) 2 Trial: an international multicentre randomised controlled trial of timing of ECV for breech pregnancies. BJOG 2011; 118:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/51\">",
"      Hutton EK, Kaufman K, Hodnett E, et al. External cephalic version beginning at 34 weeks' gestation versus 37 weeks' gestation: a randomized multicenter trial. Am J Obstet Gynecol 2003; 189:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/52\">",
"      Mensink WF, Huisjes HJ. [Is external version useful in breech presentation?]. Ned Tijdschr Geneeskd 1980; 124:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/53\">",
"      Van Veelen AJ, Van Cappellen AW, Flu PK, et al. Effect of external cephalic version in late pregnancy on presentation at delivery: a randomized controlled trial. Br J Obstet Gynaecol 1989; 96:916.",
"     </a>",
"    </li>",
"    <li>",
"     Royal College of Obstetricians and Gynaecologists (RCOG). External cephalic version and reducing the incidence of breech presentation. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2006 Dec.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/55\">",
"      Burr R, Helyer P, Robson SC. A training model for external cephalic version. Eur J Obstet Gynecol Reprod Biol 2001; 99:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/56\">",
"      Keriakos R, Abdelmalek B, Campbell L. Sheffield modified technique for external cephalic version. J Obstet Gynaecol 2009; 29:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/57\">",
"      Kuppens SM, Francois AM, Hasaart TH, et al. [Fewer breech deliveries after implementation of a modified cephalic version protocol]. Ned Tijdschr Geneeskd 2010; 154:A63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/58\">",
"      Cluver C, Hofmeyr GJ, Gyte GM, Sinclair M. Interventions for helping to turn term breech babies to head first presentation when using external cephalic version. Cochrane Database Syst Rev 2012; 1:CD000184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/59\">",
"      Impey L, Pandit M. Tocolysis for repeat external cephalic version in breech presentation at term: a randomised, double-blinded, placebo-controlled trial. BJOG 2005; 112:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/60\">",
"      Stergiotou I, Talbot F, Yoong W. The use of atosiban and ritodrine in external cephalic version. Acta Obstet Gynecol Scand 2007; 86:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/61\">",
"      Belfort MA. Intravenous nitroglycerin as a tocolytic agent for intrapartum external cephalic version. S Afr Med J 1993; 83:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/62\">",
"      Andarsio, F, Feng, TI. External cephalic version: nitroglycerin versus terbutaline. Am J Obstet Gynecol 2000; 182:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/63\">",
"      Yanny H, Johanson R, Balwin KJ, et al. Double-blind randomised controlled trial of glyceryl trinitrate spray for external cephalic version. BJOG 2000; 107:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/64\">",
"      Bujold E, Marquette GP, Ferreira E, et al. Sublingual nitroglycerin versus intravenous ritodrine as tocolytic for external cephalic version: a double-blinded randomized trial. Am J Obstet Gynecol 2003; 188:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/65\">",
"      Bujold E, Boucher M, Rinfret D, et al. Sublingual nitroglycerin versus placebo as a tocolytic for external cephalic version: a randomized controlled trial in parous women. Am J Obstet Gynecol 2003; 189:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/66\">",
"      Morgan PJ, Kung R, Tarshis J. Nitroglycerin as a uterine relaxant: a systematic review. J Obstet Gynaecol Can 2002; 24:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/67\">",
"      Hilton J, Allan B, Swaby C, et al. Intravenous nitroglycerin for external cephalic version: a randomized controlled trial. Obstet Gynecol 2009; 114:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/68\">",
"      Wilcox CB, Nassar N, Roberts CL. Effectiveness of nifedipine tocolysis to facilitate external cephalic version: a systematic review. BJOG 2011; 118:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/69\">",
"      Goetzinger KR, Harper LM, Tuuli MG, et al. Effect of regional anesthesia on the success rate of external cephalic version: a systematic review and meta-analysis. Obstet Gynecol 2011; 118:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/70\">",
"      Johnson RL, Elliott JP. Fetal acoustic stimulation, an adjunct to external cephalic version: a blinded, randomized crossover study. Am J Obstet Gynecol 1995; 173:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/71\">",
"      Benifla, JL, Goffinet, F, Bascou, V, Darai, E, Proust, A, Madelenat, P. Transabdominal amnio-infusion facilitates external version manouver after initial failure (translation). Journal de Gynecologie, Obstetrique et Biologie de la Reproduction (Paris) 1995; 24:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/72\">",
"      Adama van Scheltema PN, Feitsma AH, Middeldorp JM, et al. Amnioinfusion to facilitate external cephalic version after initial failure. Obstet Gynecol 2006; 108:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/73\">",
"      Hofmeyr GJ, G&uuml;lmezoglu AM. Maternal hydration for increasing amniotic fluid volume in oligohydramnios and normal amniotic fluid volume. Cochrane Database Syst Rev 2002; :CD000134.",
"     </a>",
"    </li>",
"    <li>",
"     Hofmeyr, GJ. Breech presentation and abnormal lie in late pregnancy. In: Chalmers, I, Enkin, MW, Keirse, MJNC, editors. Effective Care in Pregnancy and Childbirth. Oxford: Oxford University Press 1989, 653-665.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/75\">",
"      Hofmeyr GJ, Sonnendecker EW. Cardiotocographic changes after external cephalic version. Br J Obstet Gynaecol 1983; 90:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/76\">",
"      Boucher M, Marquette GP, Varin J, et al. Fetomaternal hemorrhage during external cephalic version. Obstet Gynecol 2008; 112:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/77\">",
"      Khoo CL, Bollapragada S, Mackenzie F. Massive fetomaternal hemorrhage following failed external cephalic version: case report. J Perinat Med 2006; 34:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/78\">",
"      Shankar M, Gough GW, Chakravarti S, Vellacott ID. Massive feto-maternal haemorrhage with good perinatal outcome following failed external cephalic version. Fetal Diagn Ther 2004; 19:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8281/abstract/79\">",
"      Ben-Meir A, Elram T, Tsafrir A, et al. The incidence of spontaneous version after failed external cephalic version. Am J Obstet Gynecol 2007; 196:157.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6779 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_5_8281=[""].join("\n");
var outline_f8_5_8281=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FACTORS ASSOCIATED WITH REDUCED SUCCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISKS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ALTERNATIVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Expectant management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Postural maneuvers to facilitate spontaneous version",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Moxibustion and acupuncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COST-EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREPROCEDURE REQUISITES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TIMING AND OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Version during labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ancillary measures to enhance success",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Tocolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H34864055\">",
"      Tocolysis and regional anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Epidural or spinal analgesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34863512\">",
"      - Vibroacoustic stimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Amnioinfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Maternal hydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Postprocedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6779\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6779|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/38/21092\" title=\"figure 1\">",
"      External cephalic version",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6779|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/9/21659\" title=\"table 1\">",
"      Risks of external cephalic version",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43203?source=related_link\">",
"      Amnioinfusion: Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21449?source=related_link\">",
"      Cesarean delivery: Postoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=related_link\">",
"      Inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13448?source=related_link\">",
"      Overview of breech presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=related_link\">",
"      Prevention of Rh(D) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/11/5306?source=related_link\">",
"      Twin pregnancy: Labor and delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_5_8282="Cesarean delivery: Preoperative issues";
var content_f8_5_8282=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cesarean delivery: Preoperative issues",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/5/8282/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/5/8282/contributors\">",
"     Vincenzo Berghella, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/5/8282/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/5/8282/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/5/8282/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/5/8282/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/5/8282/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cesarean delivery (also called cesarean section and cesarean birth) refers to the delivery of a baby through surgical incisions in the abdomen and uterus. Cesarean deliveries are categorized as either primary (ie, first cesarean delivery) or repeat (ie, after a previous cesarean birth). The total cesarean delivery rate is the sum of these two components.",
"   </p>",
"   <p>",
"    The cesarean delivery rate worldwide is about 15 percent of births [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/1\">",
"     1",
"    </a>",
"    ]. The mean cesarean delivery rate in developed countries is 21.1 percent, but only 2 percent in the least developed countries. A World Health Organization (WHO) survey of 122 facilities in nine Asian countries reported an overall rate of cesarean delivery of 27.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/2\">",
"     2",
"    </a>",
"    ]. A similar WHO survey of eight Latin American countries observed an overall cesarean delivery rate of 35.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, over one million cesarean deliveries are performed annually and accounted for 32.8 percent of US births in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/4\">",
"     4",
"    </a>",
"    ]. Worldwide, Mexico, Brazil, Italy, Iran, Argentina, Dominican Republic, Cuba, and Korea have the highest rates (over 35 percent) and Africa has the lowest (under 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/5\">",
"     5",
"    </a>",
"    ]. In Brazil, the wealthiest 10 percent of women have a cesarean delivery rate of 77 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/6\">",
"     6",
"    </a>",
"    ]. The cesarean delivery rate in China ranges from 20 to 60 percent, depending on whether the hospital is rural or urban [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The cesarean rate was 25 percent in teaching hospitals in India [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/10\">",
"     10",
"    </a>",
"    ], but 8.5 percent overall [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review preoperative issues relating to cesarean delivery. Surgical technique, postoperative issues, repeat cesarean delivery, and trial of labor after cesarean delivery are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14682?source=see_link\">",
"       \"Cesarean delivery: Technique\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21449?source=see_link\">",
"       \"Cesarean delivery: Postoperative issues\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37862?source=see_link\">",
"       \"Repeat cesarean delivery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=see_link\">",
"       \"Choosing the route of delivery after cesarean birth\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cesarean delivery is performed when the clinician and patient feel that abdominal delivery is likely to provide a better maternal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal outcome than vaginal delivery. The term \"elective cesarean delivery\" should probably be eliminated because a cesarean delivery is either",
"    <span class=\"nowrap\">",
"     \"medically/obstetrically",
"    </span>",
"    indicated\" or \"on maternal request,\" and never truly \"elective.\" Cesarean delivery on maternal request is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/21/344?source=see_link\">",
"     \"Cesarean delivery on maternal request\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to perform an indicated cesarean delivery may be made antepartum or as a result of concerns identified after labor has begun (\"unscheduled cesarean delivery\" or \"unplanned cesarean delivery\"). The terms \"scheduled cesarean delivery\" or \"planned cesarean delivery\" are used when the decision to perform a cesarean delivery does not occur as a consequence of a complication of labor, but is planned antepartum, such as in the case of repeat cesarean delivery, fetal malpresentation, or placenta previa.",
"   </p>",
"   <p>",
"    The four most common indications for cesarean delivery account for approximately 80 percent of these deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure to progress during labor (30 percent)",
"     </li>",
"     <li>",
"      Previous hysterotomy (usually related to cesarean delivery, but also related to myomectomy or other uterine surgery) (30 percent)",
"     </li>",
"     <li>",
"      Nonreassuring fetal status (10 percent)",
"     </li>",
"     <li>",
"      Fetal malpresentation (11 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional, less common indications for cesarean delivery include, but are not limited to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal placentation (eg, placenta previa, vasa previa, placenta accreta)",
"     </li>",
"     <li>",
"      Maternal infection (eg, herpes simplex or human immunodeficiency virus)",
"     </li>",
"     <li>",
"      Multiple gestation",
"     </li>",
"     <li>",
"      Fetal bleeding diathesis",
"     </li>",
"     <li>",
"      Funic presentation or cord prolapse",
"     </li>",
"     <li>",
"      Macrosomia",
"     </li>",
"     <li>",
"      Mechanical obstruction to vaginal birth (eg, large leiomyoma or condyloma acuminata, severely displaced pelvic fracture, fetal anomalies such as severe hydrocephalus)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See individual topic reviews on each subject).",
"   </p>",
"   <p>",
"    Cesarean delivery may also be indicated in women who are at increased risk of complications from tissue trauma related to cervical dilation, the descent and expulsion of the fetus, or episiotomy. Some examples include women with invasive cervical cancer or active perianal inflammatory bowel disease, and those who have undergone repair of a rectovaginal fistula or pelvic organ prolapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25834?source=see_link\">",
"     \"Fertility, pregnancy, and nursing in inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=see_link\">",
"     \"Pelvic floor disorders associated with pregnancy and childbirth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9097?source=see_link\">",
"     \"Fecal incontinence related to pregnancy and vaginal delivery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6826?source=see_link\">",
"     \"Cervical cancer in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cesarean delivery may be performed, but is not routinely indicated for fetal issues, such as extremely or very low birth weight (&lt;1000 g and &le;1500 g, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/12\">",
"     12",
"    </a>",
"    ], or certain congenital anomalies (eg, open neural tube defects, some skeletal dysplasias, and gastroschisis with herniated liver) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. We do not recommend cesarean delivery for these indications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20374?source=see_link\">",
"     \"Intrapartum management of the low birthweight vertex fetus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=see_link\">",
"     \"Overview of the management of myelomeningocele (spina bifida)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35464?source=see_link\">",
"     \"Obstetrical management of gastroschisis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38454?source=see_link\">",
"     \"Obstetrical management of omphalocele\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no absolute contraindications to cesarean delivery. In contrast to other types of surgery, the risks and benefits of the procedure need to be considered as they apply to two patients (mother and fetus). However, many pregnant women have a low tolerance for accepting any fetal risk from vaginal birth, irrespective of the maternal risks associated with operative intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREOPERATIVE ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Checklists can be helpful in preoperative assessment, and are available from various organizations, such as the American College of Obstetricians and Gynecologists (ACOG) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Assessment of fetal pulmonary maturity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elective term cesarean delivery should be scheduled for &ge;39 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/19\">",
"     19",
"    </a>",
"    ]. Fetal pulmonary maturity can be inferred if:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review of the patient's prenatal record confirms a gestational age of &ge;39 weeks of gestation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=see_link\">",
"       \"Prenatal assessment of gestational age\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      Tests on amniotic fluid suggest a low risk of neonatal respiratory distress. However, testing is only indicated in women of uncertain gestational age. Testing to confirm pulmonary maturity in order to proceed with an elective delivery before 39 weeks should generally be avoided. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42919?source=see_link\">",
"       \"Assessment of fetal lung maturity\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data from large observational studies have consistently shown that neonatal respiratory morbidity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    composite neonatal morbidity is higher after scheduled cesarean delivery than vaginal delivery, but decreases as gestational age increases from 37 to 39 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/20-29\">",
"     20-29",
"    </a>",
"    ]. As an example, a large trial evaluated respiratory morbidity (eg, respiratory distress syndrome, transient tachypnea of the newborn) in term infants delivered without prior assessment of fetal lung maturity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/22\">",
"     22",
"    </a>",
"    ]. Compared with infants of women who intended to have a vaginal delivery, those delivered by scheduled cesarean delivery had a significantly increased risk of respiratory morbidity at any gestational age before 40 weeks: 37 weeks (OR 3.9, 95% CI 2.4-6.5; 10 versus 2.8 percent), 38 weeks (OR 3.0, 95% CI 2.1-4.3; 5.1 versus 1.7 percent), 39 weeks (OR 1.9, 95% CI 1.2-3.0; 2.1 versus 1.1 percent), 40 weeks (OR 0.9, 95% CI 0.2-3.7; 1.5 versus 1.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/21/344?source=see_link&amp;anchor=H15#H15\">",
"     \"Cesarean delivery on maternal request\", section on 'Increased risk of respiratory problems in offspring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risks of iatrogenic early term birth (37 to 38 weeks) appear to outweigh any theoretical benefits when the indication for delivery is &ldquo;soft&rdquo;, such as suspected macrosomia without maternal diabetes or history of fetal, maternal, or obstetric complication in a previous pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any surgical procedure, women undergoing cesarean delivery should have a preoperative anesthesiology consultation. Those whose procedure-related risks are above baseline should have a",
"    <strong>",
"     preadmission",
"    </strong>",
"    consultation with an anesthesiologist. Characteristics that place the patient at increased risk include, but are not limited to, those listed in the table (",
"    <a class=\"graphic graphic_table graphicRef68666 \" href=\"UTD.htm?12/24/12683\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The choice of regional or general anesthesia is influenced by factors such as the urgency of the procedure, maternal status, and physician and patient preference. Issues related to anesthesia for cesarean delivery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39977?source=see_link\">",
"     \"Anesthesia for cesarean delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A baseline hemoglobin measurement is recommended in patients who are undergoing major surgery, such as cesarean delivery, that is expected to result in significant blood loss. A normal value obtained within one month of surgery probably does not need to be repeated preoperatively in uncomplicated pregnancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnant women generally have a blood type and antibody screen performed as part of routine prenatal care. A repeat type and screen preoperatively probably can be safely omitted in women at low-risk of hemorrhagic complications during surgery and who do not have a known red blood cell antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. Fewer than 1 percent of such women receive a perioperative blood transfusion. Risk factors for transfusion include: placental abnormalities (eg, previa, accreta, or abruption), eclampsia or HELLP syndrome (ie, Hemolysis, Elevated Liver function tests, Low Platelets), preoperative hematocrit less than 25 percent, general anesthesia, and a history of five or more cesarean deliveries. Alternatively, the surgeon may consider a \"hold clot\" order in low-risk patients: blood is drawn and held, but no tests are performed unless clinically indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;To reduce the risk of postoperative infection, a single intravenous dose of a narrow spectrum antibiotic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ) should be administered preoperatively to all women undergoing cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/35-41\">",
"     35-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of antibiotic prophylaxis was illustrated in a systematic review of 86 randomized trials that compared infection outcomes after both scheduled and \"in labor\" cesarean delivery with or without the use of prophylactic antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/41\">",
"     41",
"    </a>",
"    ]. Antibiotic prophylaxis significantly reduced the incidence of postoperative fever, endometritis, wound infection, urinary tract infection, and serious maternal infectious complications compared to controls receiving no antibiotic treatment. The relative risk of endometritis was reduced by approximately 60 percent after scheduled cesarean delivery, \"in labor\" cesarean delivery, and for all patients (relative risk = 0.39, 0.40, and 0.36, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Choice of drug and dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal choice of antibiotic is not well-defined.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     Cefazolin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    appear to be similarly effective [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/42\">",
"     42",
"    </a>",
"    ] and superior to several other regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/35\">",
"     35",
"    </a>",
"    ]. Our preference is cefazolin. A guideline developed jointly by the American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), the Surgical Infection Society (SIS), and the Society for Healthcare Epidemiology of America (SHEA) recommends 2 grams cefazolin for patients &lt;120 kg and 3 grams for patients &ge;120 kg (",
"    <a class=\"graphic graphic_table graphicRef87200 \" href=\"UTD.htm?12/1/12317\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/43\">",
"     43",
"    </a>",
"    ]; the Medical Letter suggests 1 gram for patients &lt;80 kg and 2 grams for those &ge;80 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/44\">",
"     44",
"    </a>",
"    ]. We suggest consideration of the 2 gram dose in patients &lt;120 kg, as this dose has an excellent safety profile and, in one study, &ge;20 percent of obese and extremely obese women (body mass index [BMI] &ge;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    did not achieve minimal inhibitory concentrations for Gram-negative rods in adipose samples at skin incision even with a 2 gram dose [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few data comparing these drugs against extended spectrum antibiotic combinations (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17269?source=see_link\">",
"     cefotetan",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One randomized trial that evaluated this issue reported lower endometritis and wound infection rates when extended spectrum antibiotics were administered after surgery in addition to surgical prophylaxis. In this trial, 597 women undergoing scheduled and unscheduled cesarean deliveries received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17269?source=see_link\">",
"       cefotetan",
"      </a>",
"      (2 g) at cord clamping and then were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg intravenously at cord clamping) followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (1 g orally) 6 to 12 hours later or placebo (at cord clamping and again postoperatively) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/47\">",
"       47",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Extended spectrum antibiotic prophylaxis continued after surgery was associated with a significant reduction in postpartum endometritis (16.9 versus 24.7 percent) and wound infection (0.8 versus 3.6 percent). Follow-up observational studies by the same group affirmed these findings [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]. The authors postulated that these results were due to coverage against Ureaplasma urealyticum provided by the extended antibiotic regimen. However, since no cultures were performed, a different mechanism may have accounted for the reduction in postoperative infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We would like to see confirmatory data from randomized trials at other institutions before recommending use of extended spectrum antibiotic prophylaxis, given the higher cost of these drugs and the potential increase in antibiotic resistant infection with this approach. It is possible that a subset of high risk women may benefit from extended spectrum antibiotics; this needs to be investigated in appropriately designed trials. Prophylaxis against ureaplasmas is unlikely to be important since clinical endometritis generally responds to antibiotic treatments that do not cover this organism. It would also be appropriate to evaluate one-time dosing (at the time of surgery) of broad spectrum antibiotics versus a standard antimicrobial (eg, cephalosporin) in a clinical trial setting before instituting a broad-spectrum regimen, as the trials above may have been affected by the continuation of antibiotics after the surgery.",
"   </p>",
"   <p>",
"    We avoid use of amoxicillin-clavulanic acid because of concerns raised about its safety. In a meta-analysis of placebo-controlled randomized trials of antibiotic therapy in women with preterm rupture of membranes, use of amoxicillin-clavulanic acid was associated with a significant increase in the number of babies who developed necrotizing enterocolitis (RR 4.60, 95% CI 1.98-10.72; two trials:",
"    <span class=\"nowrap\">",
"     29/1236",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     6/1256)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/50\">",
"     50",
"    </a>",
"    ]. The wide confidence interval shows that these findings need to be confirmed by larger studies; in the meantime, we avoid its use since safe and effective alternatives are available. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Penicillin allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with a history of serious penicillin allergy (immediate hypersensitivity reaction), combination therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (500 mg) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (600 mg) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    (1.5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    intravenously provides broad coverage [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Clindamycin monotherapy is an alternative, but coverage is narrower and infection rates are higher [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Clindamycin is not typically active against enterococci, Mycoplasma pneumoniae, and aerobic Gram negative bacilli. Guidelines developed jointly by the American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), the Surgical Infection Society (SIS), and the Society for Healthcare Epidemiology of America (SHEA) recommend clindamycin and an aminoglycoside (gentamicin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    ) in women with beta-lactam allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A cephalosporin can be given to patients at low risk of a serious IgE-mediated reaction. The risk of a penicillin-allergic patient reacting to a cephalosporin may be assessed based upon the results of penicillin skin testing (if available), the clinical features of the penicillin reaction, and the time elapsed since the last reaction to penicillin (",
"    <a class=\"graphic graphic_algorithm graphicRef61102 \" href=\"UTD.htm?25/10/25760\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=see_link\">",
"     \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Number of doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use a single dose regimen, given that a systematic review of randomized trials showed that single dose regimens were as effective as multiple dose regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/55\">",
"     55",
"    </a>",
"    ]. However, some data (see above) suggest that continuation of a broad-spectrum regimen for 6 to 12 hours postoperatively may decrease infectious morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial therapy should be administered within 60 minutes before making the skin incision to ensure adequate drug tissue levels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/52,56\">",
"     52,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This recommendation is supported by a meta-analysis of randomized trials that compared infection rates in women assigned to a single preincision dose of antibiotic prophylaxis versus those assigned to administration after cord clamping [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/57\">",
"     57",
"    </a>",
"    ]. Preincision prophylaxis was significantly more effective than delayed administration for prevention of endometritis (RR 0.59, 95% CI 0.37-0.94) and was not associated with an increase in proven neonatal sepsis, sepsis workups, or admission to the neonatal intensive care unit, although the trials had limited power to detect adverse neonatal effects.",
"   </p>",
"   <p>",
"    Delaying antibiotic administration until after cord clamping in an attempt to avoid interference with neonatal cultures had been a common practice, but is not necessary and is no longer requested by pediatricians [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/36,38\">",
"     36,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Woman already on antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the woman in labor already receiving antibiotics for GBS prophylaxis and later needing cesarean delivery, we do not add further antibiotic prophylaxis, although others centers administer a single dose of a broad spectrum antibiotic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For the woman already receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    for chorioamnionitis, we add one dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and continue ampicillin and gentamicin or switch to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    until the patient is afebrile for at least 24 hours. Bacteroides resistance to clindamycin is increasing; in areas of high resistance, ampicillin-sulbactam is preferable.",
"   </p>",
"   <p>",
"    There are no randomized trials assessing efficacy of antibiotic regimens in these clinical scenarios.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Thromboembolism prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 80 percent of fatal puerperal pulmonary embolisms occur after cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/58\">",
"     58",
"    </a>",
"    ]. Currently, many obstetrical units in the United States provide mechanical prophylaxis to all women undergoing cesarean delivery, and add pharmacologic prophylaxis postpartum for women with additional risk factors. Unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight heparin is started 6 to&nbsp;12 hours after cesarean delivery if there is no significant bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The value of thromboprophylaxis for cesarean delivery has not been studied in adequately powered randomized clinical trials. Cesarean delivery probably increases the risk of venous thromboembolism (VTE); however, observational data suggest that the level of risk for clinically important events is modest and similar to that seen in low risk surgical patients for whom no routine thromboprophylaxis other than early ambulation is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3291433\">",
"    <span class=\"h3\">",
"     Low-risk women",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the American College of Obstetricians and Gynecologists&rsquo; recommendation to place pneumatic compression devices on all patients not already receiving pharmacologic thromboprophylaxis before cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/59\">",
"     59",
"    </a>",
"    ]. Observational studies of pregnant women suggest that pneumatic compression devices, as well as compression stockings, are safe and effective [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/60\">",
"     60",
"    </a>",
"    ]. We continue pneumatic compression until the patient is fully ambulatory [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines do not recommend prophylaxis (other than early ambulation postpartum) for women whose only risk factors for VTE are pregnancy and cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3291457\">",
"    <span class=\"h3\">",
"     High-risk women",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the American College of Obstetricians and Gynecologists&rsquo; recommendation for consideration of both mechanical and pharmacological thromboprophylaxis in women undergoing cesarean delivery at high risk of VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/59\">",
"     59",
"    </a>",
"    ]. These women may include those with BMI &gt;50",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    previous VTE, high-risk thrombophilia (inherited or acquired), or two or more less prominent risk factors for VTE.",
"   </p>",
"   <p>",
"    Unfractionated or low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    can be used; options include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    40 mg daily or unfractionated heparin 5000 every 12 hours. Pharmacologic prophylaxis is begun 6 to 12 hours postoperatively, after concerns for hemorrhage have decreased, and is continued until the woman is fully ambulating [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/63\">",
"     63",
"    </a>",
"    ]. However, there are no data from randomized trials to support or refute this approach.",
"   </p>",
"   <p>",
"    Pneumatic compression devices are left in place until the patient is ambulatory and until anticoagulation therapy has been restarted [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines recommend prophylaxis for women undergoing scheduled cesarean delivery who have additional risk factors for VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/62\">",
"     62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with one additional major risk factor for VTE or two additional minor risk factors for VTE should receive pharmacologic thromboprophylaxis while in the hospital following delivery. If anticoagulants are contraindicated, graduated compression stockings or a pneumatic compression device should be used.",
"     </li>",
"     <li>",
"      Women with multiple additional risk factors for VTE should receive pharmacologic thromboprophylaxis plus graduated compression stockings",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pneumatic compression devices while in the hospital following delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    According to the ACCP, major risk factors include strict bedrest for &ge;1 week antepartum, postpartum hemorrhage &ge;1000 mLs at surgery, previous VTE, preeclampsia with fetal growth restriction, antithrombin deficiency, factor V Leiden (homozygous or heterozygous), prothrombin G20210A (homozygous or heterozygous), blood transfusion, infection, and some medical conditions (lupus, heart disease, sickle cell disease). Minor risk factors include BMI &gt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    multiple gestation, postpartum hemorrhage &gt;1000 mL, smoking &gt;10",
"    <span class=\"nowrap\">",
"     cigarettes/day,",
"    </span>",
"    birth weight &lt;25",
"    <sup>",
"     th",
"    </sup>",
"    centile, protein C or S deficiency, or preeclampsia. If the cesarean delivery is performed emergently, the presence of only one minor risk factor is sufficient to warrant VTE prophylaxis.",
"   </p>",
"   <p>",
"    Others have also considered the following potential risk factors for VTE: malignancy, lower body orthopedic cast, age over 35 years, and nephrotic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/64-73\">",
"     64-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Royal College of Obstetricians and Gynaecologists (RCOG) and Society of Obstetricians and Gynaecologists of Canada (SOGC) recommend pharmacologic thromboprophylaxis for women with additional risk factors for VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This subject is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=see_link&amp;anchor=H5#H5\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\", section on 'Cesarean section'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Fetal heart rate monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetal heart rate should be documented prior to cesarean delivery. The value of continuous or intermittent fetal heart rate monitoring prior to scheduled cesarean delivery in low risk women is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/76\">",
"     76",
"    </a>",
"    ]. If possible, laboring patients who were monitored in the labor room should continue to be monitored after transfer to the operating room when surgery is significantly delayed. There are no randomized trials assessing the utility for electronic fetal heart rate monitoring before cesarean delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Fetal presentation and placental location",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ultrasound for assessment of placental location and fetal presentation, or Leopold maneuvers to assess fetal presentation, are probably useful, but their effectiveness has not been prospectively studied in a randomized trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Bladder catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinicians insert a urethral catheter at the start of the case to prevent bladder distention, which can impede exposure of the lower uterine segment. The catheter is also useful for instilling dye if a cystotomy is suspected and monitoring urine output. However, there is no strong evidence that routine placement of an indwelling catheter is advantageous, and this practice is associated with an increased risk of postoperative urinary tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/77\">",
"     77",
"    </a>",
"    ]. As an alternative, patients at low risk of intraoperative complications can be asked to void shortly before the procedure, and an indwelling catheter can be inserted intraoperatively or postoperatively if required [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/78-81\">",
"     78-81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hair removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis including 11 randomized controlled trials found no difference in the rate of surgical site infection in non-pregnant patients who had hair removed prior to surgery and those who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/82\">",
"     82",
"    </a>",
"    ]. There are no randomized trials assessing this intervention specifically before cesarean delivery.",
"   </p>",
"   <p>",
"    If hair needs to be removed, it should be clipped rather than shaved, as patients who are shaved are more likely to develop surgical site infection. Use of a depilatory cream is also preferable to shaving. Clipping should be performed just before surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10805?source=see_link\">",
"     \"Controversies in control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Skin preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large randomized trial (n = 849 subjects) found that preoperative cleansing of the patient's skin with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    -alcohol was superior to cleansing with povidone-iodine for preventing surgical-site infection after clean-contaminated surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/84\">",
"     84",
"    </a>",
"    ]. The overall rate of surgical-site infection was significantly lower in the chlorhexidine-alcohol group than in the povidone-iodine group (9.5 versus 16.1 percent, RR 0.59; 95% CI 0.41-0.85). Based on these data, we prep the abdominal surgical site with a chlorhexidine-alcohol scrub before cesarean delivery.",
"   </p>",
"   <p>",
"    The benefit of bathing with an antiseptic preparation prior to surgery to reduce the risk of surgical site infection is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/85-88\">",
"     85-88",
"    </a>",
"    ]. In a meta-analysis of six trials involving 10,007 participants, preoperative bathing with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    conferred no benefit over preoperative bathing with other products for reduction of SSI [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data were derived from trials in general surgical patients; less data are available for patients undergoing cesarean delivery. A systematic review of trials performed in these patients (5 trials, 1462 women) and using various techniques of skin preparation concluded there was insufficient evidence to determine the optimal method [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Well-designed randomized trials are needed to determine whether one antiseptic is more effective than another for preventing post-cesarean wound infection, whether other factors are clinically more important than the type of antiseptic, and the comparative costs, risks, and benefits of various antiseptics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Vaginal antimicrobial preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of a vaginal povidone-iodine scrub to abdominal skin cleaning before cesarean delivery was assessed in a meta-analysis of five randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/90\">",
"     90",
"    </a>",
"    ]. Compared with abdominal preparation alone, the combination of abdominal and vaginal preparation significantly reduced the frequency of post-cesarean endometritis (RR 0.39, 95% CI 0.16-0.97; 3.6 versus 7.2 percent). This benefit was primarily related to the large effect of this intervention in women with ruptured membranes (RR 0.13, 95% CI 0.02-0.66;",
"    <span class=\"nowrap\">",
"     1/70",
"    </span>",
"    versus 12",
"    <span class=\"nowrap\">",
"     /78);",
"    </span>",
"    vaginal preparation did not result in a statistically significant reduction in endometritis in women with intact membranes. The rates of wound infection and postoperative fever were not significantly reduced regardless of membrane status. However, this meta-analysis failed to address the important confounder of how skin cleaning was performed. Since we use a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    -alcohol scrub before cesarean delivery (discussed above) and administer prophylactic antibiotics, we do not believe there is any additional benefit to vaginal preparation and do not perform it.",
"   </p>",
"   <p>",
"    The use of intravaginal antibiotics has also been evaluated, but data are limited.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    gel (5 mg intravaginally before cesarean delivery) resulted in a decrease in the incidence of postpartum endometritis, but no other significant effects [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Drapes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical site is draped with nonadhesive drapes, as they appear to be associated with a lower rate of wound infection than adhesive drapes for cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/40,92,93\">",
"     40,92,93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Uterine displacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The uterus is displaced at least 15 degrees to the left to reduce aortocaval compression (\"supine hypotensive syndrome\") [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/94-98\">",
"     94-98",
"    </a>",
"    ]. A wedge, pillow, or rolled blanket may be used, or the table can be tilted. The optimum method and maternal position have not been determined [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     EMERGENCY DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;One-half to 1 percent of deliveries require emergency intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. An emergency cesarean delivery is defined as a cesarean delivery that is performed after labor has begun; by comparison, a scheduled or elective cesarean is performed before labor has begun. Emergency cesareans are sometimes further classified by degree of urgency; for example: (1) an immediate threat to life of the mother or fetus is present, (2) signs of maternal or fetal compromise are present but are not immediately life threatening, or (3) delivery is needed but there is no evidence of maternal or fetal compromise.",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists and the American Academy of Pediatrics (AAP) have suggested that facilities providing obstetrical services should be capable of beginning an emergency cesarean delivery within 30 minutes of the decision to perform the operation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/102\">",
"     102",
"    </a>",
"    ]. This criterion is based upon the practical constraints most rural hospitals face in assembling the appropriate team of nurses, anesthetists, and surgeons. However, this threshold is not evidence-based, universally achievable, or ideal from the perspective of decreasing perinatal mortality and morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/101,103-110\">",
"     101,103-110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ability to begin an emergency cesarean delivery within 30 minutes of the decision to operate is a reasonable benchmark for monitoring the quality of labor and delivery units; the statement was not intended as a requirement that all cesarean deliveries be performed within 30 minutes of the decision. In human and animal studies, sudden complete anoxia, such as occurs with a total abruption or complete cord occlusion, probably necessitates delivery within five minutes to avoid fetal hypoxic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/111-113\">",
"     111-113",
"    </a>",
"    ], although intact survivors have been reported after longer durations of severe hypoxia. Most pregnancies with less severe fetal or maternal compromise or partial or complete recovery of nonreassuring fetal heart rate tracings will have good outcomes despite longer intervals before initiating surgery.",
"   </p>",
"   <p>",
"    Compared with nonemergent cesarean delivery, emergency cesarean is associated with increased risks of severe hemorrhage, anesthetic complications from rapid administration of general anesthesia, and accidental injury to the fetus or abdominopelvic organs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24695588\">",
"    <span class=\"h1\">",
"     GUIDELINES FROM NATIONAL ORGANIZATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selected publications on cesarean delivery from national organizations are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American College of Obstetricians and Gynecologists [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/114\">",
"       114",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      National Institute for Health and Clinical Excellence [",
"      <a class=\"abstract\" href=\"UTD.htm?8/5/8282/abstract/115\">",
"       115",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=see_link\">",
"       \"Patient information: C-section (cesarean delivery) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"       \"Patient information: C-section (cesarean delivery) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cesarean delivery is performed when the clinician and patient feel that abdominal delivery is likely to provide a better maternal or fetal outcome than vaginal delivery. A wide variety of conditions fulfill these criteria. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Before scheduled cesarean delivery, assurance of fetal pulmonary maturity should be based on a gestational age of at least 39 weeks or invasive testing. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Assessment of fetal pulmonary maturity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all women undergoing cesarean delivery, we recommend preoperative antibiotic prophylaxis rather than prophylaxis after cord clamping (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Antibiotics are given 0 to 60 minutes before making the incision. We use a single intravenous dose of a narrow spectrum antibiotic, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      (1 g if &le;60 kg, 2 g for &gt;60 kg) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      (2 g). Multiple doses and broad spectrum antibiotics are more costly, without clearly improving outcome. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antibiotic prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all women undergoing cesarean delivery, we suggest mechanical thromboprophylaxis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For women undergoing cesarean delivery at high risk of venous thromboembolism, we suggest mechanical thromboprophylaxis plus pharmacological thromboprophylaxis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Pharmacologic prophylaxis is begun 6 to 12 hours postoperatively, after concerns for hemorrhage have decreased. Mechanical and pharmacological prophylaxis are continued until the woman is fully ambulating. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Thromboembolism prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/1\">",
"      Betr&aacute;n AP, Merialdi M, Lauer JA, et al. Rates of caesarean section: analysis of global, regional and national estimates. Paediatr Perinat Epidemiol 2007; 21:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/2\">",
"      Lumbiganon P, Laopaiboon M, G&uuml;lmezoglu AM, et al. Method of delivery and pregnancy outcomes in Asia: the WHO global survey on maternal and perinatal health 2007-08. Lancet 2010; 375:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/3\">",
"      Betr&aacute;n AP, Gulmezoglu AM, Robson M, et al. WHO global survey on maternal and perinatal health in Latin America: classifying caesarean sections. Reprod Health 2009; 6:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/4\">",
"      Births: Final data for 2010. Natl Vital Stat Rep 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/5\">",
"      Gibbons L, Belizan JM, Lauer JA, et al. Inequities in the use of cesarean section deliveries in the world. Am J Obstet Gynecol 2012; 206:331.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/6\">",
"      Ronsmans C, Holtz S, Stanton C. Socioeconomic differentials in caesarean rates in developing countries: a retrospective analysis. Lancet 2006; 368:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/7\">",
"      Tang S, Li X, Wu Z. Rising cesarean delivery rate in primiparous women in urban China: evidence from three nationwide household health surveys. Am J Obstet Gynecol 2006; 195:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/8\">",
"      Lei H, Wen SW, Walker M. Determinants of caesarean delivery among women hospitalized for childbirth in a remote population in China. J Obstet Gynaecol Can 2003; 25:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/9\">",
"      Zhang J, Liu Y, Meikle S, et al. Cesarean delivery on maternal request in southeast China. Obstet Gynecol 2008; 111:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/10\">",
"      Kambo I, Bedi N, Dhillon BS, Saxena NC. A critical appraisal of cesarean section rates at teaching hospitals in India. Int J Gynaecol Obstet 2002; 79:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/11\">",
"      Penn Z, Ghaem-Maghami S. Indications for caesarean section. Best Pract Res Clin Obstet Gynaecol 2001; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/12\">",
"      Alfirevic Z, Milan SJ, Livio S. Caesarean section versus vaginal delivery for preterm birth in singletons. Cochrane Database Syst Rev 2012; 6:CD000078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/13\">",
"      Luthy DA, Wardinsky T, Shurtleff DB, et al. Cesarean section before the onset of labor and subsequent motor function in infants with meningomyelocele diagnosed antenatally. N Engl J Med 1991; 324:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/14\">",
"      How HY, Harris BJ, Pietrantoni M, et al. Is vaginal delivery preferable to elective cesarean delivery in fetuses with a known ventral wall defect? Am J Obstet Gynecol 2000; 182:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/15\">",
"      Walker SP, McCarthy EA, Ugoni A, et al. Cesarean delivery or vaginal birth: a survey of patient and clinician thresholds. Obstet Gynecol 2007; 109:67.",
"     </a>",
"    </li>",
"    <li>",
"     Lyerly, AD, Mitchell, LM, Armstrong, EM, et al. Risks, values, and decision making surrounding pregnancy. Obstet Gynecol 2007; 109;979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/17\">",
"      American College of Obstetricians and Gynecologists. Patient Safety Checklist no. 4: preoperative planned cesarean delivery. Obstet Gynecol 2011; 118:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/18\">",
"      American College of Obstetricians and Gynecologists. Patient Safety Checklist no. 3: scheduling planned cesarean delivery. Obstet Gynecol 2011; 118:1469.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists and American Academy of Pediatrics. Guidelines For Perinatal Care. 7th Ed, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/20\">",
"      Stutchfield P, Whitaker R, Russell I, Antenatal Steroids for Term Elective Caesarean Section (ASTECS) Research Team. Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial. BMJ 2005; 331:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/21\">",
"      Zanardo V, Padovani E, Pittini C, et al. The influence of timing of elective cesarean section on risk of neonatal pneumothorax. J Pediatr 2007; 150:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/22\">",
"      Hansen AK, Wisborg K, Uldbjerg N, Henriksen TB. Risk of respiratory morbidity in term infants delivered by elective caesarean section: cohort study. BMJ 2008; 336:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/23\">",
"      Zanardo V, Simbi AK, Franzoi M, et al. Neonatal respiratory morbidity risk and mode of delivery at term: influence of timing of elective caesarean delivery. Acta Paediatr 2004; 93:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/24\">",
"      Morrison JJ, Rennie JM, Milton PJ. Neonatal respiratory morbidity and mode of delivery at term: influence of timing of elective caesarean section. Br J Obstet Gynaecol 1995; 102:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/25\">",
"      Wax JR, Herson V, Carignan E, et al. Contribution of elective delivery to severe respiratory distress at term. Am J Perinatol 2002; 19:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/26\">",
"      Yee W, Amin H, Wood S. Elective cesarean delivery, neonatal intensive care unit admission, and neonatal respiratory distress. Obstet Gynecol 2008; 111:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/27\">",
"      Clark SL, Miller DD, Belfort MA, et al. Neonatal and maternal outcomes associated with elective term delivery. Am J Obstet Gynecol 2009; 200:156.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/28\">",
"      Wilmink FA, Hukkelhoven CW, Lunshof S, et al. Neonatal outcome following elective cesarean section beyond 37 weeks of gestation: a 7-year retrospective analysis of a national registry. Am J Obstet Gynecol 2010; 202:250.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/29\">",
"      Nir V, Nadir E, Feldman M. Late better than early elective term Cesarean section. Acta Paediatr 2012; 101:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/30\">",
"      Cousins LM, Teplick FB, Poeltler DM. Pre-cesarean blood bank orders: a safe and less expensive approach. Obstet Gynecol 1996; 87:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/31\">",
"      Ransom SB, Fundaro G, Dombrowski MP. Cost-effectiveness of routine blood type and screen testing for cesarean section. J Reprod Med 1999; 44:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/32\">",
"      Rouse DJ, MacPherson C, Landon M, et al. Blood transfusion and cesarean delivery. Obstet Gynecol 2006; 108:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/33\">",
"      American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Anesthesiology 2007; 106:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/34\">",
"      Chua SC, Joung SJ, Aziz R. Incidence and risk factors predicting blood transfusion in caesarean section. Aust N Z J Obstet Gynaecol 2009; 49:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/35\">",
"      Faro S, Martens MG, Hammill HA, et al. Antibiotic prophylaxis: is there a difference? Am J Obstet Gynecol 1990; 162:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/36\">",
"      Cunningham FG, Leveno KJ, DePalma RT, et al. Perioperative antimicrobials for cesarean delivery: before or after cord clamping? Obstet Gynecol 1983; 62:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/37\">",
"      Thigpen BD, Hood WA, Chauhan S, et al. Timing of prophylactic antibiotic administration in the uninfected laboring gravida: a randomized clinical trial. Am J Obstet Gynecol 2005; 192:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/38\">",
"      Gordon HR, Phelps D, Blanchard K. Prophylactic cesarean section antibiotics: maternal and neonatal morbidity before or after cord clamping. Obstet Gynecol 1979; 53:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/39\">",
"      Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers Workgroup, et al. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/40\">",
"      Berghella V, Baxter JK, Chauhan SP. Evidence-based surgery for cesarean delivery. Am J Obstet Gynecol 2005; 193:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/41\">",
"      Smaill FM, Gyte GM. Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section. Cochrane Database Syst Rev 2010; :CD007482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/42\">",
"      Alfirevic Z, Gyte GM, Dou L. Different classes of antibiotics given to women routinely for preventing infection at caesarean section. Cochrane Database Syst Rev 2010; :CD008726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/43\">",
"      Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013; 70:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/44\">",
"      Antimicrobial prophylaxis for surgery. Treat Guidel Med Lett 2012; 10:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/45\">",
"      Pevzner L, Swank M, Krepel C, et al. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. Obstet Gynecol 2011; 117:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/46\">",
"      Tita AT, Rouse DJ, Blackwell S, et al. Emerging concepts in antibiotic prophylaxis for cesarean delivery: a systematic review. Obstet Gynecol 2009; 113:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/47\">",
"      Andrews WW, Hauth JC, Cliver SP, et al. Randomized clinical trial of extended spectrum antibiotic prophylaxis with coverage for Ureaplasma urealyticum to reduce post-cesarean delivery endometritis. Obstet Gynecol 2003; 101:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/48\">",
"      Tita AT, Hauth JC, Grimes A, et al. Decreasing incidence of postcesarean endometritis with extended-spectrum antibiotic prophylaxis. Obstet Gynecol 2008; 111:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/49\">",
"      Tita AT, Owen J, Stamm AM, et al. Impact of extended-spectrum antibiotic prophylaxis on incidence of postcesarean surgical wound infection. Am J Obstet Gynecol 2008; 199:303.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/50\">",
"      Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev 2010; :CD001058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/51\">",
"      ACOG Committee on Practice Bulletins--Gynecology. ACOG practice bulletin No. 104: antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2009; 113:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/52\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 120: Use of prophylactic antibiotics in labor and delivery. Obstet Gynecol 2011; 117:1472.",
"     </a>",
"    </li>",
"    <li>",
"     Cecatti JG. Antibiotic prophylaxis for caesarean section: RHL commentary (last revised: 18 January 2005). The WHO Reproductive Health Library; Geneva: World Health Organization.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/54\">",
"      Bratzler DW, Houck PM, Surgical Infection Prevention Guideline Writers Workgroup. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg 2005; 189:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/55\">",
"      Hopkins L, Smaill F. Antibiotic prophylaxis regimens and drugs for cesarean section. Cochrane Database Syst Rev 2000; :CD001136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/56\">",
"      Committee opinion no. 465: antimicrobial prophylaxis for cesarean delivery: timing of administration. Obstet Gynecol 2010; 116:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/57\">",
"      Baaqeel H, Baaqeel R. Timing of administration of prophylactic antibiotics for caesarean section: a systematic review and meta-analysis. BJOG 2013; 120:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/58\">",
"      Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/59\">",
"      James A, Committee on Practice Bulletins&mdash;Obstetrics. Practice bulletin no. 123: thromboembolism in pregnancy. Obstet Gynecol 2011; 118:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/60\">",
"      Clark SL, Belfort MA, Dildy GA, et al. Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol 2008; 199:36.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/61\">",
"      Committee on Practice Bulletins--Gynecology, American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 84: Prevention of deep vein thrombosis and pulmonary embolism. Obstet Gynecol 2007; 110:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/62\">",
"      Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/63\">",
"      SMFM, Publication Committe, with Varner MW. Thromboprophylaxis for cesarean delivery. Contemp Ob Gyn 2011; 6:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/64\">",
"      Dargaud Y, Rugeri L, Vergnes MC, et al. A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study. Br J Haematol 2009; 145:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/65\">",
"      Danilenko-Dixon DR, Heit JA, Silverstein MD, et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am J Obstet Gynecol 2001; 184:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/66\">",
"      Ettema HB, Kollen BJ, Verheyen CC, B&uuml;ller HR. Prevention of venous thromboembolism in patients with immobilization of the lower extremities: a meta-analysis of randomized controlled trials. J Thromb Haemost 2008; 6:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/67\">",
"      Jacobsen AF, Skjeldestad FE, Sandset PM. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 2008; 6:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/68\">",
"      James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006; 194:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/69\">",
"      Lindqvist P, Dahlb&auml;ck B, Mar&aacute;l K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999; 94:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/70\">",
"      Macklon NS, Greer IA. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scott Med J 1996; 41:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/71\">",
"      Simpson EL, Lawrenson RA, Nightingale AL, Farmer RD. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. BJOG 2001; 108:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/72\">",
"      Blondon M, Perrier A, Nendaz M, et al. Thromboprophylaxis with low-molecular-weight heparin after cesarean delivery. Thromb Haemost 2010; 103:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/73\">",
"      Kobayashi T, Nakabayashi M, Ishikawa M, et al. Pulmonary thromboembolism in obstetrics and gynecology increased by 6.5-fold over the past decade in Japan. Circ J 2008; 72:753.",
"     </a>",
"    </li>",
"    <li>",
"     Royal College of Obstetricians and Gynaecologists. Green-top Guideline No. 37a: Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. RCOG, London. November 2009; 1-35.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/75\">",
"      Kent N, Leduc L, Crane J, et al. PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) IN OBSTETRICS. J SOGC 2000; 22:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/76\">",
"      Committee on Obstetric Practice. ACOG Committee Opinion No. 382: Fetal Monitoring Prior to Scheduled Cesarean Delivery. Obstet Gynecol 2007; 110:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/77\">",
"      Li L, Wen J, Wang L, et al. Is routine indwelling catheterisation of the bladder for caesarean section necessary? A systematic review. BJOG 2011; 118:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/78\">",
"      Senanayake H. Elective cesarean section without urethral catheterization. J Obstet Gynaecol Res 2005; 31:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/79\">",
"      Ghoreishi J. Indwelling urinary catheters in cesarean delivery. Int J Gynaecol Obstet 2003; 83:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/80\">",
"      Barnes JS. Is it better to avoid urethral catheterization at hysterectomy and caesarean section? Aust N Z J Obstet Gynaecol 1998; 38:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/81\">",
"      Nasr AM, ElBigawy AF, Abdelamid AE, et al. Evaluation of the use vs nonuse of urinary catheterization during cesarean delivery: a prospective, multicenter, randomized controlled trial. J Perinatol 2009; 29:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/82\">",
"      Tanner J, Woodings D, Moncaster K. Preoperative hair removal to reduce surgical site infection. Cochrane Database Syst Rev 2006; :CD004122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/83\">",
"      Cruse PJ, Foord R. A five-year prospective study of 23,649 surgical wounds. Arch Surg 1973; 107:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/84\">",
"      Darouiche RO, Wall MJ Jr, Itani KM, et al. Chlorhexidine-Alcohol versus Povidone-Iodine for Surgical-Site Antisepsis. N Engl J Med 2010; 362:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/85\">",
"      Cruse PJ, Foord R. The epidemiology of wound infection. A 10-year prospective study of 62,939 wounds. Surg Clin North Am 1980; 60:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/86\">",
"      Hayek LJ, Emerson JM, Gardner AM. A placebo-controlled trial of the effect of two preoperative baths or showers with chlorhexidine detergent on postoperative wound infection rates. J Hosp Infect 1987; 10:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/87\">",
"      Rotter ML, Hirschl AM, Koller W. Effect of chlorhexidine-containing detergent, non-medicated soap or isopropanol and the influence of neutralizer on bacterial pathogenicity. J Hosp Infect 1988; 11:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/88\">",
"      Webster J, Osborne S. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection. Cochrane Database Syst Rev 2006; :CD004985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/89\">",
"      Hadiati DR, Hakimi M, Nurdiati DS. Skin preparation for preventing infection following caesarean section. Cochrane Database Syst Rev 2012; 9:CD007462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/90\">",
"      Haas DM, Morgan S, Contreras K. Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections. Cochrane Database Syst Rev 2013; 1:CD007892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/91\">",
"      Pitt C, Sanchez-Ramos L, Kaunitz AM. Adjunctive intravaginal metronidazole for the prevention of postcesarean endometritis: a randomized controlled trial. Obstet Gynecol 2001; 98:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/92\">",
"      Cordtz T, Schouenborg L, Laursen K, et al. The effect of incisional plastic drapes and redisinfection of operation site on wound infection following caesarean section. J Hosp Infect 1989; 13:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/93\">",
"      Ward HR, Jennings OG, Potgieter P, Lombard CJ. Do plastic adhesive drapes prevent post caesarean wound infection? J Hosp Infect 2001; 47:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/94\">",
"      Lee SW, Khaw KS, Ngan Kee WD, et al. Haemodynamic effects from aortocaval compression at different angles of lateral tilt in non-labouring term pregnant women. Br J Anaesth 2012; 109:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/95\">",
"      Bamber JH, Dresner M. Aortocaval compression in pregnancy: the effect of changing the degree and direction of lateral tilt on maternal cardiac output. Anesth Analg 2003; 97:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/96\">",
"      Kundra P, Velraj J, Amirthalingam U, et al. Effect of positioning from supine and left lateral positions to left lateral tilt on maternal blood flow velocities and waveforms in full-term parturients. Anaesthesia 2012; 67:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/97\">",
"      Kinsella SM, Harvey NL. A comparison of the pelvic angle applied using lateral table tilt or a pelvic wedge at elective caesarean section. Anaesthesia 2012; 67:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/98\">",
"      Calvache JA, Mu&ntilde;oz MF, Baron FJ. Hemodynamic effects of a right lumbar-pelvic wedge during spinal anesthesia for cesarean section. Int J Obstet Anesth 2011; 20:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/99\">",
"      Cluver C, Novikova N, Hofmeyr J, Hall DR. Maternal position during caesarean section for preventing maternal and neonatal complications. Cochrane Database Syst Rev 2013; :CD007623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/100\">",
"      Lagrew DC, Bush MC, McKeown AM, Lagrew NG. Emergent (crash) cesarean delivery: indications and outcomes. Am J Obstet Gynecol 2006; 194:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/101\">",
"      MacKenzie IZ, Cooke I. Prospective 12 month study of 30 minute decision to delivery intervals for \"emergency\" caesarean section. BMJ 2001; 322:1334.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Optimal goals for anesthesia care in obstetrics. ACOG Committee Opinion #256. American College of Obstetricians and Gynecologists, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/103\">",
"      James D. Caesarean section for fetal distress. BMJ 2001; 322:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/104\">",
"      Helmy WH, Jolaoso AS, Ifaturoti OO, et al. The decision-to-delivery interval for emergency caesarean section: is 30 minutes a realistic target? BJOG 2002; 109:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/105\">",
"      Tuffnell DJ, Wilkinson K, Beresford N. Interval between decision and delivery by caesarean section-are current standards achievable? Observational case series. BMJ 2001; 322:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/106\">",
"      Chauhan SP, Roach H, Naef RW 2nd, et al. Cesarean section for suspected fetal distress. Does the decision-incision time make a difference? J Reprod Med 1997; 42:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/107\">",
"      MacKenzie IZ, Cooke I. What is a reasonable time from decision-to-delivery by caesarean section? Evidence from 415 deliveries. BJOG 2002; 109:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/108\">",
"      Thomas J, Paranjothy S, James D. National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section. BMJ 2004; 328:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/109\">",
"      Holcroft CJ, Graham EM, Aina-Mumuney A, et al. Cord gas analysis, decision-to-delivery interval, and the 30-minute rule for emergency cesareans. J Perinatol 2005; 25:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/110\">",
"      Bloom SL, Leveno KJ, Spong CY, et al. Decision-to-incision times and maternal and infant outcomes. Obstet Gynecol 2006; 108:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/111\">",
"      Stallings SP, Edwards RK, Johnson JW. Correlation of head-to-body delivery intervals in shoulder dystocia and umbilical artery acidosis. Am J Obstet Gynecol 2001; 185:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/112\">",
"      Katz VL, Dotters DJ, Droegemueller W. Perimortem cesarean delivery. Obstet Gynecol 1986; 68:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/5/8282/abstract/113\">",
"      Myers RE. Two patterns of perinatal brain damage and their conditions of occurrence. Am J Obstet Gynecol 1972; 112:246.",
"     </a>",
"    </li>",
"    <li>",
"     ACOG Task Force on Cesarean Delivery Rates. Evaluation of cesarean delivery, American College of Obstetricians and Gynecologists, Washington, DC 2000.",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence (NICE). Caesarean section. file://guidance.nice.org.uk/cg132 (Accessed on January 23, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4475 Version 56.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-BFBE39938F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_5_8282=[""].join("\n");
var outline_f8_5_8282=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREOPERATIVE ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Assessment of fetal pulmonary maturity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Choice of drug and dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Penicillin allergy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Number of doses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Woman already on antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Thromboembolism prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3291433\">",
"      - Low-risk women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3291457\">",
"      - High-risk women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Fetal heart rate monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Fetal presentation and placental location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Bladder catheterization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hair removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Skin preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Vaginal antimicrobial preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Drapes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Uterine displacement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      EMERGENCY DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24695588\">",
"      GUIDELINES FROM NATIONAL ORGANIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4475\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4475|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?25/10/25760\" title=\"algorithm 1\">",
"      Admin of a cephalosporin to a patient with a hx of PCN allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4475|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/24/12683\" title=\"table 1\">",
"      Need for anesthesia consult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/1/12317\" title=\"table 2\">",
"      Antimicrobial prophylaxis for gynecologic and obstetric surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39977?source=related_link\">",
"      Anesthesia for cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42919?source=related_link\">",
"      Assessment of fetal lung maturity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6826?source=related_link\">",
"      Cervical cancer in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/21/344?source=related_link\">",
"      Cesarean delivery on maternal request",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21449?source=related_link\">",
"      Cesarean delivery: Postoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14682?source=related_link\">",
"      Cesarean delivery: Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=related_link\">",
"      Choosing the route of delivery after cesarean birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10805?source=related_link\">",
"      Controversies in control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9097?source=related_link\">",
"      Fecal incontinence related to pregnancy and vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25834?source=related_link\">",
"      Fertility, pregnancy, and nursing in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20374?source=related_link\">",
"      Intrapartum management of the low birthweight vertex fetus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35464?source=related_link\">",
"      Obstetrical management of gastroschisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38454?source=related_link\">",
"      Obstetrical management of omphalocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=related_link\">",
"      Overview of the management of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=related_link\">",
"      Pelvic floor disorders associated with pregnancy and childbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=related_link\">",
"      Prenatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37862?source=related_link\">",
"      Repeat cesarean delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_5_8283="Management anaphylaxis reaction";
var content_f8_5_8283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pharmacologic management of anaphylactic reactions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Initial management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epinephrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravenous fluids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diphenhydramine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cimetidine or other H2 blocker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocortisone or equivalent steroid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aerosolized beta-agonists and epinephrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Persistent hypotension and/or bronchospasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasopressors (epinephrine, dopamine, norepinephrine, phenylephrine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucagon (for those patients on beta-blockers)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_5_8283=[""].join("\n");
var outline_f8_5_8283=null;
var title_f8_5_8284="Periop ana agents mech";
var content_f8_5_8284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F60805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F60805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents capable of causing perioperative anaphylaxis and proposed mechanisms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Agents",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Immunologic reactions",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Non-immunologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        IgE-mediated",
"       </td>",
"       <td class=\"subtitle2\">",
"        Non-IgE mediated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuromuscular blocking agents",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Latex",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antibiotics",
"       </td>",
"       <td>",
"        <p>",
"         +",
"        </p>",
"        <p>",
"         (eg, beta-lactams)",
"        </p>",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        <p>",
"         +",
"        </p>",
"        <p>",
"         (eg, vancomycin)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        Hypnotic induction agents:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Barbituates",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Non-barbituates",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opioids",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supravital dyes",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colloids and plasma expanders",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorhexidine",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     +/-: agent may cause anaphylaxis by this mechanism.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_5_8284=[""].join("\n");
var outline_f8_5_8284=null;
var title_f8_5_8285="Clinical spectrum of fusariosis";
var content_f8_5_8285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical spectrum of fusariosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immunocompetent hosts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Non-infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mycotoxicosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Allergic bronchopulmonary fusariosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Common:",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Onychomycosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Keratitis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Uncommon:",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Cutaneous (burns, wounds)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Peritonitis (patients receiving CAPD)",
"        <sup>",
"         [2-4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Endocarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Sinusitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Endophthalmitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Thrombophlebitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Fungemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immunocompromised hosts",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Invasive infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Disseminated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Multiorgan infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Isolated fungemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Localized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         Common:",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Cellulitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Sinusitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         Less common:",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        CNS infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Endophthalmitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Arthritis/osteomyelitis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CAPD: continuous ambulatory peritoneal dialysis; CNS: central nervous system.",
"     <br>",
"      * Outbreaks of fusarial keratitis have been reported among contact lens wearers",
"      <sup>",
"       [6]",
"      </sup>",
"      .",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002; 35:909.",
"       </li>",
"       <li>",
"        Rippon JW, Larson RA, Rosenthal DM, Clayman J. Disseminated cutaneous and peritoneal hyalohyphomycosis caused by Fusarium species: three cases and review of the literature. Mycopathologia 1988; 101:105.",
"       </li>",
"       <li>",
"        Kerr CM, Perfect JR, Craven PC, et al. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Ann Intern Med 1983; 99:334.",
"       </li>",
"       <li>",
"        Flynn JT, Meislich D, Kaiser BA, et al. Fusarium peritonitis in a child on peritoneal dialysis: case report and review of the literature. Perit Dial Int 1996; 16:52.",
"       </li>",
"       <li>",
"        Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20:695.",
"       </li>",
"       <li>",
"        Patel A, Hammersmith K. Contact lens-related microbial keratitis: recent outbreaks. Curr Opin Ophthalmol 2008; 19:302.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_5_8285=[""].join("\n");
var outline_f8_5_8285=null;
var title_f8_5_8286="Patients bridged with mechanical circulatory support";
var content_f8_5_8286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Percentage of patients bridged to heart transplantation with mechanical circulatory support",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 475px; background-image: url(data:image/gif;base64,R0lGODlh9AHbAcQAAP///1e23QAAAO7u7oiIiCIiIkRERJmZmTMzM1VVVbu7uxEREXd3d93d3aqqqszMzGZmZg8PDwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD0AdsBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaEGAqkCCgAKCwILrKaztHIGBCULuAQLtb6/arckDwIjAg/AycpgqKm4BwUjBQ7L1dZaB8fQ0tQkqt/g1+LjQavEIgPHMMXk7e4yDQgNALwDALr0vevv/P0qA80KyHIFS9YLdv4SKuyBcKHDhzMaQpxIMYXEihgxXszI8eHGjiD9fQxJst3Ikiit/51MyRLYypYwZ72MSVPUzJo4O93MyRPTzp5AJ/0MStTR0KJIEx1NypTQ0qZQ/zyNSlXP1KpY61zNyhXO1q5g13wNS9bM2LJow5xNy5bL2rZwr7yNS1fK3Lp4m9zNyxfJ3r6Ah/wNTNjH4MKIcxxOzJjG4saQD0ae7OQx5csmLGPeDEAz58ueP08OLRoy6dKMT6NGrHo14dauAcOOzXc2bby2b9PNrRsu795sfwNHK3w42eLGwSJPznU5c6zOn1ONLh0q9epMr2NHqn070e7egYIPz3M8eZzmz9NMrx4m+/Ys38NHKX8+yfr2QeLPz3E/f18KCHCACATFEoN//83SwP8CCwx4zy76SJYgWQMUQEABA54jgjoSTgiWAQwAgCEA24gwzT4edsWAASYOWKKI3RgDzowpdtWMKhBomA4yHdbY1YgP5nOgj2EBWaBBLiBIpEhLRqZkk+88CaVJU6ZWZWJSXnlNllpWw2WXynwJpktjylZmX2KeSUuaaprCZpukvAmnTXPuVmdcct7pSZ56csJnn5r8CahPgxJXaFmCHkpJoopKwmijkDwKqVGTNldpVpJeqkimmiLCaaeGfAqqU6NaV2pTop4KSKqq+sFqq3y8CqtVs35Xa1Cy3mpHrrrSwWuvcvwKrFfDoldsTcIey0ayyqrBbLNoPAutWdPGV63/Jg8gWdm1lizAgAOpQBCFtNymAO4DCQiAgADzPEFuuSeAOwACC6QTo17wSkJMugjYC8W7S84o8MAEq9JDMwRk0+62+U4hQAAQRyzxxBRXHPFcAxCwCy7/NuywxSCHLPFcCMjygDwdezyuyCxb/Ja9AwzQgAD3MgEwkQ+3rPPFO6w7o7ZL3OxjzjvrvJbP34ibssruFr3zyyXHbM+4TP/rtNE+SB0z1VVXdnXLc0EAztQMd23z1yy/FeDYS5utBNFou8xDgARozbXbb8cdMsl1S02D2M4Q+IqBKOKdBNx6T/zyjGTDgAAy2diDDy9DGn544nLvkA7bNRCAAAAadsZj/5KWX445xRhr3XgM2ajz4ok9lk4E4qcHgDEECBCw4g0H1Pt6zQWnIvsRtJ9OcioMBDi6YwroyCHpwxdRPOZvges5A/7GoIAB89QTJOWFRy/E9IlXL8C8DBBTcwsNBDTQ4ECvIHSN5Ov91swGFJB/hGWLX07tiusBAb7BMXf5TzAAHJkPFMCA5NnlgONLIM90YA/Vrc5mEPyfBG2nAwawi3FtyyAP6he3s3hwZpzrnwh3QEK0raWCqrvbClm4QQ7yoGQiONnC8DXDEdZwcQ6I2czW97Ye+nCDRxNY/A5nRBoisWczUpoBm6iYH/JgXgrwmwypWIMWfm0uDWigGLfIxf+IWJEHBUghD8vYxTPqIECoSEACPhdCNh7IjTmQly4GUK862vEgeMQBuOKBALERkYl/NOMTNScAjaWij1NM5B0XqTkR6G6Ha5QkICm5gwY44JBB0+QkJRg2VeDDj6K0SCBvsDYErAuSKkylCrx4NbUJyJI0Q6UsM7PKG+QuZoO8ICJ3Kb9e1mBzMwKl9IjJAlo6bXECU+bsmFlMTubAgluLJTW9YcxlbVOV1nzD/FLkzKK9EAvj9FA5n9bBAgyAAZjU5TbXibUcMEAeNLObPPMVvH4WDJyk1MEABSbMYZqNnmADaALXcqNvFNQvhkNo2hQKQKhlUYuRPGg3JSqyvWT/k4xM4+jeKFo7MDaDeyBVmUhBNpKVZm4HaVQFHTPaNZdWrKXdnAHdYjbAJUIUbzZFHUmNx4NBimCI+4RXUAOIgqUqsJMCKEAD0xjPIgJ1ozmdwUADl9RyOXWCJ/gqxO7CQAem1GNitWFYs5qGdJoGq+F0g1sbk1acxrUNs/GnXmkEn7oOlXo9wCHoUEZT0wXUTXtNLKf82lS2wgBmMstlYf3i2EBVVpxwPWwOkPYNnxLPa3f9BGP3MFpehlYGnA3XWaV3WZ+0Fq+ZXegVo/bRyRLvtZYorbsUu9e/ls+39suaPm1rBN3aBLca1KxplVsC494AcKp46Gf1gtxFVfcH/87dUGwrOjcQEpe1p9XJdQ2z3ZICt4Td7VttM5m38PppvAwpL1Eb694Y/BKj2rxtfS27X/Ayl5uhzS4NkBndriZXtm6C7xH/awz5ApaRasQgdfvrWgojMMAO/u0VY2hgIAh4Twp2IoO1i2ELjyGvISYDb3tL3xEHLcPBbTGCNYc73bGow9hN8YlhjF678NiF5wXyDZGnPByT18Ri+fEXLbJifwZ5yTLmbpTNuwPrIQB7ks1vcTfa5H5+rMQuFrCYlVzLop7vyuozcnzBPGOrsVnKa30zleMcZh0DAH/6KwD/2GvYNjeXy13+55TnS2c/A7jOcib0cg19g602crWzI//zM59c5kE/uNBwXnSm/5zoS2t6zm90QAMV4Nnpnq3TGsY0qDmN6FYzmsSu3vShX02DmSVABCdU84JpPWZUx1jVimY1ryVtTkpPusqSBZc0lznhWK961rJusK97DGxPCzvasB42ks31aHpk+QUDSBcsHHSkyp3a2cGG9rOljW5rqzvd7NZ2u1OtAwZBAAIMmkE8kOFBEUxuz80E7bx//Wl4ZxvbnSE2Oy1N72uv++AP7xwBWRmN0D2vBSietpCr3fB3uzveCO/1wKld8I/bwAEHGDUOIDCP34WvvSPfeMk7DvKIi1zeOA+5ne8RohwQgEcu90bwBJ5zmyu8nhwnuMP/DZ5wjUM56SS3JwSGKwMDxMh5ywt4s4vO9Jvr3OmVhrrMl27yprt4BgROhXRREI8C+htC5n4x2I8t9qfPXOkepznEu370hDIc7zZI+/lksDZVDKjcL+/z12Nud7Lr3excL7vXjb7tFFgQ0hdmfNjvHvW8A37vku/7RP/e+ZozXSxEX3zkHz95vs+92KQfu+dLH/ga707XIl795yGv+t5TXvN057zsTV92GvgseReX8Ll1T3ve/575wwc960XfUWPDXgdWxvKyp7l137se+NcXfuNnH33nfx/64z/5mdP3beXLHfwLr/vmHb/71of+9fEX//xvgOf9YT6C+Id0+hd8//TXfPY3fQHod/JHgDjgaG7HZ5SVgKO3gOFXgOV3gPVHfSMVe+nHSir3fwfmffcHfwJogR1ofiOIfvtHfI83A6L2gLinAxhogBrIUtaXfya4gtKXgRJYfR0kU1TQEIE2dByogyiIgCSogANYgeR3gjN4gTqmZytySw/EgjyYhBO4hDjYhEb4hE5Ygy+lhSV4TAIgLjPTczLkhV0Ihjd1g2NohTTYgxtIgVsIh+UXA+mAPXm4Xu6nhgxoh18ohzZYhH+4g3GIhT5Ih2+IdgOzdsxmiFAoiGGYg4V4hFeogpXoh0wIiEaIh43YNppYh5AYiIg4h2KohJS4iaO4hpLYhv8UhE1pyIZCRYiqaImHiIm1GIqLaIuReHbOwoWZKItMpYioCIy5KIxPRYxZmIqiyIsniHqcGIytOIvKmIinuIzG2Iy6WIzReIyV9wVCiIxgdY3WyIy7uI3Y2I3aKI5j5YbciFfZeI7sqFbkaIrm+I7OyIqlOIjVaI/xiI/QuIrSuI+T+I/pKJDeSJCu2I/8WI8NeY8H6U3qKI/TOIwOWZATiY/oWI4GyZEZGZEf9osf6ZEIuY4VmYwXuZApSY0raZEQSZL5OJC0FpAxmZC4aJIKyZIv6Y8jyZMlSZE56ZLi1JE+WZM4eZNAiZQaOY92FZQoSSw9+ZBEKZVRiZE/uZT/JzmOO0mVVwmSTOkrU2mVRpmUIoiESumVWdmOtHiUCEeTG1mUb8mVY4mVTqmVYamSWymWIdlWd6mTfSmUVYmXf/mUg2mXgemXhwmYXQmTcSmWbvmVa0mWz1eWl0iZt2iZdyiSiwmXkMmQetmZLUmYiSmamymXexkthamWnimYo2mYpfmZaUmPecmar0mbc4mWvsiXramaoemat8mYoDmbiFmbw/mbnBmbeRKOyOmOuHmWwLmckUmXzlmUjwmdq1mcjWmb2YmdwZmasjmUu/md4dmU02ma3TmezPmcdcmbUEmcimmc5mmdvcme3kmemEmK5emYmgmfsLme4umepMmf/9p5ngDqm9v5ntXpn/Y5mQx6fvepj/k5oN/oBcqpoOl5nBYanc35oDLJobWYoBHKnfIpnO95oAFqoga6c3JRnxcanxl6nSVKoAIqoi8aBxUaojE6oiyqoeqJoycqoyDqoWzZoCkopJLpoERqlm25nyhKn+jJoxjqoymqo08KowEapElamVl6mVvai1LqpAUKpjOKoEwqo036n2P6o1Qapmh6psm5o1Y6pTVKomo6p3A6n22qolZwo0YqnX26oV2Kn3/ao4NKnWW6pmkqp1+ap4jqpi2qn7rJpguKpJRapIEKoYXqoov6plWKp5NqqZWqpJfaoaNqk0saqYkqpo4Kpf+amqn9uamPKqG5iZqdSqeK6qqyCqus+qq4SqMzeah2Wqt3aquqaqbGOqFdwKelOqShqqXNyqXP6qW9SqaouqpxWqyNeqzBKqlgKazeyq27mqvTWqe6eq2MOqtnoKzRKqjLeqSg+q6iuq6YGnFYKq+kaq+m2q5+qq+Aiq/NWK/w6qwBC60DK638SqgHa6jVqq3l6qmx6qvjeqsJK5cAG68Fy67+6q4Wu7ECy7HNV7EdG7IE67EGm7H7arL9WnzA2rDEeq4sO6ww+62p6rKnSqvgaq6fSrIYe7HzirII67MKa7Mzm7MiW7I8e69Hm69A26r0urIRi63bOrQPm6NRa63/VbAgBoF4PWK1LUu0I1u0O6uzPZu0/9oEgGMQ/xZ3XBuzN+uw4QqxE8urcWub/2IyCJF88sO2Uvu2VPuyMru2f6unMigLQQc9bdu1U0uuT0uzcwu3Syu3p+cuhBsNJgI8RHi4egu4mBu42YqodZtD7LAj4aO5e4uziSuxjyuujdu3NWszaAt3o8uwi+u1Riu2SGu7SquyTABd7KC1hlu6bmu6fKu4q0u8qeu4ZLuLIPu1zFu7YDu2uMusyXuyuiu0pHu9slu8qDu9Ebm8ztu8Yfu8tyu+uRu9Grt73hu+4Au95Cu95ku975uyLei02gu1fru5+Au8iDu82zu/C9u5/1WbvcfLuvWLpunLvus7vglcvu17vgvsvuhLvwNsvNz7sxUcpbN7uvbbutTCuQEMwPerv5kruEE4wiCcwfy7wQVMu+qbmf/7wTAcwtjruRJ8wUw7wf3bwPCrw/LLwzB5wAr8vULcwkSMwENsxEVciUDMwA/swEccxEnMxE8sxc9Yw/FrwVeMwSuswYyLwyocuS8swwJsw5BLxqrrxQZsxT6sxWjMwkj8xlAMx1TciWrcxDtsxz2Mx1i8xjdsxsW5xBCsx2zsxwTcxlzsxnGsxHU8xYHMyE4cxY0MyY8sx2UbxigsvJgcvJq8v5nMyZsMnvk7wzF8yZ/swb9qyVucwv9dTMgUnMV97Mpl7L/WO8awfMasnMOC/Mp8DKmzfMKp3MkmPMq/bKPBLMa+bMiqjMhzrMiojMzAbMqk7MnSXMwcXAbqestfjM2rXMvIy82FrM2cGsq0vMu27M2tTM7dHMHNDM6H3M7J7M7PLM40vM7mjMuOfMf3nMf5vMe5zMvpSs3DPM3QHNAA7czEPNAGLdDyLMwJrbeAPMmJvMwSHcmUDNETbdGV3MsMzc7v3NHxLMIIXb3/HNL1nM0lvc3o/M0nrcwZPdILbcwbvdLwXMr5+9D4LMk3XdE5HdEUzdMYrbyLjNP6LNT8vM+DLNMeTdMS+dLRXNAc/dGifMoaDdP/VN3UJJ3S5/yxQa3TQ83VRU3UR43V9gzWFLvVPr3TF43WPZ3WXX3Wbf2hZs3WX+3VYd3P5SzWJo3XaUzPes3SP63Wf/3Waz3Ygf3DcU3YgJ3Ygl3YdW3UumzXf3zYjP3Yjh3LfT3TCg3SNS3Zij3Xbu3Zct3YZG3ZkE2tU23VTE3QV13aWV3ZdMvZi93Zok3XlD3ad83aY03HfI3bec3bKO3bfi3btU3b/tzBqd3Qq+3a6QzcmO3QsA3aiB3b0g3dk03ayq3S6nzaqn3cT63UUY3aS63Z4v3d2z3e46zVu33drW3by63euf3Zsw3fZZ3e7I3dzJ3UmU3eyA2PyV3f/+tN3Lft3r0t4L/twtq93+Z9zN2d30D63PEd2sMt39bt3+8N4ROu2we+4E6N1FB93gQezgke05eN3xs+4h9t09P94NFN3cJ94RIe4BQupijO4ike4RYO4wDe3jFe4FVM3zlu3x/e3P394//94pHt40YO5Dse3DXu4jeu40TumzOu4tWN40le5E+u5FE+4D2e4Rzu3R6+5ELO3bLs0iFe1eWt3xous1Nu4ytO5S1u5VmO5W/u5kA9Bb6LcSV+3x2u4F/O4MhqBGkbu35u4mBe6Hyu1FRgcVmXt0N+5RVe504u6XJO6VDOzFFQuHr+6HMe6VV+6Z3O5VvO4xgOBZreGf8FEwFDuOqs3uqu/uqwHuuyPuu0Xuu2fusCgwVYl3iCYVCPWFy+zn2mBuw/NexVMOixI+zEbuzK/uvO3uzQ3uvFbgV5rnXMLu3XPj7Bju3L3u3Pzu00+e3aPu3iXg7bPu7Zbu7kvp/l7mHnru7p7u7rDu7Rju7h3e7Y9e7yHu/5Pu/2ju+GAcreXu/wPvD0fvD/TvD7bvBCC/AMoe/9zu8B7+8F7/AjJPAWz0IQP/ES//AUv/AZL4MYr/ARz/AVT/Icb/Igj/Iez98df/EfX/Ihrxgb3/IqL/PflPMqAw2pYABTc1IjAPQiIPQuwPMC4PND3/NBr/QjcHsvYPRIDwD/RC/0UO+II1D1SX/0S6/1reAzhNUCWC/1TC/2XB/0lFv0MRX1U8/0hVf2LBD2a1/2J5MKpUYCcD/2Qt9QO3H3ZS/0AJEKX//2af/zeM/08ZAKt/YHEIALC7IL7lQhjh8zFkIPjz/5LrD4dzY5lR/5kH9nY3/5jK/5ks/5k4/5jf8Cpi/6nX8ho08PIYI+qB/6pD/7Tb8AZ98CqU/7rN/5ATIDuU/5rb/7k78gaBj7ma/7m18CEJD4uC/7wL/6yY87IoAAzM8Cvy/8tG8AZmj5gWAAA5IAHEMAtwb+ljT+4V/9L+D9AED+9GD+5T8CBHBjM6D+7C/+63/+JaD+Vff9//gPAgkBAERCkk3hoK37AsYBiKRJj+VZFkQBA10ynO1U0wEUgiCzNTzeoCfGrsl85qLZKqAhaFhh2CIRCdkxIOHXGCkFCBQ2w7puv+Pxj1xhBjggAPSRAAr6Fd7tkQz+BTIiltDlKRoSOh4GolAm8mFWNqIUCHDVUT5eWiYtNBz86HWmniYJ0CKAcS56yiKIChQ8vObGeqIkqAV/FsoOICxAGAwgy04fM7jmYWdrhzUcJ6OCytp1h+oSR+aRC4efq9+5T58DMOfUwZtbNizIteLdD6dCwYyUlX/sYjEgASGTPW/xAs66Nc4hPlAE6Piot8agMk8PehVguG0kyWwKJP+ROEKlzEqVBJmcbOGSZZWLeGIWy9FS5w6cd3zSDNrCZh2gM10qoaVUohWjPIWiILrGKYmdVU8YyKHEDlUAVr1WMeCtKMqgM/cRuham69eVMhOWjCs3jI9oUQsMGNCDR969dfVqbFJ3KF7AfA3PuTP4bt8Rf/3ixbPYRmHIjYmoCMxk8mHLiNPa4fzYceUREEY0QKA5iOjSnUmDSVBWcGTGhkeTULBKcW3Kl3EjkGRg9uber4+jYLB7LvPmTpT6ImGAFsrpAqpTt2Odlivr2K+ngL4ayPboMbJLR19ebZP16cG/l0RgAa2XQdyfh59/dr86+L2jAOAf9I2iHXTdobf/XzG1MNXegfEFmOBed/yXoIAPIMCgfw8qCOEsAiAAjHMjkliiiSeimKKKK7LYoosvwhijjDPSWKONN+KYo4478tijjz8CGaSQQxJZpJFHIpmkkksy2aSTT0IZpZRTUlmllVdimaWWW3LZpZdfghmmmGOSWaaZZ6KZppprstmmm2/CGaecc9JZp5134pmnnnvy2aeffwIaqKCDElqooYcimmiZSbHwAC1+KBqppFFCACIN+k2aqaZIDkBfpbsNkIBSIzgAXUID0MKAAHBt2qqrLBKgFFzTySGKHCToJcABqMr6qq+/mpihK15AJwABA6g6Kq8iAtuss3GpugOxTE13c0KGx9LC7LPbcntHtChkuEMCDlybK7YCaNutuuvC8C2ulVLXgAP0FSDKuemym6+++/Lbr7//AhywwAMTXLDBByOcsMILM9ywww9DHLHEE1NcscUXY5yxxhtz3LHHH4Mcssgjk1yyySejnLLKK7PcsstVhgAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Includes patients receiving a left ventricular assist device (LVAD), right ventricular assist device (RVAD), or total artificial heart (TAH).",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Stehlik J, Edwards LB, Kucheryavaya MS, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report&mdash;2011. J Heart Lung Transplant 2011; 30:1078. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_5_8286=[""].join("\n");
var outline_f8_5_8286=null;
var title_f8_5_8287="Birdshot retinochoroidopathy";
var content_f8_5_8287=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Birdshot retinochoroidopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple discrete cream-colored foci of depigmentation characteristic of birdshot retinochoroidopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Tolentino, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_5_8287=[""].join("\n");
var outline_f8_5_8287=null;
     